KRAS inhibitor and pharmaceutical use thereof

Abstract

The present invention relates to a KRAS inhibitor and a pharmaceutical use thereof. In particular, the present invention relates to a KRAS inhibitor having the structure of formula (I), a preparation method therefor, a pharmaceutical composition containing same, a use thereof as a KRAS inhibitor, and a use thereof in the treatment of KRAS-related cancers or tumors. Each substituent in formula (I) is as defined in the description.

Description

A KRAS inhibitor and its pharmaceutical use TECHNICAL FIELD

[0001] The present application belongs to the field of drug synthesis, and particularly relates to a KRAS inhibitor and its pharmaceutical use. BACKGROUND

[0002] The RAS gene family includes HRAS, KRAS and NRAS, which are frequently mutated as oncogenes in tumors. Mutations in RAS proteins occur in 20-30% of human tumors. Abnormally activated RAS proteins lead to malignant phenotypes of tumor cells, including dysregulation of cell growth and programmed cell death, increased invasiveness and neovascularization. Due to the high affinity of RAS for GTP / GDP and the lack of a clear drug binding pocket, the development of drugs targeting RAS proteins has been a long-standing problem.

[0003] Under physiological conditions, RAS proteins act as molecular switches, which exhibit dynamic balance between the inactivated GDP-bound state and the activated GTP-bound state. On the one hand, under the stimulation of exogenous growth factors (such as EGFR, FGFR, etc.), RAS proteins are converted from the inactivated GDP-bound form to the activated GTP-bound form through the catalysis of guanine nucleotide exchange factors (GEFs), thereby binding to downstream effector proteins and activating downstream signaling pathways. On the other hand, RAS returns to the inactivated GDP-bound form through the intrinsic GTPase activity of RAS proteins and the catalytic action of GTPase-activating proteins (GAPs).

[0004] Missense mutations of RAS proteins often lead to abnormal activation of RAS, in which mutations at amino acid positions 12 (G12), 13 (G13) and 61 (Q61) are the most common. These mutations disrupt the original dynamic balance of the GDP / GTP binding state of RAS, causing RAS proteins to be more in the activated GTP-bound state, thereby leading to persistent activation of the RAS downstream signaling pathway.

[0005] In human tumors, KRAS mutations are the most common subtype of RAS family mutations. Studies have found that KRAS mutations are found in about 71% of pancreatic cancer, about 35% of small intestine cancer, about 35% of colorectal cancer, about 26% of biliary tract cancer, about 17% of endometrial cancer, and about 19% of lung cancer. Among them, G12D / G12V / G12C / G13D mutations are the most common types of KRAS mutations in pancreatic cancer, lung cancer and colorectal cancer. In addition, recent studies suggest that targeting KRAS WT may also bring certain therapeutic benefits in KRAS wild-type (KRAS WT) dependent tumors.

[0006] However, due to the lack of a clear drug binding pocket in the KRAS protein, the development of KRAS inhibitors has always been challenging. Recent studies have found a previously undiscovered drug binding pocket in the mutant KRAS G12C protein in the GDP-bound state. Based on these new findings, covalent binding inhibitors targeting KRAS G12C have become a hot spot in the development of KRAS inhibitors and have made some clinical progress. However, in addition to the G12C mutation, targeting other activating mutations of KRAS is still urgent, including KRAS G12D / G12V / G13D mutations. On the other hand, it was found that KRAS G12C inhibitors may have a certain probability of developing resistance after use, and may restore the abnormal activation of KRAS through KRAS G12D / G12R / G12V / G12W / G13D mutations.

[0007] Therefore, it is necessary to continue to develop safe and effective pan-KRAS inhibitors to treat more KRAS mutant / KRAS-dependent tumor patients, and to overcome the resistance of KRAS G12C inhibitors. SUMMARY

[0008] The purpose of the present application is to provide a KRAS inhibitor and its pharmaceutical application. The series of compounds of the present application have strong inhibitory effect on KRAS, and can be widely used in the preparation of drugs for treating and / or preventing KRAS-related cancer or tumor, so as to develop a new generation of KRAS inhibitors.

[0009] The first aspect of the present application provides a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof:

[0010] wherein, is a double bond or a single bond;

[0011] Y1 is O, S, N, N(R 9a ), CH2, CH, CH2CH2 or CH=CH; Y2 is O, S, N, N(R 9b ), CH2, CH, CH2CH2 or CH=CH; Y3 is O, S, N, N(R 9c ), CH2, CH, CH2CH2 or CH=CH;

[0012] Z1 is N or C(R 10a ); Z2 is N or C(R 10b );

[0013] Ring A is selected from the following structures:

[0014] R1 is selected from C 3-12Cycloalkyl, 3-12 membered heterocyclic and 5-10 membered heteroaryl substituted C 1-10 Alkyl, R2 is selected from hydrogen, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic group, or, R1 and R2 together with the nitrogen atom to which they are directly connected form a 4-12 membered heterocyclic group, said 4-12 membered heterocyclic group is optionally fused to a 5-10 membered heteroaryl group, said group is optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 12 )R 13 、-C 0-8 Alkyl-N=S(O)R 13 R 14 、-C 0-8 Alkyl-N=SR 13 R 14 、-C 0-8 Alkyl-OS(O)2R 15 、-C 0-8 Alkyl-S(O) r R 15 、-C 0-8 Alkyl-OR 16 、-C 0-8 Alkyl-C(O)OR 16 、-C 0-8 Alkyl-C(O)SR 16 、-C 0-8 Alkyl-SC(O)R 17 、-C 0-8 Alkyl-C(O)R 17 、-C 0-8 Alkyl-OC(O)R 17 、-C 0-8 Alkyl-P(O)(R 17 )2. -C 0-8 Alkyl-NR 18 R 19 、-C 0-8 Alkyl-C(=NR 18 )R 17 、-C 0-8 Alkyl-N(R 18 )-C(=NR19 )R 17 、-C 0-8 Alkyl-C(O)NR 18 R 19 and -C 0-8 Alkyl-N(R 18 )-C(O)R 17 The above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 12 )R 13 、-C 0-8 Alkyl-N=S(O)R 13 R 14 、-C 0-8 Alkyl-N=SR 13 R 14 、-C 0-8 Alkyl-OS(O)2R 15 、-C 0-8 Alkyl-S(O) r R 15 、-C 0-8 Alkyl-OR 16 、-C 0-8 Alkyl-C(O)OR 16 、-C 0-8 Alkyl-C(O)SR 16 、-C 0-8 Alkyl-SC(O)R 17 、-C 0-8 Alkyl-C(O)R 17 、-C 0-8 Alkyl-OC(O)R 17 、-C 0-8 Alkyl-P(O)(R 17 )2. -C 0-8 Alkyl-NR 18 R 19 、-C 0-8 Alkyl-C(=NR 18 )R 17 、-C 0-8 Alkyl-N(R 18 )-C(=NR19 )R 17 、-C 0-8 Alkyl-C(O)NR 18 R 19 and -C 0-8 Alkyl-N(R 18 )-C(O)R 17 substituted by a substituent;

[0015] Each R3 and each R4 are independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 12 )R 13 、-C 0-8 Alkyl-N=S(O)R 13 R 14 、-C 0-8 Alkyl-N=SR 13 R 14 、-C 0-8 Alkyl-OS(O)2R 15 、-C 0-8 Alkyl-S(O) r R 15 、-C 0-8 Alkyl-OR 16 、-C 0-8 Alkyl-C(O)OR 16 、-C 0-8 Alkyl-C(O)SR 16 、-C 0-8 Alkyl-SC(O)R 17 、-C 0-8 Alkyl-C(O)R 17 、-C 0-8 Alkyl-OC(O)R 17 、-C 0-8 Alkyl-P(O)(R 17 )2. -C 0-8 Alkyl-NR 18 R 19 、-C 0-8 Alkyl-C(=NR 18 )R 17 、-C 0-8 Alkyl-N(R 18 )-C(=NR 19 )R17 , -C 0-8 alkyl-C(O)NR 18 R 19 and -C 0-8 alkyl-N(R 18 )-C(O)R 17 , or R3and R4together with the carbon atom to which they are directly attached form a C(=CH2), C(O), C 3-6 cycloalkyl or 4-6 membered heterocyclyl, each of the above groups being independently optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C 1-10 alkyl, halogen-substituted C 1-10 alkyl, deuterium-substituted C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-10 aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 alkyl-SF5, -C 0-8 alkyl-S(O)(=N-R 12 )R 13 , -C 0-8 alkyl-N=S(O)R 13 R 14 , -C 0-8 alkyl-N=SR 13 R 14 , -C 0-8 alkyl-O-S(O)2R 15 , -C 0-8 alkyl-S(O) r R 15 , -C 0-8 alkyl-O-R 16 , -C 0-8 alkyl-C(O)OR 16 , -C 0-8 alkyl-C(O)SR 16 , -C 0-8 alkyl-S-C(O)R 17 , -C 0-8 alkyl-C(O)R 17 , -C 0-8 alkyl-O-C(O)R 17 , -C 0-8 alkyl-P(O)(R 17 )2, -C 0-8 alkyl-NR 18 R 19 , -C 0-8 alkyl-C(=NR 18 )R17 、-C 0-8 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-8 Alkyl-C(O)NR 18 R 19 and -C 0-8 Alkyl-N(R 18 )-C(O)R 17 substituted by a substituent;

[0016] R5 is selected from -NR 11a R 11b 、C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1- 10 Alkyl, C 2-10 Alkenyl, C 1-10 Alkylene, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 aryl, 3-12 membered heterocyclic group, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 12 )R 13 、-C 0-8 Alkyl-N=S(O)R 13 R 14 、-C 0-8 Alkyl-N=SR 13 R 14 、-C 0-8 Alkyl-OS(O)2R 15 、-C 0-8 Alkyl-S(O) r R 15 、-C 0-8 Alkyl-OR 16 、-C 0-8 Alkyl-C(O)OR 16 、-C 0- 8-Alkyl-C(O)SR 16 、-C 0-8 Alkyl-SC(O)R 17 、-C 0-8 Alkyl-C(O)R 17 、-C 0-8 Alkyl-OC(O)R17 -C 0-8 alkyl-P(O)(R 17 )2, -C 0-8 alkyl-NR 18 R 19 , -C 0-8 alkyl-C(=NR 18 )R 17 , -C 0-8 alkyl-N(R 18 )-C(=NR 19 )R 17 , -C 0-8 alkyl-C(O)NR 18 R 19 , and -C 0-8 alkyl-N(R 18 )-C(O)R 17 , are optionally independently further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C 1-10 alkyl, halosubstituted C 1-10 alkyl, d euterium- substituted C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-12 cycloalkyl, 3- to 12-membered heterocyclyl, C 6-10 aryl, 5- to 10-membered heteroaryl, =0, =S, -C 0-8 alkyl-SF5, -C 0- 8alkyl-S(O)(=N-R 12 )R 13 , -C 0-8 alkyl-N=S(O)R 13 R 14 , -C 0-8 alkyl-N=SR 13 R 14 , -C 0-8 alkyl-O-S(O)2R 15 , -C 0-8 alkyl-S(O) r R 15 , -C 0-8 alkyl-O-R 16 , -C 0-8 alkyl-C(O)OR 16 , -C 0-8 alkyl-C(O)SR 16 , -C 0-8 alkyl-S-C(O)R 17 , -C 0-8 alkyl-C(O)R 17 , -C 0-8alkyl-O-C(O)R 17 , -C 0- 8alkyl-P(O)(R 17 )2, -C 0-8 alkyl-NR 18 R 19 , -C 0-8 alkyl-C(=NR 18 )R 17 , -C 0-8 alkyl-N(R 18 )-C(=NR 19 )R 17 , -C 0-8 alkyl-C(O)NR 18 R 19 , and -C 0-8 alkyl-N(R 18 )-C(O)R 17 ;

[0017] each R6is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 alkyl, halogen-substituted C 1-10 alkyl, deuterium-substituted C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-10 aryl, 5-10 membered heteroaryl, -C 0-8 alkyl-SF5, -C 0-8 alkyl-S(O)(=N-R 12 )R 13 , -C 0-8 alkyl-N=S(O)R 13 R 14 , -C 0-8 alkyl-N=SR 13 R 14 , -C 0-8 alkyl-O-S(O)2R 15 , -C 0-8 alkyl-S(O) r R 15 , -C 0-8 alkyl-O-R 16 , -C 0-8 alkyl-C(O)OR 16 , -C 0-8 alkyl-C(O)SR 16 , -C 0-8 alkyl-S-C(O)R 17 , -C 0-8 alkyl-C(O)R17 、-C 0-8 Alkyl-OC(O)R 17 、-C 0-8 Alkyl-P(O)(R 17 )2. -C 0-8 Alkyl-NR 18 R 19 、-C 0-8 Alkyl-C(=NR 18 )R 17 、-C 0-8 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-8 Alkyl-C(O)NR 18 R 19 and -C 0-8 Alkyl-N(R 18 )-C(O)R 17 ;

[0018] R7 is selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 12 )R 13 、-C 0-8 Alkyl-N=S(O)R 13 R 14 、-C 0-8 Alkyl-N=SR 13 R 14 、-C 0-8 Alkyl-OS(O)2R 15 、-C 0-8 Alkyl-S(O) r R 15 、-C 0-8 Alkyl-OR 16 、-C 0-8 Alkyl-C(O)OR 16 、-C 0-8 Alkyl-C(O)SR 16 、-C 0-8 Alkyl-SC(O)R 17 、-C 0-8alkyl-C(O)R 17 , -C 0-8 alkyl-O-C(O)R 17 , -C 0-8 alkyl-P(O)(R 17 )2, -C 0-8 alkyl-NR 18 R 19 , -C 0-8 alkyl-C(=NR 18 )R 17 , -C 0-8 alkyl-N(R 18 )-C(=NR 19 )R 17 , -C 0-8 alkyl-C(O)NR 18 R 19 , and -C 0-8 alkyl-N(R 18 )-C(O)R 17 ;

[0019] each R8is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 alkyl, halogen-substituted C 1-10 alkyl, deuterium-substituted C 1-10 alkyl, cyano-substituted C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-10 aryl, 5-10 membered heteroaryl, -C 0-8 alkyl-SF5, -C 0- 8alkyl-S(O)(=N-R 12 )R 13 , -C 0-8 alkyl-N=S(O)R 13 R 14 , -C 0-8 alkyl-N=SR 13 R 14 , -C 0-8 alkyl-O-S(O)2R 15 , -C 0-8 alkyl-S(O) r R 15 , -C 0-8 alkyl-O-R 16 , -C 0-8 alkyl-C(O)OR 16 , -C 0-8 alkyl-C(O)SR 16 , -C 0-8alkyl-S-C(O)R 17 , -C 0-8 alkyl-C(O)R 17 , -C 0-8 alkyl-O-C(O)R 17 , -C 0- 8alkyl-P(O)(R 17 )2, -C 0-8 alkyl-NR 18 R 19 , -C 0-8 alkyl-C(=NR 18 )R 17 , -C 0-8 alkyl-N(R 18 )-C(=NR 19 )R 17 , -C 0-8 alkyl-C(O)NR 18 R 19 and -C 0-8 alkyl-N(R 18 )-C(O)R 17 ;

[0020] R 9a , R 9b and R 9c are each independently selected from the group consisting of hydrogen, cyano, C 1-10 alkyl, C 2-10 alkenyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-10 aryl, 5-10 membered heteroaryl, -C 0-8 alkyl-S(O) r R 15 , -C 0-8 alkyl-O-R 16 , -C 0-8 alkyl-C(O)OR 16 , -C 0-8 alkyl-C(O)SR 16 , -C 0-8 alkyl-C(O)R 17 , -C 0-8 alkyl-O-C(O)R 17 , -C 0-8 alkyl-NR 18 R 19 , -C 0-8 alkyl-C(O)NR 18 R 19 and -C 0-8 alkyl-N(R 18 )-C(O)R 17The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1- 10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 12 )R 13 、-C 0-8 Alkyl-N=S(O)R 13 R 14 、-C 0-8 Alkyl-N=SR 13 R 14 、-C 0-8 Alkyl-OS(O)2R 15 、-C 0-8 Alkyl-S(O) r R 15 、-C 0-8 Alkyl-OR 16 、-C 0-8 Alkyl-C(O)OR 16 、-C 0-8 Alkyl-C(O)SR 16 、-C 0-8 Alkyl-SC(O)R 17 、-C 0-8 Alkyl-C(O)R 17 、-C 0-8 Alkyl-OC(O)R 17 、-C 0- 8-alkyl-P(O)(R 17 )2. -C 0-8 Alkyl-NR 18 R 19 、-C 0-8 Alkyl-C(=NR 18 )R 17 、-C 0-8 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-8 Alkyl-C(O)NR 18 R 19 and -C 0-8 Alkyl-N(R 18)-C(O)R 17 substituted by a substituent;

[0021] R 10a and R 10b are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 12 )R 13 、-C 0-8 Alkyl-N=S(O)R 13 R 14 、-C 0-8 Alkyl-N=SR 13 R 14 、-C 0-8 Alkyl-OS(O)2R 15 、-C 0-8 Alkyl-S(O) r R 15 、-C 0-8 Alkyl-OR 16 、-C 0-8 Alkyl-C(O)OR 16 、-C 0-8 Alkyl-C(O)SR 16 、-C 0-8 Alkyl-SC(O)R 17 、-C 0-8 Alkyl-C(O)R 17 、-C 0-8 Alkyl-OC(O)R 17 、-C 0-8 Alkyl-P(O)(R 17 )2. -C 0-8 Alkyl-NR 18 R 19 、-C 0-8 Alkyl-C(=NR 18 )R 17 、-C 0-8 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-8 Alkyl-C(O)NR 18 R 19 and -C 0-8 Alkyl-N(R18 )-C(O)R 17 , the foregoing groups are independently further optionally substituted by one or more substituents independently selected from deuterium, halogen, cyano, nitro, azido, C1-6alkyl, 1-10 C1-6alkyl, deuterium-substituted C1-6alkyl, 1-10 C1-6alkyl, deuterium-substituted C1-6alkyl, 1-10 C1-6alkyl, deuterium-substituted C1-6alkyl, 2-10 C1-6alkenyl, C1-6alkynyl, 2- 10 C1-6alkenyl, C1-6alkynyl, 3-12 C1-6alkyl, deuterium-substituted C1-6alkyl, 6-10 C1-6alkyl, deuterium-substituted C1-6alkyl, 0- C1-6alkyl, deuterium-substituted C1-6alkyl, 0-8 C1-6alkyl, deuterium-substituted C1-6alkyl, 12 C1-6alkyl, deuterium-substituted C1-6alkyl, 13 C1-6alkyl, deuterium-substituted C1-6alkyl, 0-8 C1-6alkyl, deuterium-substituted C1-6alkyl, 13 C1-6alkyl, deuterium-substituted C1-6alkyl, 14 C1-6alkyl, deuterium-substituted C1-6alkyl, 0-8 C1-6alkyl, deuterium-substituted C1-6alkyl, 13 C1-6alkyl, deuterium-substituted C1-6alkyl, 14 C1-6alkyl, deuterium-substituted C1-6alkyl, 0-8 C1-6alkyl, deuterium-substituted C1-6alkyl, 15 C1-6alkyl, deuterium-substituted C1-6alkyl, 0-8 C1-6alkyl, deuterium-substituted C1-6alkyl, r C1-6alkyl, deuterium-substituted C1-6alkyl, 15 C1-6alkyl, deuterium-substituted C1-6alkyl, 0-8 C1-6alkyl, deuterium-substituted C1-6alkyl, 16 C1-6alkyl, deuterium-substituted C1-6alkyl, 0-8 C1-6alkyl, deuterium-substituted C1-6alkyl, 16 C1-6alkyl, deuterium-substituted C1-6alkyl, 0-8 C1-6alkyl, deuterium-substituted C1-6alkyl, 16 C1-6alkyl, deuterium-substituted C1-6alkyl, 0-8 C1-6alkyl, deuterium-substituted C1-6alkyl, 17 C1-6alkyl, deuterium-substituted C1-6alkyl, 0-8 C1-6alkyl, deuterium-substituted C1-6alkyl, 17 C1-6alkyl, deuterium-substituted C1-6alkyl, 0- C1-6alkyl, deuterium-substituted C1-6alkyl, 17 C1-6alkyl, deuterium-substituted C1-6alkyl, 0-8 C1-6alkyl, deuterium-substituted C1-6alkyl, 17 C1-6alkyl, deuterium-substituted C1-6alkyl, 0-8 C1-6alkyl, deuterium-substituted C1-6alkyl, 18 C1-6alkyl, deuterium-substituted C1-6alkyl, 19 C1-6alkyl, deuterium-substituted C1-6alkyl, 0-8 C1-6alkyl, deuterium-substituted C1-6alkyl, 18 C1-6alkyl, deuterium-substituted C1-6alkyl, 17 C1-6alkyl, deuterium-substituted C1-6alkyl, 0-8 C1-6alkyl, deuterium-substituted C1-6alkyl, 18 C1-6alkyl, deuterium-substituted C1-6alkyl, 19 C1-6alkyl, deuterium-substituted C1-6alkyl, 17 C1-6alkyl, deuterium-substituted C1-6alkyl, 0-8 C1-6alkyl, deuterium-substituted C1-6alkyl, 18 C1-6alkyl, deuterium-substituted C1-6alkyl, 19 and -C0-8 alkyl-N(R 18 )-C(O)R 17 substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =O, C

[0022] R 11a and R 11b are each independently selected from the group consisting of hydrogen, deuterium, hydroxyl, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-10 aryl, 5-10 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl, and C 1-10 alkanoyl, the aforementioned groups being independently optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =O, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 1-10 alkylene, halogen-substituted C 1-10 alkylene, deuterium-substituted C 1-10 alkylene, halogen-substituted C 1-10 alkyl, deuterium-substituted C 1-10 alkyl, C 1-10 alkoxy, C 3-12 cycloalkyl, C 3-12 cycloalkoxy, 3-12 membered heterocyclyl, 3-12 membered heterocyclyloxy, C 6-10 aryl, C 6-10 aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, mono-C 1-10 alkylamino, di-C 1-10 alkylamino, and C 1- 10 alkanoyl, the aforementioned groups being independently optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =O, C

[0023] or, R 11a and R 11b together with the nitrogen atom to which they are directly attached form a 4-10 membered heterocyclyl or 5-10 membered heteroaryl, said 4-10 membered heterocyclyl or 5-10 membered heteroaryl being optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =O, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 1-10 alkylene, halogen-substituted C 1- 10 alkylene, deuterium-substituted C 1-10 alkylene, halogen-substituted C 1-10 alkyl, deuterium-substituted C 1-10 alkyl, C1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, mono C 1-10 Alkylamino, di-C 1-10 Alkylamino and C 1-10 substituted with an alkanoyl substituent;

[0024] Each R 12 are each independently selected from hydrogen, deuterium, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-S(O) r R 15 、-C 0-8 Alkyl-C(O)OR 16 、-C 0-8 Alkyl-C(O)R 17 and -C 0-8 Alkyl-C(O)NR 18 R 19 The above groups are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2- 10 Alkynyl, halogen-substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6- 10 Aryl, 5-10 membered heteroaryl, =O, -C 0-8 Alkyl-S(O) r R 15 、-C 0-8 Alkyl-OR 16 、-C 0-8 Alkyl-C(O)OR 16 、-C 0-8 Alkyl-C(O)R 17 、-C 0-8 Alkyl-OC(O)R 17 、-C 0-8 Alkyl-NR 18 R 19 、-C 0-8alkyl-C(=NR 18 )R 17 , -C 0-8 alkyl-N(R 18 )-C(=NR 19 )R 17 , -C 0-8 alkyl-C(O)NR 18 R 19 , and -C 0-8 alkyl-N(R 18 )-C(O)R 17 ;

[0025] each R 13 and each R 14 is each independently selected from the group consisting of hydrogen, deuterium, hydroxyl, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, 3-10 membered heterocyclyl, C 6-10 aryl, and 5-10 membered heteroaryl, or R 13 and R 14 together with the sulfur atom to which they are both attached form a 3-10 membered heterocyclyl, optionally further substituted by one or more deuterium, halogen, cyano, nitro, azido, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, halosubstituted C 1-10 alkyl, deuterium- substituted C 1-10 alkyl, C 3-10 cycloalkyl, 3-10 membered heterocyclyl, C 6-10 aryl, 5-10 membered heteroaryl, -C 0-8 alkyl-S(O) r R 15 , -C 0-8 alkyl-O-R 16 , -C 0-8 alkyl-C(O)OR 16 , -C 0-8 alkyl-C(O)R 17 , -C 0-8 alkyl-O-C(O)R 17 , -C 0-8 alkyl-NR 18 R 19 , -C 0-8 alkyl-C(=NR 18 )R 17 , -C 0-8 alkyl-N(R 18 )-C(=NR 19 )R 17, -C 0-8 alkyl-C(O)NR 18 R 19 and -C 0-8 alkyl-N(R 18 )-C(O)R 17 substituted with one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =O, cyano, C

[0026] each R 15 is independently selected from the group consisting of hydrogen, deuterium, hydroxyl, C 1-10 alkyl, C 2-10 alkenyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-10 aryl, 5-10 membered heteroaryl, and -NR 18 R 19 , the foregoing groups are independently optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =O, cyano, C 1-10 alkyl, halosubstituted C 1-10 alkyl, deuterium- substituted C 1-10 alkyl, C 1-10 alkoxy, C 3-12 cycloalkyl, C 3-12 cycloalkoxy, 3-12 membered heterocyclyl, 3-12 membered heterocyclyloxy, C 6-10 aryl, C 6-10 aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, and -NR 18 R 19 substituted with one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =O, cyano, C

[0027] each R 16 is independently selected from the group consisting of hydrogen, deuterium, C 1-10 alkyl, C 2-10 alkenyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-10 aryl, and 5-10 membered heteroaryl, the foregoing groups are independently optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =O, cyano, C 1-10 alkyl, halosubstituted C 1-10 alkyl, deuterium- substituted C 1-10 alkyl, C 1-10 alkoxy, C 3-12 cycloalkyl, C 3-12 cycloalkoxy, 3-12 membered heterocyclyl, 3-12 membered heterocyclyloxy, C 6-10 aryl, C 6- 10 aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, and -NR 18 R 19 substituted with one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =O, cyano, C

[0028] each R 17independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 1-10 Alkoxy, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 18 R 19 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 18 R 19 substituted by a substituent;

[0029] Each R 18 and each R 19 are independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-10 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen-substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, mono C 1-10alkyl, C 1-10 alkyl, C 1-10 substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =0, C

[0030] or, R 18 and R 19 form, together with the nitrogen atom to which they are directly attached, a 4-10 membered heterocyclyl or 5-10 membered heteroaryl, said 4-10 membered heterocyclyl or 5-10 membered heteroaryl being optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =0, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, halogen-substituted C 1-10 alkyl, deuterium-substituted C 1-10 alkyl, C 1-10 alkoxy, C 3-12 cycloalkyl, C 3-12 cycloalkoxy, 3-12 membered heterocyclyl, 3-12 membered heterocyclyloxy, C 6-10 aryl, C 6-10 aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, mono- or di- 1- 10 alkylamino, di-C 1-10 alkylamino and C 1-10 substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =0, C

[0031] m is 0, 1, 2, 3 or 4; n is 0, 1, 2, 3, 4, 5 or 6; o is 0, 1 or 2;

[0032] and each r is independently 0, 1 or 2.

[0033] As a preferred option, in the compound of formula (I), stereoisomer thereof or pharmaceutically acceptable salt thereof, R1is selected from C 3-6 alkyl, R2is selected from hydrogen, C 1-4 alkyl, C 1- alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl and 3-6 membered heterocyclyl, or R1and R2, together with the nitrogen atom to which they are directly attached, form a 4-12 membered heterocyclyl, said 4-12 membered heterocyclyl being optionally fused to a 5-10 membered heteroaryl, said groups being optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =0, =S, -C 0-4alkyl-SF5, -C 0-4 alkyl-S(O)(=N-R 12 )R 13 , -C 0-4 alkyl-N=S(O)R 13 R 14 , -C 0- 4alkyl-N=SR 13 R 14 , -C 0-4 alkyl-O-S(O)2R 15 , -C 0-4 alkyl-S(O) r R 15 , -C 0-4 alkyl-O-R 16 , -C 0-4 alkyl-C(O)OR 16 , -C 0-4 alkyl-C(O)SR 16 , -C 0-4 alkyl-S-C(O)R 17 , -C 0-4 alkyl-C(O)R 17 , -C 0-4 alkyl-O-C(O)R 17 , -C 0-4 alkyl-P(O)(R 17 )2, -C 0-4 alkyl-NR 18 R 19 , -C 0-4 alkyl-C(=NR 18 )R 17 , -C 0-4 alkyl-N(R 18 )-C(=NR 19 )R 17 , -C 0-4 alkyl-C(O)NR 18 R 19 and -C 0-4 alkyl-N(R 18 )-C(O)R 17 , are optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =0, =S, -C 0-4alkyl-SF5, -C 0-4 alkyl-S(O)(=N-R 12 )R 13 , -C 0-4 alkyl-N=S(O)R 13 R 14 , -C 0-4 alkyl-N=SR 13 R 14 , -C 0-4 alkyl-O-S(O)2R 15 , -C 0-4 alkyl-S(O) r R 15 , -C 0-4 alkyl-O-R 16 , -C 0-4 alkyl-C(O)OR 16 , -C 0- 4alkyl-C(O)SR 16 , -C 0-4 alkyl-S-C(O)R 17 , -C 0-4 alkyl-C(O)R 17 , -C 0-4 alkyl-O-C(O)R 17 , -C 0-4 alkyl-P(O)(R 17 )2, -C 0-4 alkyl-NR 18 R 19 , -C 0-4 alkyl-C(=NR 18 )R 17 , -C 0-4 alkyl-N(R 18 )-C(=NR 19 )R 17 , -C 0-4 alkyl-C(O)NR 18 R 19 , and -C 0-4 alkyl-N(R 18 )-C(O)R 17 ;

[0034] each R3and each R4is each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, -C 0-4 alkyl-SF5, -C0-4 alkyl-S(O)(=N-R 12 )R 13 , -C 0-4 alkyl-N=S(O)R 13 R 14 , -C 0-4 alkyl-N=SR 13 R 14 , -C 0-4 alkyl-O-S(O)2R 15 , -C 0-4 alkyl-S(O) r R 15 , -C 0-4 alkyl-O-R 16 , -C 0-4 alkyl-C(O)OR 16 , -C 0-4 alkyl-C(O)SR 16 , -C 0-4 alkyl-S-C(O)R 17 , -C 0-4 alkyl-C(O)R 17 , -C 0-4 alkyl-O-C(O)R 17 , -C 0-4 alkyl-P(O)(R 17 )2, -C 0-4 alkyl-NR 18 R 19 , -C 0-4 alkyl-C(=NR 18 )R 17 , -C 0-4 alkyl-N(R 18 )-C(=NR 19 )R 17 , -C 0-4 alkyl-C(O)NR 18 R 19 and -C 0-4 alkyl-N(R 18 )-C(O)R 17 , or R3and R4together with the carbon atom to which they are directly attached form a C(=CH2), C(O), C 3-6 cycloalkyl or 4-6 membered heterocyclyl, each of the above groups being independently optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =0, =S, -C 0-4 alkyl-SF5, -C 0-4 alkyl-S(O)(=N-R 12 )R 13 , -C 0-4 alkyl-N=S(O)R 13 R 14 , -C 0- 4alkyl-N=SR 13 R 14 , -C 0-4 alkyl-O-S(O)2R 15 , -C 0-4 alkyl-S(O) r R 15 , -C 0-4 alkyl-O-R 16 , -C 0-4 alkyl-C(O)OR 16 , -C 0-4 alkyl-C(O)SR 16 , -C 0-4 alkyl-S-C(O)R 17 , -C 0-4 alkyl-C(O)R 17 , -C 0-4 alkyl-O-C(O)R 17 , -C 0-4 alkyl-P(O)(R 17 )2, -C 0-4 alkyl-NR 18 R 19 , -C 0-4 alkyl-C(=NR 18 )R 17 , -C 0-4 alkyl-N(R 18 )-C(=NR 19 )R 17 , -C 0-4 alkyl-C(O)NR 18 R 19 and -C 0-4 alkyl-N(R 18 )-C(O)R 17 ;

[0035] R5is selected from -NR 11a R 11b , C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-8Aryl and 5-8 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1- 4 alkyl, C 2-4 Alkenyl, C 1-4 Alkylene, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 aryl, 3-6 membered heterocyclic group, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 12 )R 13 、-C 0-4 Alkyl-N=S(O)R 13 R 14 、-C 0-4 Alkyl-N=SR 13 R 14 、-C 0-4 Alkyl-OS(O)2R 15 、-C 0-4 Alkyl-S(O) r R 15 、-C 0-4 Alkyl-OR 16 、-C 0-4 Alkyl-C(O)OR 16 、-C 0-4 Alkyl-C(O)SR 16 、-C 0-4 Alkyl-SC(O)R 17 、-C 0-4 Alkyl-C(O)R 17 、-C 0-4 Alkyl-OC(O)R 17 、-C 0-4 Alkyl-P(O)(R 17 )2. -C 0-4 Alkyl-NR 18 R 19 、-C 0-4 Alkyl-C(=NR 18 )R 17 、-C 0-4 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-4 Alkyl-C(O)NR 18 R 19 and -C 0-4 Alkyl-N(R 18 )-C(O)R17 The above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, nitro, azido, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 12 )R 13 、-C 0-4 Alkyl-N=S(O)R 13 R 14 、-C 0-4 Alkyl-N=SR 13 R 14 、-C 0-4 Alkyl-OS(O)2R 15 、-C 0-4 Alkyl-S(O) r R 15 、-C 0-4 Alkyl-OR 16 、-C 0-4 Alkyl-C(O)OR 16 、-C 0-4 Alkyl-C(O)SR 16 、-C 0-4 Alkyl-SC(O)R 17 、-C 0-4 Alkyl-C(O)R 17 、-C 0-4 Alkyl-OC(O)R 17 、-C 0-4 Alkyl-P(O)(R 17 )2. -C 0-4 Alkyl-NR 18 R 19 、-C 0-4 Alkyl-C(=NR 18 )R 17 、-C 0-4 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-4 Alkyl-C(O)NR 18 R 19 and -C 0-4 Alkyl-N(R 18)-C(O)R 17 substituted by a substituent;

[0036] Each R6 is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 12 )R 13 、-C 0-4 Alkyl-N=S(O)R 13 R 14 、-C 0-4 Alkyl-N=SR 13 R 14 、-C 0-4 Alkyl-OS(O)2R 15 、-C 0-4 Alkyl-S(O) r R 15 、-C 0-4 Alkyl-OR 16 、-C 0-4 Alkyl-C(O)OR 16 、-C 0-4 Alkyl-C(O)SR 16 、-C 0-4 Alkyl-SC(O)R 17 、-C 0-4 Alkyl-C(O)R 17 、-C 0-4 Alkyl-OC(O)R 17 、-C 0-4 Alkyl-P(O)(R 17 )2. -C 0-4 Alkyl-NR 18 R 19 、-C 0-4 Alkyl-C(=NR 18 )R 17 、-C 0-4 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-4 Alkyl-C(O)NR 18 R 19 and -C 0-4alkyl-N(R 18 )-C(O)R 17 ;

[0037] R7is selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, -C 0-4 alkyl-SF5, -C 0-4 alkyl-S(O)(=N-R 12 )R 13 , -C 0-4 alkyl-N=S(O)R 13 R 14 , -C 0-4 alkyl-N=SR 13 R 14 , -C 0-4 alkyl-O-S(O)2R 15 , -C 0-4 alkyl-S(O) r R 15 , -C 0-4 alkyl-O-R 16 , -C 0-4 alkyl-C(O)OR 16 , -C 0-4 alkyl-C(O)SR 16 , -C 0-4 alkyl-S-C(O)R 17 , -C 0-4 alkyl-C(O)R 17 , -C 0-4 alkyl-O-C(O)R 17 , -C 0-4 alkyl-P(O)(R 17 )2, -C 0-4 alkyl-NR 18 R 19 , -C 0-4 alkyl-C(=NR 18 )R 17 , -C 0-4 alkyl-N(R 18 )-C(=NR 19 )R 17 , -C 0-4 alkyl-C(O)NR 18 R 19 , and -C0-4 alkyl-N(R 18 )-C(O)R 17 ;

[0038] each R8is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, cyano-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3- 6cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, -C 0-4 alkyl-SF5, -C 0-4 alkyl-S(O)(=N-R 12 )R 13 , -C 0-4 alkyl-N=S(O)R 13 R 14 , -C 0-4 alkyl-N=SR 13 R 14 , -C 0-4 alkyl-O-S(O)2R 15 , -C 0-4 alkyl-S(O) r R 15 , -C 0-4 alkyl-O-R 16 , -C 0-4 alkyl-C(O)OR 16 , -C 0-4 alkyl-C(O)SR 16 , -C 0-4 alkyl-S-C(O)R 17 , -C 0-4 alkyl-C(O)R 17 , -C 0-4 alkyl-O-C(O)R 17 , -C 0-4 alkyl-P(O)(R 17 )2, -C 0-4 alkyl-NR 18 R 19 , -C 0-4 alkyl-C(=NR 18 )R 17 , -C 0-4 alkyl-N(R 18 )-C(=NR 19 )R 17 , -C 0-4alkyl-C(O)NR 18 R 19 and -C 0-4 alkyl-N(R 18 )-C(O)R 17 ;

[0039] R 11a and R 11b are each independently selected from the group consisting of hydrogen, deuterium, hydroxyl, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl, and C 1-10 alkanoyl, the aforementioned groups being independently optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =O, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkylene, halogen-substituted C 1-4 alkylene, deuterium-substituted C 1-4 alkylene, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 1-4 alkoxy, C 3-6 cycloalkyl, C 3- cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C 6-8 aryl, C 6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono-C 1-4 alkylamino, di-C 1-4 alkylamino, and C 1-4 alkanoyl;

[0040] Alternatively, R 11a and R 11b together with the nitrogen atom to which they are directly attached form a 4-6 membered heterocyclyl or 5-8 membered heteroaryl, said 4-6 membered heterocyclyl or 5-8 membered heteroaryl being optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =O, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkylene, halogen-substituted C 1-4 alkylene, deuterium-substituted C 1-4 alkylene, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono C 1-4 Alkylamino, di-C 1-4 Alkylamino and C 1-4 substituted with an alkanoyl substituent;

[0041] Among them, R 12 、R 13 、R 14 、R 15 、R 16 、R 17 、R 18 、R 19 and r are as defined for the compound of formula (I).

[0042] As a preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts, R 9a 、R 9b and R 9c Each independently selected from hydrogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-S(O) r R 15 、-C 0-4 Alkyl-OR 16 、-C 0-4 Alkyl-C(O)OR 16 、-C 0-4 Alkyl-C(O)SR 16 、-C 0-4 Alkyl-C(O)R 17 、-C 0-4 Alkyl-OC(O)R 17 、-C 0-4 Alkyl-NR 18 R 19 、-C 0-4 Alkyl-C(O)NR 18 R 19 and -C 0-4 Alkyl-N(R 18 )-C(O)R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-4alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3- to 6-membered heterocyclyl, C 6-8 aryl, 5- to 8-membered heteroaryl, =0, =S, -C 0-4 alkyl-SF5, -C 0-4 alkyl-S(O)(=N-R 12 )R 13 , -C 0-4 alkyl-N=S(O)R 13 R 14 , -C 0-4 alkyl-N=SR 13 R 14 , -C 0-4 alkyl-O-S(O)2R 15 , -C 0-4 alkyl-S(O) r R 15 , -C 0-4 alkyl-O-R 16 , -C 0-4 alkyl-C(O)OR 16 , -C 0-4 alkyl-C(O)SR 16 , -C 0-4 alkyl-S-C(O)R 17 , -C 0-4 alkyl-C(O)R 17 , -C 0-4 alkyl-O-C(O)R 17 , -C 0-4 alkyl-P(O)(R 17 )2, -C 0-4 alkyl-NR 18 R 19 , -C 0-4 alkyl-C(=NR 18 )R 17 , -C 0-4 alkyl-N(R 18 )-C(=NR 19 )R 17 , -C 0-4 alkyl-C(O)NR 18 R 19 and -C 0-4 alkyl-N(R 18 )-C(O)R 17 ;

[0043] R 10a and R10b each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3- to 6-membered heterocyclyl, C 6-8 aryl, 5- to 8-membered heteroaryl, -C 0-4 alkyl-SF5, -C 0-4 alkyl-S(O)(=N-R 12 )R 13 , -C 0-4 alkyl-N=S(O)R 13 R 14 , -C 0-4 alkyl-N=SR 13 R 14 , -C 0-4 alkyl-O-S(O)2R 15 , -C 0-4 alkyl-S(O) r R 15 , -C 0-4 alkyl-O-R 16 , -C 0-4 alkyl-C(O)OR 16 , -C 0-4 alkyl-C(O)SR 16 , -C 0-4 alkyl-S-C(O)R 17 , -C 0-4 alkyl-C(O)R 17 , -C 0- 4alkyl-O-C(O)R 17 , -C 0-4 alkyl-P(O)(R 17 )2, -C 0-4 alkyl-NR 18 R 19 , -C 0-4 alkyl-C(=NR 18 )R 17 , -C 0-4 alkyl-N(R 18 )-C(=NR 19 )R 17 , -C 0-4 alkyl-C(O)NR 18 R 19 and -C 0-4 alkyl-N(R 18 )-C(O)R 17 , are independently optionally further substituted with one or more groups selected from deuterium, halogen, cyano, nitro, azido, C 1-4alkyl, halosubstituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3- to 6-membered heterocyclyl, C 6-8 aryl, 5- to 8-membered heteroaryl, =0, =S, -C 0-4 alkyl-SF5, -C 0-4 alkyl-S(O)(=N-R 12 )R 13 , -C 0-4 alkyl-N=S(O)R 13 R 14 , -C 0-4 alkyl-N=SR 13 R 14 , -C 0-4 alkyl-O-S(O)2R 15 , -C 0-4 alkyl-S(O) r R 15 , -C 0-4 alkyl-O-R 16 , -C 0-4 alkyl-C(O)OR 16 , -C 0-4 alkyl-C(O)SR 16 , -C 0-4 alkyl-S-C(O)R 17 , -C 0-4 alkyl-C(O)R 17 , -C 0-4 alkyl-O-C(O)R 17 , -C 0-4 alkyl-P(O)(R 17 )2, -C 0-4 alkyl-NR 18 R 19 , -C 0-4 alkyl-C(=NR 18 )R 17 , -C 0-4 alkyl-N(R 18 )-C(=NR 19 )R 17 , -C 0-4 alkyl-C(O)NR 18 R 19 and -C 0-4 alkyl-N(R 18 )-C(O)R 17 ;

[0044] wherein R 12R 13 R 14 R 15 R 16 R 17 R 18 R 19 and r are defined as for the compound of formula (I).

[0045] As a further preferred option, in the compound of formula (I), its stereoisomers or its pharmaceutically acceptable salts, R 9a R 9b and R 9c are each independently selected from hydrogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -C(O)R 17 , -O-C(O)R 17 , -NR 18 R 19 , -C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 , the aforementioned groups are independently optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R 12 )R 13 , -N=S(O)R 13 R 14 , -N=SR 13 R 14 , -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R17 -O-C(O)R 17 -P(O)(R 17 )2 18 -NR 19 -C(=NR 18 )R 17 -N(R 18 )-C(=NR 19 )R 17 -C(O)NR 18 R 19 -N(R 18 )-C(O)R 17 ; and

[0046] R 10a and R 10b are each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2- 4alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=N-R 12 )R 13 , -N=S(O)R 13 R 14 , -N=SR 13 R 14 , -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(=NR 18 )R 17 , -N(R 18 )-C(=NR 19 )R 17 , -C(O)NR 18 R 19 , and -N(R 18 )-C(O)R 17 , each of which is independently optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3- to 6-membered heterocyclyl, C 6-8 aryl, 5- to 8-membered heteroaryl, =0, =S, -SF5, -S(O)(=N-R 12 )R 13 , -N=S(O)R 13 R 14 , -N=SR 13 R 14 , -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(=NR 18 )R 17 , -N(R 18 )-C(=NR 19 )R 17 , -C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ;

[0047] wherein R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and r are as defined for the compound of formula (I).

[0048] As a still further preferred option, in the compound of formula (I), its stereoisomers or its pharmaceutically acceptable salts, R 9a , R 9b and R 9c are each independently selected from hydrogen and C 1-4 alkyl, the above groups being independently optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium-substituted C1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl and 3-6 membered heterocyclyl, substituted with substituents selected from the group consisting of alkyl, halo, cyano, C

[0049] R 10a and R 10b are each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl and C 3-6 cycloalkyl, the aforementioned groups being independently optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halo-substituted C 1- 4alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, =0, =S and -SF5.

[0050] As a preferred option, in the compound of formula (I), in the stereoisomer thereof, or in the pharmaceutically acceptable salt thereof, each R 12 are each independently selected from the group consisting of hydrogen, deuterium, C 1-4 alkyl and C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, -C 0-4 alkyl-S(O) r R 15 , -C 0-4 alkyl-C(O)OR 16 , -C 0-4 alkyl-C(O)R 17 and -C 0-4 alkyl-C(O)NR 18 R 19 , the aforementioned groups being optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl and C 2-4 alkenyl, C 2-4 alkynyl, halo-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, -C 0-4 alkyl-S(O) r R 15 , -C 0-4 alkyl-O-R 16 , -C 0-4alkyl-C(O)OR 16 , -C 0-4 alkyl-C(O)R 17 , -C 0-4 alkyl-O-C(O)R 17 , -C 0-4 alkyl-NR 18 R 19 , -C 0-4 alkyl-C(=NR 18 )R 17 , -C 0-4 alkyl-N(R 18 )-C(=NR 19 )R 17 , -C 0-4 alkyl-C(O)NR 18 R 19 , and -C 0-4 alkyl-N(R 18 )-C(O)R 17 ;

[0051] each R 13 and each R 14 is each independently selected from the group consisting of hydrogen, deuterium, hydroxyl, C 1-4 alkyl, C 2-4 alkenyl, C 2- 4alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, and 5-8 membered heteroaryl, or R 13 and R 14 together with the sulfur atom to which they are directly attached form a 3-6 membered heterocyclyl, and wherein each of the above groups is optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, -C 0-4 alkyl-S(O) r R 15 , -C 0-4 alkyl-O-R 16 , -C 0-4 alkyl-C(O)OR 16 , -C 0-4 alkyl-C(O)R 17 , -C 0-4 alkyl-O-C(O)R 17 , -C 0-4alkyl-NR 18 R 19 , -C 0-4 alkyl-C(=NR 18 )R 17 , -C 0-4 alkyl-N(R 18 )-C(=NR 19 )R 17 , -C 0-4 alkyl-C(O)NR 18 R 19 , and -C 0-4 alkyl-N(R 18 )-C(O)R 17 ;

[0052] each R 15 is independently selected from the group consisting of hydrogen, deuterium, hydroxyl, C 1-4 alkyl, C 2-4 alkenyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, and -NR 18 R 19 , each of which is independently and optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =O, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 1-4 alkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C 6-8 aryl, C 6- 8aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, and -NR 18 R 19 ;

[0053] each R 16 is independently selected from the group consisting of hydrogen, deuterium, C 1-4 alkyl, C 2-4 alkenyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, and 5-8 membered heteroaryl, each of which is independently and optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =O, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 1-4 alkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 18 R 19 substituted by a substituent;

[0054] Each R 17 independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 18 R 19 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1- 4 alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6- 8 aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 18 R 19 substituted by a substituent;

[0055] Each R 18 and each R 19 are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2- 4-chain alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-10 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen-substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C3-6 cycloalkyl, C 3-6 cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C 6- 8aryl, C 6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono-C 1-4 alkylamino, di-C 1-4 alkylamino and C 1-4 substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =0, C

[0056] or, R 18 and R 19 form, together with the nitrogen atom to which they are directly attached, a 4-6 membered heterocyclyl or 5-8 membered heteroaryl, said 4-6 membered heterocyclyl or 5-8 membered heteroaryl being optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =0, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 1-4 alkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C 6- 8aryl, C 6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono-C 1-4 alkylamino, di-C 1-4 alkylamino and C 1-4 substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =0, C

[0057] and each r is independently 0, 1 or 2.

[0058] As a preferred aspect, the compound of formula (I), stereoisomer thereof, or pharmaceutically acceptable salt thereof, is a compound of formula (IIa), (IIb), (IIc), (IId), (IIe) or (IIf):

[0059] wherein each ring A is independently selected from the following structures:

[0060] each R1is independently selected from C 3-6 cycloalkyl, 3-6 membered heterocyclyl and 5-8 membered heteroaryl substituted C 1- 4alkyl, each R2is independently selected from hydrogen, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6Cycloalkyl and 3-6 membered heterocyclic group, or, R1 and R2 together with the nitrogen atom to which they are directly connected form a 4-12 membered heterocyclic group, said 4-12 membered heterocyclic group is optionally fused to a 5-10 membered heteroaryl group, said group is optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=NR 12 )R 13 、-N=S(O)R 13 R 14 、-N=SR 13 R 14 、-OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(=NR 18 )R 17 、-N(R 18 )-C(=NR 19 )R 17 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 The above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=NR 12 )R 13 、-N=S(O)R 13 R 14 、-N=SR 13 R14 -O-S(O)2R 15 -S(O) r R 15 -O-R 16 -C(O)OR 16 -C(O)SR 16 -S-C(O)R 17 -C(O)R 17 -O-C(O)R 17 -P(O)(R 17 )2 18 -NR 19 -C(=NR 18 )R 17 -N(R 18 )-C(=NR 19 )R 17 -C(O)NR 18 R 19 -N(R 18 )-C(O)R 17 ;

[0061] each R3and each R4is each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=N-R 12 )R 13 , -N=S(O)R 13 R 14 , -N=SR 13 R 14 , -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2 18 -NR 19 -C(=NR 18 )R 17 -N(R 18 )-C(=NR 19 )R17 -C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 , or R3and R4together with the carbon atom to which they are directly attached form a C(=CH2), C(O), C 3-6 cycloalkyl or 4-6 membered heterocyclyl, each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=N-R 12 )R 13 , -N=S(O)R 13 R 14 , -N=SR 13 R 14 , -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(=NR 18 )R 17 , -N(R 18 )-C(=NR 19 )R 17 , -C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ;

[0062] each R5is independently selected from -NR 11a R 11b , C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-8 aryl or 5-8 membered heteroaryl, each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4alkyl, C 2-4 alkenyl, C 1-4 alkylene, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryld 3-6 membered heterocyclyl, 5-8 membered heteroaryl, =0, =S, -SF5, -S(O)(=N-R 12 )R 13 , -N=S(O)R 13 R 14 , -N=SR 13 R 14 , -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(=NR 18 )R 17 , -N(R 18 )-C(=NR 19 )R 17 , -C(O)NR 18 R 19 , and -N(R 18 )-C(O)R 17 , are optionally further independently substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 1-4 alkylene, halosubstituted C 1-4 alkylene, deuterium- substituted C 1-4 alkylene, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =0, =S, -SF5, -S(O)(=N-R 12 )R 13 , -N=S(O)R 13 R 14 , -N=SR 13 R14 、-OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(=NR 18 )R 17 、-N(R 18 )-C(=NR 19 )R 17 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent;

[0063] Each R6 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=NR 12 )R 13 、-N=S(O)R 13 R 14 、-N=SR 13 R 14 、-OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(=NR 18 )R 17 、-N(R18 )-C(=NR 19 )R 17 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ;

[0064] Each R7 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=NR 12 )R 13 、-N=S(O)R 13 R 14 、-N=SR 13 R 14 、-OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(=NR 18 )R 17 、-N(R 18 )-C(=NR 19 )R 17 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ;

[0065] Each R8 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, cyano substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=N-R 12 )R 13 , -N=S(O)R 13 R 14 , -N=SR 13 R 14 , -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(=NR 18 )R 17 , -N(R 18 )-C(=NR 19 )R 17 , -C(O)NR 18 R 19 , and -N(R 18 )-C(O)R 17 ;

[0066] each R 11a and each R 11b is each independently selected from the group consisting of hydrogen, deuterium, hydroxyl, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, mesyl, isopropylsulfonyl, cyclopropylsulfonyl, tosyl, aminosulfonyl, dimethylaminosulfonyl, and C 1-10 alkanoyl, each of the above groups being independently optionally further substituted with one or more selected from the group consisting of deuterium, halogen, hydroxyl, =O, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkylene, halogen-substituted C 1-4 alkylene, deuterium-substituted C 1-4 alkylene, halogen-substituted C 1-4 alkylene, deuterium-substituted C 1-4 alkyl, C 1-4 alkoxy, C3-6 cycloalkyl, C 3-6 cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C 6-8 aryl, C 6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono-C 1-4 alkylamino, di-C 1-4 alkylamino and C 1-4 substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =0, C

[0067] or, R 11a and R 11b form, together with the nitrogen atom to which they are directly attached, a 4-6 membered heterocyclyl group, said 4-6 membered heterocyclyl group being optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =0, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkylene, halogen-substituted C 1-4 alkylene, deuterium-substituted C 1-4 alkylene, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 1-4 alkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C 6-8 aryl, C 6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono-C 1-4 alkylamino, di-C 1-4 alkylamino and C 1-4 substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =0, C

[0068] wherein R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , r, m, n and o are as defined for the compound of formula (I).

[0069] As a preferred aspect, the compound of formula (I), stereoisomer thereof, or pharmaceutically acceptable salt thereof is a compound of formula (IIIa), (IIIb), (IIIc), (IIId), (IIIe) or (IIIf):

[0070] wherein each ring A is independently selected from the following structures:

[0071] each R1is independently selected from the group consisting of C 3-6 C1-8alkyl substituted with 1-3 substituents independently selected from the group consisting of C 1- 4alkyl, each R2is independently selected from the group consisting of hydrogen, C 1-4 C1-8alkyl, C 2-4 C1-8alkenyl, C 2-4 C1-8alkynyl, C 3-6 C3-8cycloalkyl, and 3-6 membered heterocyclyl, or R1and R2together with the nitrogen atom to which they are both attached form a 4-12 membered heterocyclyl, optionally fused to a 5-10 membered heteroaryl, said 4-12 membered heterocyclyl and 5-10 membered heteroaryl optionally substituted with one or more substituents independently selected from the group consisting of deuterium, halogen, cyano, C 1-4 C1-8alkyl, C 2-4 C1-8alkenyl, C 2-4 C1-8alkynyl, C 3-6 C3-8cycloalkyl, 3-6 membered heterocyclyl, =0, =S, -O-R 16 , -C(O)R 17 , and -NR 18 R 19 , said 4-12 membered heterocyclyl and 5-10 membered heteroaryl optionally further substituted with one or more substituents independently selected from the group consisting of deuterium, halogen, cyano, C 1-4 C1-8alkyl, halogen-substituted C 1-4 C1-8alkyl, deuterium-substituted C 1-4 C1-8alkyl, C 2-4 C1-8alkenyl, C 2-4 C1-8alkynyl, C 3-6 C3-8cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =0, =S, -SF5, -S(O)(=N-R 12 )R 13 , -N=S(O)R 13 R 14 , -N=SR 13 R 14 , -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(=NR 18 )R 17 , -N(R 18)-C(=NR 19 )R 17 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent;

[0072] Each R3 and each R4 are independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -OR 16 and -NR 18 R 19 Alternatively, R3 and R4 together with the carbon atom to which they are directly attached form a C(=CH2), C(O), C 3-6 Cycloalkyl or 4-6 membered heterocyclic group, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=NR 12 )R 13 、-N=S(O)R 13 R 14 、-N=SR 13 R 14 、-OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(=NR 18 )R 17 、-N(R 18 )-C(=NR 19 )R 17 、-C(O)NR 18 R19 and -N(R 18 )-C(O)R 17 substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C

[0073] each R5is independently selected from the group consisting of -NR 11a R 11b , C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-8 aryl or 5-8 membered heteroaryl, each of which is independently and optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1- alkyl, C 2-4 alkenyl, C 1-4 alkylene, C 2-4 alkynylene, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, =0, =S, -SF5, -S(O) r R 15 , -O-R 16 and -NR 18 R 19 , each of which is independently and optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynylene, C 1-4 alkylene, halogen-substituted C 1-4 alkylene, deuterium-substituted C 1-4 alkylene, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =0, =S, -SF5, -S(O)(=N-R 12 )R 13 , -N=S(O)R 13 R 14 , -N=SR 13 R 14 , -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R17 )2, -NR 18 R 19 , -C(=NR 18 )R 17 , -N(R 18 )-C(=NR 19 )R 17 , -C(O)NR 18 R 19 , and -N(R 18 )-C(O)R 17 ;

[0074] each R6is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, -SF5, -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(O)NR 18 R 19 , and -N(R 18 )-C(O)R 17 ;

[0075] each R7is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, -SF5, -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ;

[0076] Each R 8a and each R 8b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, cyano substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ;

[0077] Each R 11a and each R 11b are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl, and C 1-10 alkanoyl, the above groups are independently optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =0, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkylene, halogen-substituted C 1-4 alkylene, deuterium-substituted C 1-4 alkylene, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 1-4 alkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C 6-8 aryl, C 6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono-C 1-4 alkylamino, di-C 1-4 alkylamino, and C 1-4 substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =0, C

[0078] or, R 11a and R 11b form, together with the nitrogen atom to which they are directly attached, a 4-6 membered heterocyclyl group, said 4-6 membered heterocyclyl group being optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =0, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkylene, halogen-substituted C 1-4 alkylene, deuterium-substituted C 1-4 alkylene, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 1-4 alkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C 6-8 aryl, C 6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono-C 1-4 alkylamino, di-C 1-4 alkylamino, and C 1-4 substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =0, C

[0079] wherein R 12 , R 13 , R 14 , R 15R 16 R 17 R 18 R 19 r, m and n are as defined for the compound of formula (I).

[0080] As a further preferred aspect, in the compound of formula (I), stereoisomer thereof, or pharmaceutically acceptable salt thereof, the compound of formula (I) is a compound of formula (IVa1), (IVb1), (IVc1), (IVd1), (IVe1), or (IVf1):

[0081] wherein each ring A is independently selected from the following structures:

[0082] each R 1a and each R 1b is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -C(O)R 17 , and -NR 18 R 19 , said groups being optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halo-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(O)NR 18 R 19 , and -N(R 18 )-C(O)R 17 ;

[0083] each R 1c is independently selected from hydrogen, deuterium, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -C(O)R 17 , and -NR 18 R 19 , the aforementioned groups being optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(O)NR 18 R 19 , and -N(R 18 )-C(O)R 17 ;

[0084] each R3and each R4is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -SF5, -O-R 16 , and -NR 18 R 19 , or R3and R4together with the carbon atom to which they are directly attached form a C(=CH2), C(O), C 3-6 cycloalkyl, or 4-6 membered heterocyclyl, the aforementioned groups being independently optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =0, =S, -SF5, -0-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ;

[0085] each R 5a , each R 5b and each R 5c is independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 , -O-R 16 and -NR 18 R 19 , or, R 5a and one of R 5b or R 5c together with the moiety to which they are directly attached form a C 3-4 cycloalkyl or 3-4 membered heterocyclyl, R 5b or R 5c are each as previously defined, or, R 5a and R 5b together with the carbon atom to which they are directly attached form C(=CH2), R 5c are each as previously defined, the aforementioned groups are each independently optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent;

[0086] Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 aryl, 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -S(O) r R 15 、-OR 16 and -NR 18 R 19 , or, R 5d and R 5e Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8aryl, 5-8 membered heteroaryl, =0, =S, -SF5, -0-S(0)2R 15 -S(O) r R 15 -O-R 16 -C(O)OR 16 -C(O)SR 16 -S-C(O)R 17 -C(O)R 17 -O-C(O)R 17 -P(O)(R 17 )2, -NR 18 R 19 -C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ;

[0087] each R 5f and each R 5g is independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 -O-R 16 and -NR 18 R 19 , or R 5f and R 5g , together with the carbon atom they are attached to, form a C 3-4 cycloalkyl, 3-4 membered heterocyclyl or C(=CH2), which are independently optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =0, =S, -SF5, -0-S(0)2R 15 -S(O) r R 15 -O-R 16 -C(O)OR 16 -C(O)SR16 -S-C(O)R 17 -C(O)R 17 -O-C(O)R 17 -P(O)(R 17 )2 18 -NR 19 -C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ;

[0088] each R6is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, -SF5, -O-S(O)2R 15 -S(O) r R 15 -O-R 16 -C(O)OR 16 -C(O)SR 16 -S-C(O)R 17 -C(O)R 17 -O-C(O)R 17 -P(O)(R 17 )2 18 -NR 19 -C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ;

[0089] each R7is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, -SF5, -O-S(O)2R 15 -S(O) r R 15 -O-R 16 -C(O)OR 16-C(O)SR 16 -S-C(O)R 17 -C(O)R 17 -O-C(O)R 17 -P(O)(R 17 )2, -NR 18 R 19 -C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ;

[0090] each R 8a and each R 8b is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, cyano-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, -SF5, -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ;

[0091] each s is independently 0 or 1;

[0092] wherein R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , r and n are as defined for the compound of formula (I).

[0093] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or its pharmaceutically acceptable salts, each R 1a and each R 1b is independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2- 4alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -C(O)R 17 and -NR 18 R 19 , each of which is optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, =S, -O-R 16 and -NR 18 R 19 ;

[0094] each R 1c is independently selected from the group consisting of hydrogen, deuterium, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -C(O)R 17 and -NR 18 R 19 , each of which is optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, =S, -O-R 16 and -NR 18 R 19 ;

[0095] each R 5a and R 5b , together with the carbon atom to which they are directly attached, form a C 3-4 cycloalkyl, each of which is independently optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, =0, =S, -SF5, -O-R 16 , -C(O)OR 16 , and -NR 18 R 19 substituted;

[0096] each R 5c is independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , and -NR 18 R 19 ;

[0097] each R 5d and each R 5e is independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryl and 3-6 membered heterocyclyl, -S(O) r R 15 , -O-R 16 , and -NR 18 R 19 , or, R 5d and R 5e together with the carbon atom to which they are directly attached form a C 3-4 cycloalkyl, 3-4 membered heterocyclyl, or C(=CH2), each of which is independently optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , and -NR 18 R 19 ;

[0098] each R 5f and each R 5g is independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C6-8 aryl and 3-6 membered heterocyclyl, -S(O) r R 15 , -O-R 16 , and -NR 18 R 19 , or R 5f and R 5g together with the carbon atom to which they are directly attached form a C 3-4 cycloalkyl, 3-4 membered heterocyclyl, or C(=CH2), each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -C(O)OR 16 , -O-C(O)R 17 , and -NR 18 R 19 ;

[0099] wherein R 15 , R 16 , R 17 , R 18 , R 19 and r are as defined for the compound of formula (I).

[0100] As a still further preferred embodiment, in the compound of formula (I), stereoisomer or pharmaceutically acceptable salt thereof, each R 1a and each R 1b is each independently selected from hydrogen, deuterium, halogen, cyano, and C 1-4 alkyl, each of which is optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, and deuterium- substituted C 1-4 alkyl;

[0101] each R 1c is each independently selected from hydrogen, deuterium, cyano, C 1-4 alkyl, and -C(O)R 17 , each of which is optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1- 4alkyl, =O, =S, and -O-R 16 ;

[0102] each R 5a and R 5bTogether with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl and deuterium substituted C 1-4 substituted by an alkyl substituent;

[0103] Each R 5c are each independently selected from hydrogen, deuterium, halogen, cyano and C 1-4 alkyl;

[0104] Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl and -SR 15 , or, R 5d and R 5e Together with the carbon atom to which it is directly attached, it forms C(=CH2), and the above groups are independently optionally further substituted with one or more radicals selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl and deuterium substituted C 1- 4 alkyl substituents;

[0105] Each R 5f and each R 5g are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 6-8 Aryl and C 6-8 Aryl and 3-6 membered heterocyclic group, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, -OR 16 、-C(O)OR 16 、-OC(O)R 17 and -OC(O)R 17 substituted by a substituent;

[0106] Among them, R 15 、R 16 and R 17 As defined for the compounds of formula (I).

[0107] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R 1a and each R 1bare each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano and methyl, the above groups being optionally further substituted by one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl;

[0108] Each R 1c are each independently selected from hydrogen, deuterium, cyano, methyl, ethyl, n-propyl, isopropyl and -C(O)R 17a , the above groups are optionally further substituted by one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, =O, =S and hydroxy;

[0109] Each R 5a and R 5b Together with the carbon atom to which it is directly attached, it forms a cyclopropyl or cyclobutyl group, which groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl;

[0110] Each R 5c are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl and isopropyl;

[0111] Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl and -S-CH3, or, R 5d and R 5e Together with the carbon atom to which it is directly attached, they form C(=CH2), the above groups being independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl;

[0112] Each R 5f and each R 5g are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, phenyl and The above groups are independently optionally further substituted with one or more selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl, trideuterium methyl, -OR 16a 、-C(O)OR 16a and -OC(O)R 17a substituted by a substituent;

[0113] R 16a is selected from the group consisting of pyrimidinyl, pyridinyl, phenyl, amino and dimethylamino;

[0114] R 17a Selected from cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, amino, dimethylamino,

[0115] As a still further preferred embodiment, in the compound of formula (I), its stereoisomers or its pharmaceutically acceptable salts, each R 1a and each R 1b is independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2- 4alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -C(O)R 17 and -NR 18 R 19 , said groups being optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, =S, -O-R 16 and -NR 18 R 19 ;

[0116] each R 1c is independently selected from the group consisting of hydrogen, deuterium, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -C(O)R 17 and -NR 18 R 19 , said groups being optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, =S, -O-R 16 and -NR 18 R 19 ;

[0117] each R 5a and R 5b form together with the carbon atom to which they are directly attached a C(=CH2), said group being independently optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4alkyl, halo-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, =0, =S, -SF5, -O-R 16 , -C(O)OR 16 , and -NR 18 R 19 substituted;

[0118] each R 5c is independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , and -NR 18 R 19 ;

[0119] each R 5d and each R 5e is independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryl and 3-6 membered heterocyclyl, -S(O) r R 15 , -O-R 16 , and -NR 18 R 19 , or, R 5d and R 5e together with the carbon atom to which they are directly attached form a 3-4 membered heterocyclyl or C(=CH2), each of which is independently optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halo-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , and -NR 18 R 19 ;

[0120] each R 5f and each R 5g is independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C6-8 aryl and 3-6 membered heterocyclyl, -S(O) r R 15 , -O-R 16 , and -NR 18 R 19 , or R 5f and R 5g together with the carbon atom to which they are directly attached form a C 3-4 cycloalkyl, 3-4 membered heterocyclyl, or C(=CH2), each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -C(O)OR 16 , -O-C(O)R 17 , and -NR 18 R 19 ;

[0121] wherein R 15 , R 16 , R 17 , R 18 , R 19 , and r are as defined for the compound of formula (I).

[0122] As a still further preferred embodiment, in the compound of formula (I), stereoisomer thereof, or pharmaceutically acceptable salt thereof, each R 1a and each R 1b is each independently selected from hydrogen, deuterium, halogen, cyano, and C 1-4 alkyl, each of which is optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, and deuterium- substituted C 1-4 alkyl;

[0123] each R 1c is each independently selected from hydrogen, deuterium, cyano, C 1-4 alkyl, and -C(O)R 17 , each of which is optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1- 4alkyl, =O, =S, and -O-R 16 ;

[0124] each R 5a and R 5btogether with the carbon atom to which they are directly attached, form C(=CH2), and the aforementioned groups are independently optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C1-C6-alkyl, 1-4 halo-substituted C1-C6-alkyl, 1-4 deuterium-substituted C1-C6-alkyl, 1-4 substituted by substituents from the group consisting of deuterium, halogen, cyano, C1-C6-alkyl,

[0125] each R 5c is independently selected from the group consisting of hydrogen, deuterium, halogen, cyano and C1-C6-alkyl, 1-4 C1-C6-alkyl;

[0126] each R 5d and each R 5e is independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C1-C6-alkyl, 1-4 C1-C6-alkyl and -SR 15 , or, R 5d and R 5e together with the carbon atom to which they are directly attached, form C(=CH2), and the aforementioned groups are independently optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C1-C6-alkyl, 1-4 halo-substituted C1-C6-alkyl, 1-4 deuterium-substituted C1-C6-alkyl, 1- substituted by substituents from the group consisting of deuterium, halogen, cyano, C1-C6-alkyl,

[0127] each R 5f and each R 5g is independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C1-C6-alkyl, 1-4 C1-C6-alkyl, C 6-8 aryl and C 6-8 aryl and 3- to 6-membered heterocyclyl, which are independently optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C1-C6-alkyl, 1-4 halo-substituted C1-C6-alkyl, 1-4 deuterium-substituted C1-C6-alkyl, 1-4 C1-C6-alkyl, -O-R 16 , -C(O)OR 16 , -O-C(O)R 17 and -O-C(O)R 17 substituted by substituents from the group consisting of deuterium, halogen, cyano, C1-C6-alkyl,

[0128] wherein R 15 , R 16 and R 17 are as defined for the compound of formula (I).

[0129] As a still further preferred option, in the compound of formula (I), in the stereoisomer thereof or in the pharmaceutically acceptable salt thereof, each R 1a and each R 1bare each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano and methyl, the above groups being optionally further substituted by one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl;

[0130] Each R 1c are each independently selected from hydrogen, deuterium, cyano, methyl, ethyl, n-propyl, isopropyl and -C(O)R 17a , the above groups are optionally further substituted by one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, =O, =S and hydroxy;

[0131] Each R 5a and R 5b Together with the carbon atom to which it is directly attached, they form C(=CH2), the above groups being independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl;

[0132] Each R 5c are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl and isopropyl;

[0133] Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl and -S-CH3, or, R 5d and R 5e Together with the carbon atom to which it is directly attached, they form C(=CH2), the above groups being independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl;

[0134] Each R 5f and each R 5g are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, phenyl and The above groups are independently optionally further substituted with one or more selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl, trideuterium methyl, -OR 16a 、-C(O)OR 16a and -OC(O)R 17a substituted by a substituent;

[0135] R 16a is selected from the group consisting of pyrimidinyl, pyridinyl, phenyl, amino and dimethylamino;

[0136] R 17a Selected from cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, amino, dimethylamino,

[0137] As a still further preferred embodiment, in the compound of formula (I), its stereoisomers or its pharmaceutically acceptable salts, each R 1a and each R 1b is independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2- 4alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -C(O)R 17 and -NR 18 R 19 , said groups being optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, =0, =S, -O-R 16 and -NR 18 R 19 ;

[0138] each R 1c is independently selected from the group consisting of hydrogen, deuterium, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -C(O)R 17 and -NR 18 R 19 , said groups being optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, =0, =S, -O-R 16 and -NR 18 R 19 ;

[0139] each R 5a and R 5c , together with the moiety they are directly attached to, form a C 3-4 cycloalkyl, said group being independently optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, cyano, C1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3- to 6-membered heterocyclyl, =0, =S, -SF5, -O-R 16 , -C(O)OR 16 , and -NR 18 R 19 substituted;

[0140] each R 5b is independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 3-6 cycloalkyl, 3- to 6-membered heterocyclyl, -O-R 16 , and -NR 18 R 19 ;

[0141] each R 5d and R 5e is independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3- to 6-membered heterocyclyl, C 6-8 aryl, C 6-8 aryl and 3- to 6-membered heterocyclyl, -S(O) r R 15 , -O-R 16 , and -NR 18 R 19 , or R 5d and R 5e together with the carbon atom directly connecting the same form a C 3-4 cycloalkyl, 3- to 4-membered heterocyclyl, or C(=CH2), each of which is independently optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3- to 6-membered heterocyclyl, -O-R 16 , and -NR 18 R 19 substituted;

[0142] each R 5f and R 5g is independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3- to 6-membered heterocyclyl, C6-8 aryl, C 6-8 aryl and 3-6 membered heterocyclyl, -S(O) r R 15 , -O-R 16 and -NR 18 R 19 , or, R 5f and R 5g together with the carbon atom to which they are directly attached form a C 3-4 cycloalkyl, 3-4 membered heterocyclyl or C(=CH2), each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -C(O)OR 16 , -O-C(O)R 17 and -NR 18 R 19 ;

[0143] wherein R 15 , R 16 , R 17 , R 18 , R 19 and r are as defined for the compound of formula (I).

[0144] As a still further preferred option, in the compound of formula (I), in the stereoisomer thereof or in the pharmaceutically acceptable salt thereof, each R 1a and each R 1b is each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano and C 1-4 alkyl, each of which is optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl and deuterium- substituted C 1-4 alkyl;

[0145] each R 1c is each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl and -C(O)R 17 , each of which is optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, =O, =S and -O-R 16 ;

[0146] each R5a and R 5c together with the moiety to which they are directly attached form a C 3-4 cycloalkyl, each of the above groups being independently optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl and deuterium- substituted C 1-4 alkyl;

[0147] each R 5b is independently selected from the group consisting of hydrogen, deuterium, halogen, cyano and C 1-4 alkyl;

[0148] each R 5d and R 5e are each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl and -SR 15 , or, R 5d and R 5e together with the carbon atom to which they are directly attached form C(=CH2), each of the above groups being independently optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl and deuterium- substituted C 1-4 alkyl;

[0149] each R 5f and R 5g are each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 6-8 aryl and C 6- 8-6 membered heterocyclyl, each of the above groups being independently optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, -O-R 16 , -C(O)OR 16 , -O-C(O)R 17 and -O-C(O)R 17 ;

[0150] wherein R 15 , R 16 and R 17 are as defined for the compound of formula (I).

[0151] As a still further preferred option, in the compound of formula (I), in the stereoisomer thereof or in the pharmaceutically acceptable salt thereof, each R 1a and each R 1bare each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano and methyl, the above groups being optionally further substituted by one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl;

[0152] Each R 1c are each independently selected from hydrogen, deuterium, cyano, methyl, ethyl, n-propyl, isopropyl and -C(O)R 17a , the above groups are optionally further substituted by one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, =O, =S and hydroxy;

[0153] Each R 5a and R 5c Together with the moiety to which it is directly attached, it forms a cyclopropyl or cyclobutyl group, which groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl;

[0154] Each R 5b are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl and isopropyl;

[0155] Each R 5d and R 5e Each is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl and -S-CH3, or, R 5d and R 5e Together with the carbon atom to which it is directly attached, they form C(=CH2), the above groups being independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl;

[0156] Each R 5f and each R 5g are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, phenyl and The above groups are independently optionally further substituted with one or more selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl, trideuterium methyl, -OR 16a 、-C(O)OR 16a and -OC(O)R 17a substituted by a substituent;

[0157] R 16a is selected from the group consisting of pyrimidinyl, pyridinyl, phenyl, amino and dimethylamino;

[0158] R 17a Selected from cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, amino, dimethylamino,

[0159] As a still further preferred embodiment, in the compounds of formula (I), its stereoisomers or its pharmaceutically acceptable salts, in the compounds of formula (IVa1), R 1a and R 1b are each independently selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -C(O)R 17 and -NR 18 R 19 , said groups being optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 and -NR 18 R 19 ;

[0160] R 1c is selected from the group consisting of hydrogen, deuterium, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -NR 18 R 19 and -C(O)R 17 , said groups being optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C 2- alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, =S, -SF5, -O-R 16 and -NR 18 R 19 ;

[0161] R 5a , R 5b and R 5c are each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF5, -O-R 16 and -NR 18 R 19 , the aforementioned groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -NR 18 R 19 ;

[0162] R 5d and R 5e are each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF5, -O-R 16 and -NR 18 R 19 , or R 5d and R 5e together with the carbon atom directly connecting the same form a C 3-4 cycloalkyl, 3-4 membered heterocyclyl or C(=CH2), the aforementioned groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -NR 18 R 19 and -C(O)OR 16 ;

[0163] R 5f and R 5g are each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF5, -O-R 16 and -NR 18 R 19 , or, R 5f and R 5g together with the carbon atom to which they are directly attached form a C 3-4 cycloalkyl, 3-4 membered heterocyclyl or C(=CH2), each of the above groups being independently optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -C(O)OR 16 , -O-C(O)R 17 and -NR 18 R 19 ;

[0164] wherein R 16 , R 17 , R 18 and R 19 are as defined for the compound of formula (I).

[0165] As a still further preferred option, in the compound of formula (I), in the compound of formula (IVa1), R 1a and R 1b are each independently selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, C 3-6 cycloalkyl and 3-6 membered heterocyclyl, each of the above groups being optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 and -NR 18 R 19 ;

[0166] R 1cSelected from hydrogen, deuterium, cyano, C 1-4 Alkyl and -C(O)R 17 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, =O, =S and -OR 16 substituted by a substituent;

[0167] R 5a 、R 5b and R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl and C 3-6 Cycloalkyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 substituted by a substituent;

[0168] R 5d and R 5e are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl and 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -OR 16 and -NR 18 R 19 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -C(O)OR 16 substituted by a substituent;

[0169] R 5f and R 5g are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl and 3-6 membered heterocyclic group, -OR16 and -NR 18 R 19 , or, R 5f and R 5g together with the carbon atom to which they are directly attached form a C 3-4 cycloalkyl, 3-4 membered heterocyclyl, or C(=CH2), each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -C(O)OR 16 , -O-C(O)R 17 , and -NR 18 R 19 ;

[0170] wherein R 16 , R 17 , R 18 , and R 19 are as defined for the compound of formula (I).

[0171] As a still further preferred embodiment, in the compound of formula (IVa1), R 1a and R 1b are each independently selected from deuterium, fluorine, and chlorine.

[0172] R 1c is selected from hydrogen, deuterium, cyano, methyl, ethyl, n-propyl, i-propyl, and -C(O)R 17a , each of which is optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, i-propyl, trifluoromethyl, trideuteromethyl, =O, =S, and hydroxyl;

[0173] R 5a , R 5b , and R 5c are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, C 1-4 alkyl, and C 3-6 cycloalkyl, each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, methyl, ethyl, n-propyl, i-propyl, trifluoromethyl, trideuteromethyl, hydroxyl, and amino;

[0174] R 5d and R 5e are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, i-propyl, -S-CH3, phenyl, and The above groups are independently optionally further substituted with one or more selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuterium, -OR 16a and -C(O)OR 16a substituted by a substituent;

[0175] R 5f and R 5g are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, -S-CH3, phenyl and Or, R 5f and R 5g The carbon atom to which it is directly attached forms a cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl or C(=CH2), which groups are independently optionally further substituted by one or more groups selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteromethyl, -OR 16a 、-C(O)OR 16a and -OC(O)R 17a substituted by a substituent;

[0176] R 16a is selected from the group consisting of pyrimidinyl, pyridinyl, phenyl, amino and dimethylamino;

[0177] R 17a Selected from cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, amino, dimethylamino,

[0178] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, in the compound of formula (IVa1), R 1a and R 1b are each independently hydrogen;

[0179] R 1c -C(O)R 17 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1- 4 alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -OR 16 and -NR 18 R 19 substituted by a substituent;

[0180] R 5a R 5b R 5c each independently is selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryloxy and 5-8 membered heteroaryl, -0-R 16 and -NR 18 R 19 , each of which is independently optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -0-R 16 and -NR 18 R 19 ;

[0181] R 5d R 5e each independently is selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryloxy and 5-8 membered heteroaryl, -SF5, -S(O) r R 15 , -0-R 16 and -NR 18 R 19 , or R 5d and R 5e together with the carbon atom to which they are directly attached form a C 3-4 cycloalkyl, 3-4 membered heterocyclyl or C(=CH2), each of which is independently optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8aryl, 5-8 membered heteroaryl, =0, =S, -SF5, -0-S(0)2R 15 , -S(O) r R 15 , -0-R 16 , -C(0)OR 16 , -C(0)SR 16 , -S-C(0)R 17 , -C(0)R 17 , -0-C(0)R 17 , -P(0)(R 17 )2, -NR 18 R 19 , -C(0)NR 18 R 19 and -N(R 18 )-C(0)R 17 ;

[0182] R 5f and R 5g are each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 , -0-R 16 , and -NR 18 R 19 , or, R 5f and R 5g together with the carbon atom to which they are directly attached form a C 3-4 cycloalkyl, 3-4 membered heterocyclyl or C(=CH2), each of which is independently optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =0, =S, -SF5, -0-S(0)2R 15 , -S(O) r R 15 , -0-R 16 , -C(0)OR 16 , -C(0)SR16 -S-C(O)R 17 -C(O)R 17 -O-C(O)R 17 -P(O)(R 17 )2 18 -NR 19 -C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ;

[0183] wherein R 15 , R 16 , R 17 , R 18 , R 19 and r are as defined for the compound of formula (I).

[0184] As a still further preferred embodiment, in the compound of formula (IVa1), R 1a and R 1b are each independently hydrogen;

[0185] R 1c is -C(O)R 17 , which is optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1- 4alkyl, halosubstituted C 1-4 2alkyl, deuterium- substituted C 1-4 1-3alkyl, =0, =S, and -O-R 16 ;

[0186] R 5a , R 5b and R 5c are each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 1-3alkyl, and C 3-6 3-6cycloalkyl, which are independently optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 1-3alkyl, halosubstituted C 1-4 1-3alkyl, deuterium- substituted C 1-4 1-3alkyl, C 3-6 3-6cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , and -NR 18 R 19 ;

[0187] R 5d and R 5e are each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 1-3alkyl, and C2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF5, -O-R 16 and -NR 18 R 19 , each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , and -C(O)OR 16 ;

[0188] R 5f and R 5g each independently is selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryl and 3-6 membered heterocyclyl, -O-R 16 , and -NR 18 R 19 , or R 5f and R 5g together with the carbon atom directly connecting them form a C 3-4 cycloalkyl, 3-4 membered heterocyclyl, or C(=CH2), each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -C(O)OR 16 , -O-C(O)R 17 , and -NR 18 R 19 ;

[0189] wherein R 16 , R 17 , R 18 and R 19 are as defined for the compound of formula (I).

[0190] As a still further preferred option, in the compound of formula (I), its stereoisomers or its pharmaceutically acceptable salts, in the compound of formula (IVa1), R 1a and R1b each independently hydrogen;

[0191] R 1c -C(O)R 17a , the aforementioned groups are optionally further substituted with one or more substituents selected from the group consisting of deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, i-propyl, trifluoromethyl, trideuteromethyl, =0, =S, and hydroxyl;

[0192] R 5a , R 5b , and R 5c each independently is selected from the group consisting of hydrogen, deuterium, fluorine, chlorine, cyano, C 1-4 alkyl, and C 3-6 cycloalkyl, the aforementioned groups independently are optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, cyano, methyl, ethyl, n-propyl, i-propyl, trifluoromethyl, trideuteromethyl, hydroxyl, and amino;

[0193] R 5d , and R 5e each independently is selected from the group consisting of hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, i-propyl, -S-CH3, phenyl, and the aforementioned groups independently are optionally further substituted with one or more substituents selected from the group consisting of deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, i-propyl, trifluoromethyl, trideuteromethyl, -O-R 16a , and -C(O)OR 16a ;

[0194] R 5f , and R 5g each independently is selected from the group consisting of hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, i-propyl, -S-CH3, phenyl, and or, R 5f , and R 5g together with the carbon atom they are directly attached to form a cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl, or C(=CH2), the aforementioned groups independently are optionally further substituted with one or more substituents selected from the group consisting of deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, i-propyl, trifluoromethyl, trideuteromethyl, -O-R 16a , -C(O)OR 16a , and -O-C(O)R 17a ;

[0195] R 16a is selected from the group consisting of pyrimidinyl, pyridinyl, phenyl, amino, and dimethylamino;

[0196] R 17aselected from cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl, amino, dimethylamino,

[0197] As a still further preferred embodiment, in the compound of formula (I), its stereoisomers or its pharmaceutically acceptable salts, in the compound of formula (IVa1), R 1a and R 1b are each independently hydrogen; R 1c is hydrogen;

[0198] R 5a , R 5b and R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -O-R 16 and -NR 18 R 19 , the aforementioned groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 and -NR 18 R 19 ;

[0199] R 5d and R 5e are each independently selected from hydrogen, C 1-4 alkyl, C 6-8 aryl, C 6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl and -S(O) r R 15 , the aforementioned groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8aryl, 5-8 membered heteroaryl, =0, =S, -SF5, -0-S(0)2R 15 , -S(O) r R 15 , -0-R 16 , -C(0)OR 16 , -C(0)SR 16 , -S-C(0)R 17 , -C(0)R 17 , -0-C(0)R 17 , -P(0)(R 17 )2, -NR 18 R 19 , -C(0)NR 18 R 19 , and -N(R 18 )-C(0)R 17 ;

[0200] R 5f and R 5g are each independently selected from hydrogen, C 1-4 alkyl, C 6-8 aryl, C 6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, and -S(O) r R 15 , the aforementioned groups are independently optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halo-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =0, =S, -SF5, -0-S(0)2R 15 , -S(O) r R 15 , -0-R 16 , -C(0)OR 16 , -C(0)SR 16 , -S-C(0)R 17 , -C(0)R 17 , -0-C(0)R 17 , -P(0)(R 17 )2, -NR 18 R 19 , -C(0)NR 18 R 19 , and -N(R 18 )-C(0)R 17substituents of R 5d and R 5f are not simultaneously H;

[0201] wherein R 15 , R 16 , R 17 , R 18 , R 19 and r are as defined for the compound of formula (I).

[0202] As a still further preferred embodiment, in the compound of formula (IVa1), R 1a and R 1b are each independently hydrogen; R 1c is hydrogen;

[0203] R 5a , R 5b and R 5c are each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl and C 3-6 cycloalkyl, each of which is independently optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3- to 6-membered heterocyclyl, -O-R 16 and -NR 18 R 19 is substituted;

[0204] R 5d and R 5e are each independently selected from the group consisting of hydrogen, C 6-8 aryl and 3- to 6-membered heterocyclyl, each of which is independently optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3- to 6-membered heterocyclyl, -O-R 16 and -C(O)OR 16 is substituted;

[0205] R 5f and R 5g are each independently selected from the group consisting of hydrogen, C 1-4 alkyl, C 6-8 aryl, C 6-8 aryl and 3- to 6-membered heterocyclyl, each of which is independently optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, cyano, C1-4 alkyl, halo-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -C(O)OR 16 , -O-C(O)R 17 and -NR 18 R 19 substituted; provided that R 5d and R 5f are not simultaneously H; wherein R 16 , R 17 , R 18 and R 19 are as defined for the compound of formula (I).

[0206] As a still further preferred option, in the compound of formula (I), its stereoisomers or its pharmaceutically acceptable salts, in the compound of formula (IVa1), R 1a and R 1b are each independently hydrogen; R 1c is hydrogen;

[0207] R 5a , R 5b and R 5c are each independently selected from hydrogen, deuterium, fluoro, chloro, cyano, methyl, ethyl, n-propyl, i-propyl, cyclopropyl and cyclobutyl, the aforementioned groups being independently and optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, methyl, ethyl, n-propyl, i-propyl, trifluoromethyl, trideuteromethyl, hydroxyl and amino;

[0208] R 5d and R 5e are each independently selected from hydrogen or -S-CH3;

[0209] R 5f and R 5g are each independently selected from hydrogen, -CH2-O-C(O)R 17a and the aforementioned groups being independently and optionally further substituted by one or more substituents selected from deuterium, fluoro, chloro, cyano, methyl, ethyl, n-propyl, i-propyl, trifluoromethyl and trideuteromethyl; provided that R 5d and R 5f are not simultaneously H;

[0210] R 17a is selected from cyclopropyl, cyclobutyl, oxacyclopropyl, oxacyclobutyl, azacyclopropyl, azacyclobutyl, amino, dimethylamino,

[0211] As a still further preferred embodiment, in the compound of formula (I), its stereoisomers or its pharmaceutically acceptable salts, in the compound of formula (IVb1), formula (IVc1), formula (IVd1), formula (IVe1) or formula (IVf1), each R 1a and each R 1b is each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -C(O)R 17 and -NR 18 R 19 , said groups are optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ;

[0212] each R 1c is each independently selected from the group consisting of hydrogen, deuterium, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -NR 18 R 19 and -C(O)R 17the aforementioned groups are optionally further substituted by one or more substituents independently selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3- to 6-membered heterocyclyl, C 6-8 aryl, 5- to 8-membered heteroaryl, =0, =S, -SF5, -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ;

[0213] each R 5a , each R 5b and each R 5c are each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3- to 6-membered heterocyclyl, C 6-8 aryl, C 6-8 aryl and 3- to 6-membered heterocyclyl, 5- to 8-membered heteroaryl, -SF5, -S(O) r R 15 , -O-R 16 and -NR 18 R 19 , the aforementioned groups being independently optionally further substituted by one or more substituents independently selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1- 4alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3- to 6-membered heterocyclyl, C 6-8 aryl, 5- to 8-membered heteroaryl, =0, =S, -SF5, -O-S(O)2R15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent;

[0214] Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 、-OR 16 and -NR 18 R 19 , or, R 5d and R 5e Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17-C(O)R 17 -O-C(O)R 17 -P(O)(R 17 )2 18 -NR 19 R 18 -C(O)NR 19 R 18 -C(O)R 17 ;

[0215] each R 5f and each R 5g is independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 , -O-R 16 , and -NR 18 R 19 , or, R 5f and R 5g together with the carbon atom they are attached to form a C 3-4 cycloalkyl, 3-4 membered heterocyclyl, or C(=CH2), which is independently optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(O)NR 18 R 19and -N(R 18 )-C(O)R 17 substituted by a substituent;

[0216] Among them, R 15 、R 16 、R 17 、R 18 、R 19 and r are as defined for the compound of formula (I).

[0217] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, in the compound of formula (IVb1), formula (IVc1), formula (IVd1), formula (IVe1) or formula (IVf1), each R 1a and each R 1b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic groups, the above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 substituted by a substituent;

[0218] Each R 1c are each independently selected from hydrogen, deuterium, cyano, C 1-4 Alkyl and -C(O)R 17 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1- 4 alkyl, =O, =S and -OR 16 substituted by a substituent;

[0219] Each R 5a , each R 5b and each R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl and C 3-6 Cycloalkyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1- 4 alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 and -NR 18 R 19 substituted;

[0220] each R 5d and each R 5e is each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 , -O-R 16 and -NR 18 R 19 , the aforementioned groups are independently optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 and -C(O)OR 16 ;

[0221] each R 5f and each R 5g is each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryl and 3-6 membered heterocyclyl, -S(O) r R 15 , -O-R 16 and -NR 18 R 19 , or, R 5f and R 5g together with the carbon atom to which they are directly attached form a C 3-4 cycloalkyl, 3-4 membered heterocyclyl or C(=CH2), the aforementioned groups are independently optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -C(O)OR 16 , -O-C(O)R 17 and -NR18 R 19 substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, methyl, ethyl, n-propyl, i-propyl, trifluoromethyl, trideuteromethyl, =0, =S, and hydroxy;

[0222] wherein R 15 , R 16 , R 17 , R 18 , R 19 and r are defined as for the compound of formula (I).

[0223] As a still further preferred option, in the compound of formula (I), in the compound of formula (IVb1), formula (IVc1), formula (IVd1), formula (IVe1), or formula (IVf1), each R 1a and each R 1b is each independently selected from the group consisting of hydrogen, deuterium, fluorine, and chlorine;

[0224] each R 1c is each independently selected from the group consisting of hydrogen, deuterium, cyano, methyl, ethyl, n-propyl, i-propyl, and -C(O)R 17a , which is optionally further substituted by one or more substituents selected from the group consisting of deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, i-propyl, trifluoromethyl, trideuteromethyl, =0, =S, and hydroxy;

[0225] each R 5a , each R 5b , and each R 5c is each independently selected from the group consisting of hydrogen, deuterium, fluorine, chlorine, cyano, C 1-4 alkyl, and C 3-6 cycloalkyl, which is independently optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, methyl, ethyl, n-propyl, i-propyl, trifluoromethyl, trideuteromethyl, hydroxy, and amino;

[0226] each R 5d , and each R 5e is each independently selected from the group consisting of hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, i-propyl, -S-CH3, phenyl, and which is independently optionally further substituted by one or more substituents selected from the group consisting of deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, i-propyl, trifluoromethyl, trideuteromethyl, -O-R 16a , and -C(O)OR 16a ;

[0227] each R 5f , and each R 5g is each independently selected from the group consisting of hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, i-propyl, -S-CH3, phenyl, and or R 5fand R 5g with the carbon atom to which it is directly attached forming a cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl, or C(=CH2), each of which is independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, i-propyl, trifluoromethyl, trideuteromethyl, -O-R 16a , -C(O)OR 16a , and -O-C(O)R 17a ;

[0228] R 16a is selected from pyrimidinyl, pyridinyl, phenyl, amino, and dimethylamino;

[0229] R 17a is selected from cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl, amino, dimethylamino,

[0230] As a further preferred aspect, the compound of formula (I), stereoisomer thereof, or pharmaceutically acceptable salt thereof, is a compound of formula (IVa2), (IVb2), (IVc2), (IVd2), (IVe2), or (IVf2):

[0231] wherein each ring A is independently selected from the following structures:

[0232] each R 1a , each R 1b , and each R 1c is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -C(O)R 17 , and -NR 18 R 19 , each of which is optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -O-S(O)2R 15、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent;

[0233] Each R3 and each R4 are independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -OR 16 and -NR 18 R 19 Alternatively, R3 and R4 together with the carbon atom to which they are directly attached form a C(=CH2), C(O), C 3-6 Cycloalkyl or 4-6 membered heterocyclic group, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R18 )-C(O)R 17 substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C

[0234] each R 5a , each R 5b and each R 5c is independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 , -O-R 16 and -NR 18 R 19 , or, R 5a and R 5b or R 5c one of them, together with the moiety to which they are directly attached, form a C 3-4 cycloalkyl or 3-4 membered heterocyclyl, R 5b or R 5c is as defined before, or, R 5a and R 5b together with the carbon atom to which they are directly attached form C(=CH2), R 5c is as defined before, and the above mentioned groups are independently optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(O)NR 18 R19 and -N(R 18 )-C(O)R 17 substituted by one or more substituents independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C

[0235] each R 5d and each R 5e is each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 , -O-R 16 , and -NR 18 R 19 , or, R 5d and R 5e together with the carbon atom to which they are directly attached form a C 3-4 cycloalkyl, 3-4 membered heterocyclyl, or C(=CH2), each of which is independently optionally further substituted by one or more substituents independently selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by one or more substituents independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C

[0236] each R 5f and each R 5gare each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 、-OR 16 and -NR 18 R 19 , or, R 5f and R 5g Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent;

[0237] Each R6 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ;

[0238] Each R7 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ;

[0239] Each R 8a and each R 8b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, cyano substituted C 1-4 Alkyl, C 2-4 Alkenyl, C2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, -SF5, -0-S(0)2R 15 , -S(O) r R 15 , -0-R 16 , -C(0)OR 16 , -C(0)SR 16 , -S-C(0)R 17 , -C(0)R 17 , -0-C(0)R 17 , -P(0)(R 17 )2, -NR 18 R 19 , -C(0)NR 18 R 19 and -N(R 18 )-C(0)R 17 ;

[0240] each s is independently 0 or 1 ;

[0241] wherein, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , r and n are as defined for the compound of formula (I).

[0242] As a still further preferred aspect, in the compound of formula (I), stereoisomer thereof, or pharmaceutically acceptable salt thereof, each R 1a , each R 1b and each R 1c is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -0-R 16 and -NR 18 R 19 , optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, =0, -0-R 16 and -NR 18 R 19 ;

[0243] Among them, R 16 、R 18 and R 19 As defined for the compounds of formula (I).

[0244] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R 1a , each R 1b and each R 1c Each is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxyl, amino and dimethylamino, and the above groups are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxyl, amino and dimethylamino.

[0245] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R 1a , each R 1b and each R 1c As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R 5a , each R 5b and each R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl and 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 , or, R 5a With R 5b or R 5c One of them together with its directly connected part forms a C 3-4 Cycloalkyl or 3-4 membered heterocyclic group, R 5b or R 5c Another definition is as above, or, R 5a With R 5b Together with the carbon atom to which it is directly attached, it forms C(=CH2), R 5c As defined above, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 and -NR 18 R 19 substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C

[0246] each R 5d and each R 5e is each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryl and 3-6 membered heterocyclyl, -O-R 16 and -NR 18 R 19 , or R 5d and R 5e together with the carbon atom they are attached to form a C 3-4 cycloalkyl, 3-4 membered heterocyclyl or C(=CH2), which are independently optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 and -NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C

[0247] each R 5f and each R 5g is each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryl and 3-6 membered heterocyclyl, -O-R 16 and -NR 18 R 19 , or R 5f and R 5g together with the carbon atom they are attached to form a C 3-4 cycloalkyl, 3-4 membered heterocyclyl or C(=CH2), which are independently optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R16 and -NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted with one or more substituents selected from the group consisting of deuterium, fluoro, chloro, cyano, methyl, ethyl, n-propyl, i-propyl, trifluoromethyl, trideuteromethyl, cyclopropyl, cyclobutyl, oxacyclopropyl, oxacyclobutyl, azacyclopropyl, azacyclobutyl, hydroxy, amino, and dimethylamino;

[0248] wherein R 16 , R 17 , R 18 , and R 19 are as defined for the compound of formula (I).

[0249] As a still further preferred embodiment, in the compound of formula (I), stereoisomer or pharmaceutically acceptable salt thereof, each R 5a , each R 5b , and each R 5c is independently selected from the group consisting of hydrogen, deuterium, fluoro, chloro, cyano, methyl, ethyl, n-propyl, i-propyl, cyclopropyl, cyclobutyl, oxacyclopropyl, oxacyclobutyl, azacyclopropyl, azacyclobutyl, phenyl, hydroxy, amino, and dimethylamino, or R 5a and R 5b or R 5c , together with the moiety to which they are directly attached, form a cyclopropyl, cyclobutyl, oxacyclopropyl, oxacyclobutyl, azacyclopropyl, or azacyclobutyl, R 5b or R 5c , is as previously defined, or R 5a and R 5b , together with the carbon atom to which they are directly attached, form C(=CH2), R 5c is as previously defined, and the foregoing groups are each independently optionally further substituted with one or more substituents selected from the group consisting of deuterium, fluoro, chloro, cyano, methyl, ethyl, n-propyl, i-propyl, trifluoromethyl, trideuteromethyl, cyclopropyl, cyclobutyl, oxacyclopropyl, oxacyclobutyl, azacyclopropyl, azacyclobutyl, hydroxy, amino, and dimethylamino;

[0250] each R 5d and each R 5e is independently selected from the group consisting of hydrogen, deuterium, fluoro, chloro, cyano, methyl, ethyl, n-propyl, i-propyl, cyclopropyl, cyclobutyl, oxacyclopropyl, oxacyclobutyl, azacyclopropyl, azacyclobutyl, phenyl, hydroxy, amino, and dimethylamino, or R 5d and R 5etogether with the carbon atom to which they are directly attached, form a cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl or C(=CH2), each of which is independently optionally further substituted with one or more substituents selected from the group consisting of deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, i-propyl, trifluoromethyl, trideuteromethyl, cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl, hydroxyl, amino and dimethylamino;

[0251] each R 5f and each R 5g is each independently selected from the group consisting of hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, i-propyl, cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl, phenyl, hydroxyl, amino and dimethylamino, or, R 5f and R 5g together with the carbon atom to which they are directly attached, form a cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl or C(=CH2), each of which is independently optionally further substituted with one or more substituents selected from the group consisting of deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, i-propyl, trifluoromethyl, trideuteromethyl, cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl, hydroxyl, amino and dimethylamino.

[0252] As a still further preferred option, in the compound of formula (I), stereoisomer thereof, or pharmaceutically acceptable salt thereof, each R 5a , each R 5b and each R 5c is each independently selected from the group consisting of hydrogen, deuterium and fluorine;

[0253] each R 5d and each R 5e is each independently hydrogen;

[0254] each R 5f and each R 5g is each independently hydrogen. As a further preferred option, in the compound of formula (I), stereoisomer thereof, or pharmaceutically acceptable salt thereof, the compound of formula (I) is a compound of formula (IVa3), formula (IVb3), formula (IVc3), formula (IVd3), formula (IVe3) or formula (IVf3):

[0255] wherein each ring A is each independently selected from the following structures:

[0256] each R 1a and each R 1b is each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)R 17 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent;

[0257] Each R 1c are each independently selected from hydrogen, deuterium, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)R 17 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8aryl, 5-8 membered heteroaryl, =0, =S, -SF5, -0-S(0)2R 15 , -S(O) r R 15 , -0-R 16 , -C(0)OR 16 , -C(0)SR 16 , -S-C(0)R 17 , -C(0)R 17 , -0-C(0)R 17 , -P(0)(R 17 )2, -NR 18 R 19 , -C(0)NR 18 R 19 , and -N(R 18 )-C(0)R 17 ;

[0258] each R3and each R4is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -SF5, -0-R 16 and -NR 18 R 19 , or R3and R4together with the carbon atom to which they are directly attached form a C(=CH2), C(O), C 3-6 cycloalkyl, or 4-6 membered heterocyclyl, each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =0, =S, -SF5, -0-S(0)2R 15 , -S(O) r R 15 , -0-R 16 , -C(0)OR 16 , -C(0)SR 16 , -S-C(0)R 17 , -C(0)R 17 , -0-C(0)R 17 , -P(0)(R 17 )2, -NR 18 R 19-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ;

[0259] each R 5a , each R 5b and each R 5c is independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 , -O-R 16 , and -NR 18 R 19 , or, R 5a and one of R 5b or R 5c together with the moiety to which they are directly attached form a C 3-4 cycloalkyl or 3-4 membered heterocyclyl, R 5b or R 5c is as previously defined, or, R 5a and R 5b together with the carbon atom to which they are directly attached form C(=CH2), R 5c is as previously defined, and the foregoing groups are each independently optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R19 -C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted with one or more substituents independently selected from the group consisting of deuterium, halogen, cyano, C

[0260] each R 5d and each R 5e is each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 , -O-R 16 , and -NR 18 R 19 , or, R 5d and R 5e together with the carbon atom to which they are directly attached form a C 3-4 cycloalkyl, 3-4 membered heterocyclyl, or C(=CH2), each of which is independently optionally further substituted with one or more substituents independently selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted with one or more substituents independently selected from the group consisting of deuterium, halogen, cyano, C

[0261] each R5f and each R 5g is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 , -O-R 16 , and -NR 18 R 19 , or, R 5f and R 5g together with the carbon atom they are attached to form a C 3-4 cycloalkyl, 3-4 membered heterocyclyl, or C(=CH2), each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =0, =S, -SF5, -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(O)NR 18 R 19 , and -N(R 18 )-C(O)R 17 ;

[0262] each R6is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ;

[0263] Each R7 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ;

[0264] Each R 8a and each R 8b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, cyano substituted C 1-4alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, -SF5, -0-S(0)2R 15 , -S(O) r R 15 , -0-R 16 , -C(0)OR 16 , -C(0)SR 16 , -S-C(0)R 17 , -C(0)R 17 , -0-C(0)R 17 , -P(0)(R 17 )2, -NR 18 R 19 , -C(0)NR 18 R 19 and -N(R 18 )-C(0)R 17 ;

[0265] each s is independently 0 or 1 ; each t is independently 0, 1 or 2;

[0266] wherein R 15 , R 16 , R 17 , R 18 , R 19 , r and n are as defined for the compound of formula (I).

[0267] As a still further preferred option, in the compound of formula (I), in the stereoisomer thereof or in the pharmaceutically acceptable salt thereof, each R 1a and each R 1b is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 3- 6cycloalkyl, 3-6 membered heterocyclyl, -0-R 16 and -NR 18 R 19 , which are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, =0, -0-R 16 and -NR 18 R 19 ;

[0268] each R 1ceach independently selected from the group consisting of hydrogen, deuterium, cyano, C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, =0, -0-R 16 and -NR 18 R 19 , the aforementioned groups being optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, =0, -0-R 16 and -NR 18 R 19 ;

[0269] wherein R 16 , R 18 and R 19 are as defined for the compound of formula (I).

[0270] As a still further preferred option, in the compound of formula (I), in the stereoisomer thereof or in the pharmaceutically acceptable salt thereof, each R 1a and each R 1b is independently selected from the group consisting of hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl, hydroxy, amino and dimethylamino, the aforementioned groups being optionally further substituted by one or more substituents selected from the group consisting of deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteromethyl, cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl, hydroxy, amino and dimethylamino;

[0271] each R 1c is independently selected from the group consisting of hydrogen, deuterium, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl, hydroxy, amino and dimethylamino, the aforementioned groups being optionally further substituted by one or more substituents selected from the group consisting of deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteromethyl, cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl, hydroxy, amino and dimethylamino.

[0272] As a still further preferred option, in the compound of formula (I), in the stereoisomer thereof or in the pharmaceutically acceptable salt thereof, each R 5a , each R 5b and each R 5c is independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl and 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 , or, R 5a With R 5b or R 5c One of them together with its directly connected part forms a C 3-4 Cycloalkyl or 3-4 membered heterocyclic group, R 5b or R 5c Another definition is as above, or, R 5a With R 5b Together with the carbon atom to which it is directly attached, it forms C(=CH2), R 5c As defined above, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 substituted by a substituent;

[0273] Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl and 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 , or, R 5d and R 5e Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent;

[0274] each R 5f and each R 5g is each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryl and 3-6 membered heterocyclyl, -O-R 16 and -NR 18 R 19 , or, R 5f and R 5g together with the carbon atom to which they are directly attached form a C 3-4 cycloalkyl, 3-4 membered heterocyclyl or C(=CH2), each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 and -NR 18 R 19 and -N(R 18 )-C(O)R 17 ;

[0275] wherein R 16 , R 17 , R 18 and R 19 are as defined for the compound of formula (I).

[0276] As a still further preferred option, in the compound of formula (I), stereoisomer thereof, or pharmaceutically acceptable salt thereof, each R 5a , each R 5b and each R 5c is each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl, phenyl, hydroxy, amino and dimethylamino, or, R 5a and R 5b or R 5c together with the moiety to which they are directly attached form a cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl or azetidinyl, R 5b or R 5c are as previously defined, or, R 5a and R 5b together with the carbon atom to which they are directly attached form C(=CH2), R 5ceach R is independently selected from the group consisting of hydrogen, deuterium, fluoro, chloro, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxacyclobutyl, azacyclobutyl, phenyl, hydroxy, amino, and dimethylamino, or R

[0277] each R is independently selected from the group consisting of hydrogen, deuterium, fluoro, chloro, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxacyclobutyl, azacyclobutyl, phenyl, hydroxy, amino, and dimethylamino, or R 5d each R is independently selected from the group consisting of hydrogen, deuterium, fluoro, chloro, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxacyclobutyl, azacyclobutyl, phenyl, hydroxy, amino, and dimethylamino, or R 5e each R is independently selected from the group consisting of hydrogen, deuterium, fluoro, chloro, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxacyclobutyl, azacyclobutyl, phenyl, hydroxy, amino, and dimethylamino, or R 5d each R is independently selected from the group consisting of hydrogen, deuterium, fluoro, chloro, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxacyclobutyl, azacyclobutyl, phenyl, hydroxy, amino, and dimethylamino, or R 5e and R together with the carbon atom to which they are directly attached form a cyclopropyl, cyclobutyl, oxacyclobutyl, azacyclobutyl, or C(=CH2), each of which is independently optionally further substituted with one or more substituents selected from the group consisting of deuterium, fluoro, chloro, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteromethyl, cyclopropyl, cyclobutyl, oxacyclobutyl, azacyclobutyl, hydroxy, amino, and dimethylamino;

[0278] each R is independently selected from the group consisting of hydrogen, deuterium, fluoro, chloro, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxacyclobutyl, azacyclobutyl, phenyl, hydroxy, amino, and dimethylamino, or R 5f each R is independently selected from the group consisting of hydrogen, deuterium, fluoro, chloro, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxacyclobutyl, azacyclobutyl, phenyl, hydroxy, amino, and dimethylamino, or R 5g each R is independently selected from the group consisting of hydrogen, deuterium, fluoro, chloro, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxacyclobutyl, azacyclobutyl, phenyl, hydroxy, amino, and dimethylamino, or R 5f each R is independently selected from the group consisting of hydrogen, deuterium, fluoro, chloro, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxacyclobutyl, azacyclobutyl, phenyl, hydroxy, amino, and dimethylamino, or R 5g and R together with the carbon atom to which they are directly attached form a cyclopropyl, cyclobutyl, oxacyclobutyl, azacyclobutyl, or C(=CH2), each of which is independently optionally further substituted with one or more substituents selected from the group consisting of deuterium, fluoro, chloro, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteromethyl, cyclopropyl, cyclobutyl, oxacyclobutyl, azacyclobutyl, hydroxy, amino, and dimethylamino.

[0279] As a further preferred aspect, the compound of formula (I), stereoisomer thereof, or pharmaceutically acceptable salt thereof is a compound of formula (IVa4), (IVb4), (IVc4), (IVd4), (IVe4), or (IVf4):

[0280] wherein each ring A is independently selected from the following structures: wherein each ring A is independently selected from the following structures:

[0281] each R 1a is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -C(O)R 17 , and -NR 18 R 19 , the aforementioned groups being optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =0, =S, -SF5, -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(O)NR 18 R 19 , and -N(R 18 )-C(O)R 17 ;

[0282] each R 1b is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -C(O)R 17 , and -NR 18 R 19 , the aforementioned groups being optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =0, =S, -SF5, -0-S(0)2R 15 , -S(O) r R 15 , -0-R 16 , -C(0)OR 16 , -C(0)SR 16 , -S-C(0)R 17 , -C(0)R 17 , -0-C(0)R 17 , -P(0)(R 17 )2, -NR 18 R 19 , -C(0)NR 18 R 19 and -N(R 18 )-C(0)R 17 ;

[0283] each R 1c is independently selected from the group consisting of hydrogen, deuterium, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -0-R 16 , -C(0)R 17 and -NR 18 R 19 , said groups being optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =0, =S, -SF5, -0-S(0)2R 15 , -S(O) r R 15 , -0-R 16 , -C(0)OR 16 , -C(0)SR 16 , -S-C(0)R 17 , -C(0)R 17 , -0-C(0)R 17 , -P(0)(R 17 )2, -NR 18 R19 -C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituents;

[0284] each R3and each R4are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -SF5, -O-R 16 and -NR 18 R 19 , or R3and R4together with the carbon atom to which they are both attached form a C(=CH2), C(O), C 3-6 cycloalkyl or 4-6 membered heterocyclyl, each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =0, =S, -SF5, -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituents;

[0285] each R 5a , each R 5b and each R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 , -O-R 16 , and -NR 18 R 19 , or, R 5a and R 5b or R 5c wherein one of R 3-4 cycloalkyl or 3-4 membered heterocyclyl, R 5b or R 5c is as previously defined, or, R 5a and R 5b together with the carbon atom to which they are directly attached form C(=CH2), R 5c are as previously defined, the foregoing groups are each independently further optionally substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =0, =S, -SF5, -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ;

[0286] each R 5d and each R 5e is each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 , -O-R 16 , and -NR 18 R 19 , or R 5d and R 5e together with the carbon atom to which they are directly attached form a C 3-4 cycloalkyl, 3-4 membered heterocyclyl, or C(=CH2), each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =0, =S, -SF5, -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ;

[0287] each R 5f and each R 5g is each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 , -O-R 16 , and -NR18 R 19 5f 5g 3-4 1-4 1-4 1-4 2-4 2-4 3-6 6-8 15 r 15 16 16 16 17 17 17 17 18 19 18 19 18 17 1-4 1-4 1-4 2-4 2-4 3-6 6-8 15 r 15 16 16 16 17 17 17 17

[0288] 1-4 1-4 1-4 2-4 2-4 3-6 6-8 15 r 15 16 16 16 17 17 17 17 ​​​​​​​​​​​​​​​​​​​​​​​​​​​)2, -NR 18 R 19 , -C(O)NR 18 R 19 , and -N(R 18 )-C(O)R 17 ;

[0289] each R7is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, -SF5, -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(O)NR 18 R 19 , and -N(R 18 )-C(O)R 17 ;

[0290] each R 8a and each R 8b is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, cyano-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, -SF5, -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R17 -O-C(O)R 17 -P(O)(R 17 )2, -NR 18 R 19 -C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ;

[0291] each s is independently 0 or 1 ;

[0292] wherein R 15 , R 16 , R 17 , R 18 , R 19 , r and n are as defined for the compound of formula (I).

[0293] As a still further preferred embodiment, in the compound of formula (I), stereoisomer or pharmaceutically acceptable salt thereof, each R 1a is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 and -NR 18 R 19 , which are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, =0, -O-R 16 and -NR 18 R 19 ;

[0294] each R 1b is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 and -NR 18 R 19 , which are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, =0, -O-R 16 and -NR 18 R 19 ;

[0295] each R 1c is independently selected from the group consisting of hydrogen, deuterium, cyano, C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 and -NR 18 R 19 , the aforementioned groups being optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, =0, -O-R 16 and -NR 18 R 19 ;

[0296] wherein R 16 , R 18 and R 19 are as defined for the compound of formula (I).

[0297] As a still further preferred option, in the compound of formula (I), in the stereoisomer thereof or in the pharmaceutically acceptable salt thereof, each R 1a is independently selected from the group consisting of hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl, hydroxy, amino and dimethylamino, the aforementioned groups being optionally further substituted by one or more substituents selected from the group consisting of deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteromethyl, cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl, hydroxy, amino and dimethylamino;

[0298] each R 1b is independently selected from the group consisting of hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl, hydroxy, amino and dimethylamino, the aforementioned groups being optionally further substituted by one or more substituents selected from the group consisting of deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteromethyl, cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl, hydroxy, amino and dimethylamino;

[0299] each R 1cEach is independently selected from hydrogen, deuterium, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxyl, amino and dimethylamino, and the above groups are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxyl, amino and dimethylamino.

[0300] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R 5a , each R 5b and each R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl and 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 , or, R 5a With R 5b or R 5c One of them together with its directly connected part forms a C 3-4 Cycloalkyl or 3-4 membered heterocyclic group, R 5b or R 5c Another definition is as above, or, R 5a With R 5b Together with the carbon atom to which it is directly attached, it forms C(=CH2), R 5c As defined above, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 substituted by a substituent;

[0301] Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl and 3-6 membered heterocyclic group, -OR 16 and -NR18 R 19 , or R 5d and R 5e , together with the carbon atom to which they are directly attached, form a C 3-4 cycloalkyl, 3-4 membered heterocyclyl, or C(=CH2), each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , and -NR 18 R 19 , and -N(R 18 )-C(O)R 17 ;

[0302] each R 5f and each R 5g is each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryl, and 3-6 membered heterocyclyl, -O-R 16 , and -NR 18 R 19 , or R 5f and R 5g , together with the carbon atom to which they are directly attached, form a C 3-4 cycloalkyl, 3-4 membered heterocyclyl, or C(=CH2), each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , and -NR 18 R 19 , and -N(R 18 )-C(O)R 17 ;

[0303] wherein R 16 , R 17 , R 18 , and R 19 are as defined for the compound of formula (I).

[0304] As a still further preferred embodiment, in the compound of formula (I), in the stereoisomer thereof, or in the pharmaceutically acceptable salt thereof, each R 5a , each R5b and each R 5c are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, phenyl, hydroxyl, amino and dimethylamino, or R 5a With R 5b or R 5c One of them together with the part to which it is directly attached forms a cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine or azetidinyl group, R 5b or R 5c Another definition is as above, or, R 5a With R 5b Together with the carbon atom to which it is directly attached, it forms C(=CH2), R 5c The definitions are as described above, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino;

[0305] Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, phenyl, hydroxyl, amino and dimethylamino, or R 5d and R 5e together with the carbon atom to which it is directly attached, form a cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl or C(═CH 2 ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino;

[0306] Each R 5f and each R 5g are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, phenyl, hydroxyl, amino and dimethylamino, or R 5f and R 5gtogether with the carbon atom to which it is attached, form a cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl, or C(=CH2), each of which is independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, i-propyl, trifluoromethyl, trideuteromethyl, cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl, hydroxyl, amino, and dimethylamino.

[0307] As still further preferred embodiments, in the compound of formula (I), stereoisomer thereof, or pharmaceutically acceptable salt thereof, each R 5a , each R 5b , and each R 5c is independently selected from hydrogen, deuterium, and fluorine;

[0308] each R 5d , and each R 5e is independently hydrogen;

[0309] each R 5f , and each R 5g is independently hydrogen.

[0310] As further preferred embodiments, in the compound of formula (I), stereoisomer thereof, or pharmaceutically acceptable salt thereof, the compound of formula (I) is a compound of formula (IVa5), formula (IVb5), formula (IVc5), formula (IVd5), formula (IVe5), or formula (IVf5):

[0311] wherein each ring A is independently selected from the following structures:

[0312] each R 1a is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -C(O)R 17 , -C(O)NR 18 R 19 , and -NR 18 R 19 , each of which is optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =0, =S, -SF5, -0-S(0)2R 15 , -S(O) r R 15 , -0-R 16 , -C(0)OR 16 , -C(0)SR 16 , -S-C(0)R 17 , -C(0)R 17 , -0-C(0)R 17 , -P(0)(R 17 )2, -NR 18 R 19 , -C(0)NR 18 R 19 and -N(R 18 )-C(0)R 17 ;

[0313] each R 1b and each R 1c is each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -0-R 16 , -C(0)R 17 , -C(0)NR 18 R 19 and -NR 18 R 19 , said groups being optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =0, =S, -SF5, -0-S(0)2R 15 , -S(O) r R 15 , -0-R 16 , -C(0)OR 16 , -C(0)SR 16 , -S-C(0)R 17 , -C(0)R 17 , -0-C(0)R 17 , -P(0)(R17 )2, -NR 18 R 19 , -C(O)NR 18 R 19 , and -N(R 18 )-C(O)R 17 ;

[0314] each R3and each R4are each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -SF5, -O-R 16 , and -NR 18 R 19 , or R3and R4together with the carbon atom to which they are directly attached form a C(=CH2), C(O), C 3-6 cycloalkyl, or 4-6 membered heterocyclyl, each of which is independently optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(O)NR 18 R 19 , and -N(R 18 )-C(O)R 17 ;

[0315] each R 5a , each R 5b , and each R 5c are each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 、-OR 16 and -NR 18 R 19 , or, R 5a With R 5b or R 5c One of them together with its directly connected part forms a C 3-4 Cycloalkyl or 3-4 membered heterocyclic group, R 5b or R 5c Another definition is as above, or, R 5a With R 5b Together with the carbon atom to which it is directly attached, it forms C(=CH2), R 5c As defined above, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent;

[0316] Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryld 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 , -O-R 16 , and -NR 18 R 19 , or, R 5d and R 5e together with the carbon atom to which they are directly attached form a C 3-4 cycloalkyl, 3-4 membered heterocyclyl, or C(=CH2), each of the above groups being independently optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =0, =S, -SF5, -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ;

[0317] each R 5f and each R 5g is each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryld 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF5, -S(O) r R 15-O-R 16 and -NR 18 R 19 , or R 5f and R 5g together with the carbon atom to which they are directly attached form a C 3-4 cycloalkyl, 3-4 membered heterocyclyl, or C(=CH2), each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =0, =S, -SF5, -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ;

[0318] each R6is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, -SF5, -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(O)NR 18 R 19 , and -N(R 18 )-C(O)R 17 ;

[0319] each R7is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, -SF5, -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(O)NR 18 R 19 , and -N(R 18 )-C(O)R 17 ;

[0320] each R 8a and each R 8b is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, cyano-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, -SF5, -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16-S-C(O)R 17 -C(O)R 17 -O-C(O)R 17 -P(O)(R 17 )2, -NR 18 R 19 -C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ;

[0321] each s is independently 0 or 1 ;

[0322] wherein R 15 , R 16 , R 17 , R 18 , R 19 , r and n are as defined for the compound of formula (I).

[0323] As a still further preferred embodiment, in the compound of formula (I), stereoisomer or pharmaceutically acceptable salt thereof, each R 1a is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -C(O)NR 18 R 19 and -NR 18 R 19 , which are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, -O-R 16 and -NR 18 R 19 ;

[0324] each R 1b and each R 1c is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -C(O)NR 18 R 19 and -NR 18 R 19 , which are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, =0, -0-R 16 and -NR 18 R 19 substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, i-propyl, cyclopropyl, cyclobutyl, oxacyclopropyl, oxacyclobutyl, azacyclopropyl, azacyclobutyl, hydroxyl, -C(O)NR

[0325] wherein R 16 , R 18 and R 19 are as defined for the compound of formula (I).

[0326] As a still further preferred option, in the compound of formula (I), in the stereoisomer thereof or in the pharmaceutically acceptable salt thereof, each R 1a is each independently selected from the group consisting of hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, i-propyl, cyclopropyl, cyclobutyl, oxacyclopropyl, oxacyclobutyl, azacyclopropyl, azacyclobutyl, hydroxyl, -C(O)NR 18 R 19 and -NR 18 R 19 , the aforementioned groups being optionally further substituted with one or more substituents selected from the group consisting of deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, i-propyl, trifluoromethyl, trideuteromethyl, cyclopropyl, cyclobutyl, oxacyclopropyl, oxacyclobutyl, azacyclopropyl, azacyclobutyl, hydroxyl, amino and dimethylamino;

[0327] each R 1b and each R 1c is each independently selected from the group consisting of hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, i-propyl, cyclopropyl, cyclobutyl, oxacyclopropyl, oxacyclobutyl, azacyclopropyl, azacyclobutyl, hydroxyl, -C(O)NR 18 R 19 and -NR 18 R 19 , the aforementioned groups being optionally further substituted with one or more substituents selected from the group consisting of deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, i-propyl, trifluoromethyl, trideuteromethyl, cyclopropyl, cyclobutyl, oxacyclopropyl, oxacyclobutyl, azacyclopropyl, azacyclobutyl, hydroxyl, amino and dimethylamino;

[0328] R 18 and R 19 is each independently selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, i-propyl, trifluoromethyl, trideuteromethyl, cyclopropyl, cyclobutyl, oxacyclopropyl, oxacyclobutyl, azacyclopropyl and azacyclobutyl.

[0329] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R 5a , each R 5b and each R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl and 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 , or, R 5a With R 5b or R 5c One of them together with its directly connected part forms a C 3-4 Cycloalkyl or 3-4 membered heterocyclic group, R 5b or R 5c Another definition is as above, or, R 5a With R 5b Together with the carbon atom to which it is directly attached, it forms C(=CH2), R 5c As defined above, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 substituted by a substituent;

[0330] Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl and 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 , or, R 5d and R 5e Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 and -NR 18 R 19 and -NR 18 -C(O)R 17 substituted with one or more substituents selected from the group consisting of deuterium, halogen, cyano, C

[0331] each R 5f and each R 5g is each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C 6-8 aryl and 3-6 membered heterocyclyl, -O-R 16 and -NR 18 R 19 , or, R 5f and R 5g together with the carbon atom to which they are directly attached form a C 3-4 cycloalkyl, 3-4 membered heterocyclyl or C(=CH2), each of which is independently optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 and -NR 18 R 19 and -NR 18 -C(O)R 17 substituted with one or more substituents selected from the group consisting of deuterium, halogen, cyano, C

[0332] wherein R 16 , R 17 , R 18 and R 19 are as defined for the compound of formula (I).

[0333] As a still further preferred option, in the compound of formula (I), in the stereoisomer thereof or in the pharmaceutically acceptable salt thereof, each R 5a , each R 5b and each R 5c is each independently selected from the group consisting of hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl, phenyl, hydroxy, amino and dimethylamino, or, R 5a and R 5b or R 5cone of R and R, together with the moiety to which it is directly attached, forms a cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, or azetidinyl group, R 5b or R 5c another definition is as previously described, or, R 5a and R 5b together with the carbon atom to which they are directly attached form C(=CH2), R 5c each of the foregoing groups is independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, i-propyl, trifluoromethyl, trideuteromethyl, cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl, hydroxyl, amino, and dimethylamino;

[0334] each R 5d and each R 5e is each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, i-propyl, cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl, phenyl, hydroxyl, amino, and dimethylamino, or, R 5d and R 5e together with the carbon atom to which they are directly attached form a cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl, or C(=CH2), each of the foregoing groups is independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, i-propyl, trifluoromethyl, trideuteromethyl, cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl, hydroxyl, amino, and dimethylamino;

[0335] each R 5f and each R 5g is each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, i-propyl, cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl, phenyl, hydroxyl, amino, and dimethylamino, or, R 5f and R 5g together with the carbon atom to which they are directly attached form a cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl, or C(=CH2), each of the foregoing groups is independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, i-propyl, trifluoromethyl, trideuteromethyl, cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl, hydroxyl, amino, and dimethylamino.

[0336] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R3 and each R4 are independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 Alternatively, R3 and R4 together with the carbon atom to which they are directly attached form a C(=CH2), C(O), C 3-6 Cycloalkyl or 4-6 membered heterocyclic group, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 substituted by a cycloalkyl substituent;

[0337] Among them, R 16 、R 18 and R 19 As defined for the compounds of formula (I).

[0338] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R3 and each R4 are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxyl, amino and dimethylamino; or, R3 and R4 together with the carbon atom to which they are directly attached form a C(=CH2), C(O), cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine or azetidinyl, and the above groups are independently optionally further substituted by one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl and cyclobutyl.

[0339] As a further preferred embodiment, among the compounds of formula (I), stereoisomers thereof or pharmaceutically acceptable salts thereof, the compounds of formula (I) are compounds of formula (IVa6), formula (IVb6), formula (IVc6), formula (IVd6), formula (IVe6) or formula (IVf6):

[0340] Wherein, ring A is selected from the following structures:

[0341] Each R 1a and each R 1beach independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -C(O)R 17 , and -NR 18 R 19 , said groups being optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(O)NR 18 R 19 , and -N(R 18 )-C(O)R 17 ;

[0342] each R 1c is independently selected from the group consisting of hydrogen, deuterium, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -C(O)R 17 , and -NR 18 R 19 , said groups being optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =0, =S, -SF5, -0-S(0)2R 15 , -S(O) r R 15 , -0-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -0-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ;

[0343] each R3and each R4are each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -SF5, -0-R 16 and -NR 18 R 19 , or R3and R4together with the carbon atom to which they are directly attached form a C(=CH2), C(O), C 3-6 cycloalkyl or 4-6 membered heterocyclyl, each of which is independently optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =0, =S, -SF5, -0-S(0)2R 15 , -S(O) r R 15 , -0-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -0-C(O)R 17 , -P(O)(R 17 )2, -NR18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent;

[0344] Each R6 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ;

[0345] Each R7 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R17 )2, -NR 18 R 19 , -C(O)NR 18 R 19 , and -N(R 18 )-C(O)R 17 ;

[0346] each R 8a and each R 8b is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, cyano-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, -SF5, -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(O)NR 18 R 19 , and -N(R 18 )-C(O)R 17 ;

[0347] each R 11a and each R 11b is independently selected from hydrogen, deuterium, hydroxyl, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, mesyl, isopropylsulfonyl, cyclopropylsulfonyl, tosyl, aminosulfonyl, dimethylaminosulfonyl, and C 1-10 alkanoyl, each of the above groups being independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C1-4 alkylene, halo-substituted C 1-4 alkylene, deuterium-substituted C 1-4 alkylene, halo-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 1-4 alkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkoxy, 3- to 6-membered heterocyclyl, 3- to 6-membered heterocyclyloxy, C 6-8 aryl, C 6-8 aryloxy, 5- to 8-membered heteroaryl, 5- to 8-membered heteroaryloxy, amino, mono- C 1-4 alkylamino, di-C 1-4 alkylamino and C 1-4 substituted by one or more substituents selected from the group consisting of alkyl, deuterium- substituted C

[0348] or, R 11a and R 11b form, together with the nitrogen atom to which they are directly attached, a 4- to 6-membered heterocyclyl, which is optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =0, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkylene, halo-substituted C 1-4 alkylene, deuterium-substituted C 1-4 alkylene, halo-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 1-4 alkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkoxy, 3- to 6-membered heterocyclyl, 3- to 6-membered heterocyclyloxy, C 6-8 aryl, C 6-8 aryloxy, 5- to 8-membered heteroaryl, 5- to 8-membered heteroaryloxy, amino, mono- C 1-4 alkylamino, di-C 1-4 alkylamino and C 1-4 substituted by one or more substituents selected from the group consisting of alkyl, deuterium- substituted C

[0349] wherein R 15 , R 16 , R 17 , R 18 , R 19 , r and n are as defined for the compound of formula (I).

[0350] As a further preferred option, in the compound of formula (I), in the stereoisomer thereof or in the pharmaceutically acceptable salt thereof, each R 1a and each R 1b is each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4alkyl, C 3- 6cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 and -NR 18 R 19 , said groups being optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 and -NR 18 R 19 ;

[0351] each R 1c is independently selected from the group consisting of hydrogen, C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl and -C(O)R 17 , said groups being optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, -O-R 16 and -NR 18 R 19 ;

[0352] wherein R 16 , R 17 , R 18 and R 19 are as defined for the compound of formula (I).

[0353] As a still further preferred option, in the compound of formula (I), in the stereoisomer thereof or in the pharmaceutically acceptable salt thereof, each R 1a and each R 1b is independently selected from the group consisting of hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, i-propyl, cyclopropyl, cyclobutyl, oxacyclopropyl, oxacyclobutyl, azacyclopropyl, azacyclobutyl, hydroxy, amino and dimethylamino, said groups being optionally further substituted by one or more substituents selected from the group consisting of deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, i-propyl, trifluoromethyl, trideuteromethyl, cyclopropyl, cyclobutyl, oxacyclopropyl, oxacyclobutyl, azacyclopropyl, azacyclobutyl, hydroxy, amino and dimethylamino;

[0354] each R 1ceach independently selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxacyclopropyl, oxacyclobutyl, azacyclopropyl, azacyclobutyl, and -C(O)R 17a , the aforementioned groups being optionally further substituted by one or more substituents selected from the group consisting of deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteromethyl, cyclopropyl, cyclobutyl, oxacyclopropyl, oxacyclobutyl, azacyclopropyl, azacyclobutyl, hydroxyl, amino, and dimethylamino;

[0355] R 17a , the aforementioned groups being optionally further substituted by one or more substituents selected from the group consisting of deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteromethyl, cyclopropyl, cyclobutyl, oxacyclopropyl, oxacyclobutyl, azacyclopropyl, azacyclobutyl, hydroxyl, amino, and dimethylamino;

[0356] As a still further preferred embodiment, in the compound of formula (I), stereoisomer thereof, or pharmaceutically acceptable salt thereof, each R3and each R4together with the carbon atom to which they are directly attached form a C(=CH2), C(O), cyclopropyl, cyclobutyl, oxacyclopropyl, oxacyclobutyl, azacyclopropyl, or azacyclobutyl, the aforementioned groups being optionally further substituted by one or more substituents selected from the group consisting of deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteromethyl, cyclopropyl, and cyclobutyl. 3-6 cycloalkyl, and 4-6 membered heterocyclyl, the aforementioned groups being independently optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, the aforementioned groups being optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C

[0357] As a still further preferred embodiment, in the compound of formula (I), stereoisomer thereof, or pharmaceutically acceptable salt thereof, each R3and each R4together with the carbon atom to which they are directly attached form a C(=CH2), C(O), cyclopropyl, cyclobutyl, oxacyclopropyl, oxacyclobutyl, azacyclopropyl, or azacyclobutyl, the aforementioned groups being optionally further substituted by one or more substituents selected from the group consisting of deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteromethyl, cyclopropyl, and cyclobutyl.

[0358] As a still further preferred embodiment, in the compound of formula (I), stereoisomer thereof, or pharmaceutically acceptable salt thereof, each R 11a and each R 11b each independently selected from the group consisting of hydrogen, hydroxyl, C 1-4 alkyl, C 3-6 cycloalkyl, and 4-6 membered heterocyclyl, the aforementioned groups being independently optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, C 1-4 alkylene, halogen-substituted C 1-4 alkylene, deuterium-substituted C1-4 alkylene, halo-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 1-4 alkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkoxy, 3- to 6-membered heterocyclyl, 3- to 6-membered heterocyclyloxy, amino, mono- C 1-4 alkylamino, di-C 1-4 alkylamino and C 1-4 substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =0, C

[0359] or, R 11a and R 11b form, together with the nitrogen atom to which they are directly attached, a 4- to 6-membered heterocyclyl, said 4- to 6-membered heterocyclyl being optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =0, C 1-4 alkyl, C 1-4 alkylene, halo-substituted C 1-4 alkylene, deuterium-substituted C 1-4 alkylene, halo-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 1-4 alkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkoxy, 3- to 6-membered heterocyclyl, 3- to 6-membered heterocyclyloxy, amino, mono- C 1-4 alkylamino, di-C 1-4 alkylamino and C 1-4 substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =0, C

[0360] As a still further preferred option, in the compound of formula (I), in the stereoisomer thereof or in the pharmaceutically acceptable salt thereof, each R 11a and each R 11b is each independently selected from the group consisting of hydrogen, hydroxyl, methyl, ethyl, n-propyl, i-propyl, cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl and azetidinyl, the above groups being independently optionally further substituted by one or more substituents selected from the group consisting of deuterium, fluorine, chlorine, hydroxyl, =0, methyl, ethyl, n-propyl, i-propyl, trifluoromethyl, trideuteromethyl, methylene, monofluoromethylene, difluoromethylene, methoxy, cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl, amino and dimethylamino;

[0361] or, R 11a and R 11b form, together with the nitrogen atom to which they are directly attached, an oxiranyl, oxetanyl, oxolanyl, oxanyl, aziridinyl, azetidinyl, azinanyl, azepanyl or each of the above groups is optionally further substituted with one or more substituents selected from deuterium, halogen, hydroxyl, =0, methyl, ethyl, n-propyl, i-propyl, trifluoromethyl, trideuteromethyl, methylene, monofluoromethylene, difluoromethylene, methoxy, cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl, amino, and dimethylamino.

[0362] As a further preferred aspect, the compound of formula (I), stereoisomer thereof, or pharmaceutically acceptable salt thereof, is a compound of formula (IVa7), (IVb7), (IVc7), (IVd7), (IVe7), or (IVf7):

[0363] wherein each ring A is independently selected from the following structures:

[0364] each R 1a and each R 1b is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -C(O)R 17 , and -NR 18 R 19 , each of the above groups being optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =0, =S, -SF5, -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(O)NR 18 R19 and -N(R 18 )-C(O)R 17 substituted with one or more substituents selected from the group consisting of deuterium, halogen, cyano, C

[0365] each R 1c is each independently selected from the group consisting of hydrogen, deuterium, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 , -C(O)R 17 , and -NR 18 R 19 , the aforementioned groups being optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(O)NR 18 R 19 , and -N(R 18 )-C(O)R 17 substituted with one or more substituents selected from the group consisting of deuterium, halogen, cyano, C

[0366] each R3and each R4is each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -SF5, -O-R 16 , and -NR 18 R 19 , or R3and R4together with the carbon atom to which they are directly attached form a C(=CH2), C(O), C 3-6Cycloalkyl or 4-6 membered heterocyclic group, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent;

[0367] Each R6 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R17 ;

[0368] each R7is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, -SF5, -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19 , -C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ;

[0369] each R 8a and each R 8b is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, cyano-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, -SF5, -O-S(O)2R 15 , -S(O) r R 15 , -O-R 16 , -C(O)OR 16 , -C(O)SR 16 , -S-C(O)R 17 , -C(O)R 17 , -O-C(O)R 17 , -P(O)(R 17 )2, -NR 18 R 19、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ;

[0370] Each R 11a are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 1-4 Alkylene, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl and 5-8 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2- 4-chain alkynyl, C 1-4 Alkylene, halogen substituted C 1-4 Alkylene, deuterium substituted C 1-4 Alkylene, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono C 1-4 Alkylamino, di-C 1-4 Alkylamino and C 1-4 substituted with an alkanoyl substituent;

[0371] Each R 11b are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl and 5-8 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1- 4 Alkylene, halogen substituted C 1-4 Alkylene, deuterium substituted C 1-4 Alkylene, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C3-6 cycloalkyl, C 3-6 cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C 6-8 aryl, C 6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono-C 1-4 alkylamino, di-C 1-4 alkylamino and C 1-4 substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =0, C

[0372] each R 11c is independently selected from the group consisting of hydrogen, deuterium, hydroxyl, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl and 5-8 membered heteroaryl, each of which is independently optionally further substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =0, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1- 4alkylene, halogen-substituted C 1-4 alkylene, deuterium-substituted C 1-4 alkylene, halogen-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 1-4 alkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C 6-8 aryl, C 6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono-C 1-4 alkylamino, di-C 1-4 alkylamino and C 1-4 substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxyl, =0, C

[0373] wherein R 15 , R 16 , R 17 , R 18 , R 19 , r and n are as defined for the compound of formula (I).

[0374] As a still further preferred option, in the compound of formula (I), in the stereoisomer thereof or in the pharmaceutically acceptable salt thereof, each R 1a and each R 1b is independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, C 3- 6cycloalkyl, 3-6 membered heterocyclyl, -O-R16 and -NR 18 R 19 , the aforementioned groups are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -O-R 16 and -NR 18 R 19 ;

[0375] each R 1c is independently selected from hydrogen, C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl and -C(O)R 17 , the aforementioned groups are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 alkyl, halosubstituted C 1-4 alkyl, deuterium- substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, 5-8 membered heteroaryl, -O-R 16 and -NR 18 R 19 ;

[0376] wherein R 16 , R 17 , R 18 and R 19 are as defined for the compound of formula (I).

[0377] As a still further preferred option, in the compound of formula (I), in the stereoisomer thereof or in the pharmaceutically acceptable salt thereof, each R 1a and each R 1b is independently hydrogen.

[0378] each R 1c is independently hydrogen.

[0379] As a still further preferred option, in the compound of formula (I), in the stereoisomer thereof or in the pharmaceutically acceptable salt thereof, each R3and each R4is independently hydrogen or deuterium.

[0380] As a still further preferred option, in the compound of formula (I), in the stereoisomer thereof or in the pharmaceutically acceptable salt thereof, each R 11a is independently selected from hydrogen, deuterium, hydroxyl, methyl, ethyl and methylene, the aforementioned groups being independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine or hydroxyl.

[0381] Each R 11b are each independently selected from hydrogen, deuterium, hydroxy, methyl and ethyl, the above groups being independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine or hydroxy;

[0382] Each R 11c Each is independently selected from hydrogen, deuterium, hydroxy, methyl, ethyl and methylene, and the above groups are independently optionally further substituted by one or more substituents selected from deuterium, fluorine, chlorine or hydroxy.

[0383] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each Each is independently selected from the following structures:

[0384] Each R 6a , each R 6b , each R 6c and each R 6d are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -OR 16 and -NR 18 R 19 ;

[0385] Among them, R 16 、R 18 and R 19 As defined for the compounds of formula (I).

[0386] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each Each is independently selected from the following structures:

[0387] Each R 6a , each R 6b , each R 6c and each R 6d Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, methoxy, ethoxy, n-propoxy, isopropoxy, cyclopropyloxy, amino, monomethylamino and dimethylamino.

[0388] As a further preferred embodiment, each R7is independently selected from hydrogen, deuterium, halogen, cyano, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6cyanoalkyl, C2-C6alkenyl, C2-C6haloalkenyl, C2-C6deuteroalkenyl, C2-C6cyanoalkenyl, C2-C6alkynyl, C2-C6haloalkynyl, C2-C6deuteroalkynyl, C2-C6cyanoalkynyl, C3-C6cycloalkyl, 3- to 6-membered heterocyclyl, -O-R 1-4 alkyl, C 1-4 haloalkyl, C 1-4 deuteroalkyl, C 2-4 cyanoalkyl, C 2-4 alkenyl, C 3-6 alkynyl, C 16 6cycloalkyl, 3- to 6-membered heterocyclyl, -SF5, -O-R 17 , -NR 18 R 19 , and -N(R 18 )-C(O)R 17 ;

[0389] wherein R 16 , R 17 , R 18 , and R 19 are as defined for the compound of Formula (I).

[0390] As a further preferred embodiment, each R7is independently selected from hydrogen, deuterium, halogen, cyano, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6cyanoalkyl, C2-C6alkenyl, C2-C6haloalkenyl, C2-C6deuteroalkenyl, C2-C6cyanoalkenyl, C2-C6alkynyl, C2-C6haloalkynyl, C2-C6deuteroalkynyl, C2-C6cyanoalkynyl, C3-C6cycloalkyl, 3- to 6-membered heterocyclyl, -O-R

[0391] As a further preferred embodiment, each R 8a and each R 8b is independently selected from hydrogen, deuterium, halogen, cyano, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6cyanoalkyl, C2-C6alkenyl, C2-C6haloalkenyl, C2-C6deuteroalkenyl, C2-C6cyanoalkenyl, C2-C6alkynyl, C2-C6haloalkynyl, C2-C6deuteroalkynyl, C2-C6cyanoalkynyl, C3-C6cycloalkyl, 3- to 6-membered heterocyclyl, -O-R 1-4 alkyl, C 1-4 haloalkyl, C 1-4 deuteroalkyl, C 1-4 cyanoalkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3- 6cycloalkyl, 3- to 6-membered heterocyclyl, -SF5, -O-R 16 , -NR 18 R 19 , and -N(R 18 )-C(O)R 17 ;

[0392] wherein R 16 , R17 R 18 and R 19 as defined in the compound of formula (I).

[0393] As a still further preferred aspect, each R 8a and each R 8b is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteromethyl, cyano-substituted methyl, ethenyl, ethynyl, cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl, -SF5, hydroxy, methoxy, ethoxy, n-propyloxy, isopropyloxy, cyclopropyloxy, amino, monomethylamino, and dimethylamino.

[0394] As a most preferred aspect, the compound of formula (I), stereoisomer thereof, or pharmaceutically acceptable salt thereof includes, but is not limited to, the following compounds:

[0395] A second aspect of the present application provides a pharmaceutical composition comprising the compound of formula (I), stereoisomer thereof, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0396] A third aspect of the present application further relates to use of the compound of formula (I), stereoisomer thereof, or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a KRAS-associated tumor.

[0397] As a preferred aspect, the KRAS-associated tumor is a tumor associated with wild-type KRAS, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D, or KRAS Q61H.

[0398] As a further preferred aspect, the tumor is a cancer.

[0399] As a further preferred aspect, the tumor is an adenoma, a lymphoma, a mesothelioma, a lung cancer, an esophageal cancer, a gastric cancer, a pancreatic cancer, a liver cancer, a bile duct cancer, a gallbladder cancer, a cancer of the ampulla, a small intestinal cancer, a large intestinal cancer, a kidney cancer, a testicular cancer, a hematological cancer, a hemangioma, a myeloma, a chondroma, a cancer of the skull, a brain cancer, a glioma, a uterine cancer, a vulvar cancer, a vaginal cancer, a cancer of the fallopian tube, a bladder cancer, a urethral cancer, a prostate cancer, an adrenal tumor, a sarcoma, a myxoma, a rhabdomyoma, a fibroma, a lipoma, a bronchial cancer, a Hodgkin's disease, a malignant melanoma, a basal cell carcinoma, a squamous cell carcinoma, a chondrodysplasia, a psoriasis, or a neuroblastoma.

[0400] The present application also relates to the compound of formula (I), its stereoisomer or its pharmaceutically acceptable salt for treating a tumor related to wild-type KRAS, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D or KRAS Q61H.

[0401] The present application also relates to a method for treating a tumor related to KRAS, comprising administering the compound of formula (I), its stereoisomer or its pharmaceutically acceptable salt to a patient in need thereof.

[0402] As a preferred solution, the tumor is adenoma, lymphoma, mesothelioma, lung cancer, esophageal cancer, gastric cancer, pancreatic cancer, liver cancer, cholangiocarcinoma, gallbladder cancer, ampullary cancer, small intestinal cancer, large intestinal cancer, kidney cancer, testicular cancer, blood cancer, angioma, myeloma, chondroma, skull cancer, brain cancer, glioma, uterine cancer, vulvar cancer, vaginal cancer, fallopian tube cancer, bladder cancer, urethral cancer, prostate cancer, adrenal tumor, sarcoma, myxoma, rhabdomyoma, fibroma, lipoma, bronchial cancer, Hodgkin's disease, malignant melanoma, basal cell carcinoma, squamous cell carcinoma, chondrodysplasia, psoriasis or neuroblastoma. DETAILED DESCRIPTION

[0403] The inventors of the present application have made extensive and in-depth research and first developed a KRAS inhibitor with the following formula (I) structure. The series of compounds of the present application can be widely used in the preparation of drugs for treating and / or preventing KRAS related cancer or tumor, and are expected to develop into a new generation of KRAS inhibitors. On this basis, the present application is completed.

[0404] DETAILED DESCRIPTION: Unless otherwise indicated or specifically stated, the following terms used in the specification and claims have the following meanings.

[0405] "Alkyl" refers to straight chain or branched chain saturated aliphatic hydrocarbon radicals, preferably including straight chain and branched chain alkyl groups of from 1 to 10 or 1 to 6 carbon atoms or 1 to 4 carbon atoms, including but not limited to methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, s-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, or various branched isomers thereof, and the like. "C 1-10 "Alkyl" refers to straight chain and branched chain alkyl groups including from 1 to 10 carbon atoms, "C 1-4 "Alkyl" refers to straight chain and branched chain alkyl groups including from 1 to 4 carbon atoms, "C 0-8 "Alkyl" refers to straight chain and branched chain alkyl groups including from 0 to 8 carbon atoms, "C 0-4 "Alkyl" refers to straight chain and branched chain alkyl groups including from 0 to 4 carbon atoms.

[0406] Alkyl groups can be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more (preferably 1, 2, 3, or 4) groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1- 10 halo-substituted C 1-10 deuterium-substituted C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-10 aryl, 5-10 membered heteroaryl, =0, =S, -C 0-8 alkyl-SF5, -C 0-8 alkyl-S(O)(=N-R 12 )R 13 , -C 0-8 alkyl-N=S(O)R 13 R14 -C 0-8 alkyl-N=SR 13 R 14 -C 0-8 alkyl-O-S(O)2R 15 -C 0-8 alkyl-S(O) r R 15 -C 0-8 alkyl-O-R 16 -C 0-8 alkyl-C(O)OR 16 -C 0-8 alkyl-C(O)SR 16 -C 0-8 alkyl-S-C(O)R 17 -C 0-8 alkyl-C(O)R 17 -C 0-8 alkyl-O-C(O)R 17 -C 0- 8alkyl-P(O)(R 17 )2, -C 0-8 alkyl-NR 18 R 19 -C 0-8 alkyl-C(=NR 18 )R 17 -C 0-8 alkyl-N(R 18 )-C(=NR 19 )R 17 -C 0-8 alkyl-C(O)NR 18 R 19 and -C 0-8 alkyl-N(R 18 )-C(O)R 17 .

[0407] “Alkylene” refers to a radical of the formula “=R”, where “R” is an “alkyl” group as defined above less two hydrogen atoms. Preferred include straight chain alkyl groups of 1 to 10 or 1 to 6 carbon atoms or 1 to 4 carbon atoms and branched chain alkyl groups less two hydrogen atoms, including but not limited to methylene (=CH2), ethylene (=CHCH3), hexylene (=CH(CH2)4CH3), and the like. For example, in the following compound: The boxed line with the arrow pointing to it is a methylene group.

[0408] Alkylene groups can be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more (preferably 1, 2, 3, or 4) groups independently selected from deuterium, halogen, cyano, C1-10 alkyl, halogen-substituted C 1-10 alkyl, deuterium-substituted C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-12 cycloalkyl, 3- to 12-membered heterocyclyl, C 6-10 aryl, 5- to 10-membered heteroaryl, -C 0-8 alkyl-SF5, -C 0-8 alkyl-S(O)(=N-R 12 )R 13 , -C 0- 8alkyl-N=S(O)R 13 R 14 , -C 0-8 alkyl-N=SR 13 R 14 , -C 0-8 alkyl-O-S(O)2R 15 , -C 0-8 alkyl-S(O) r R 15 , -C 0-8 alkyl-O-R 16 , -C 0-8 alkyl-C(O)OR 16 , -C 0-8 alkyl-C(O)SR 16 , -C 0-8 alkyl-S-C(O)R 17 , -C 0-8 alkyl-C(O)R 17 , -C 0-8 alkyl-O-C(O)R 17 , -C 0-8 alkyl-P(O)(R 17 )2, -C 0-8 alkyl-NR 18 R 19 , -C 0-8 alkyl-C(=NR 18 )R 17 , -C 0-8 alkyl-N(R 18 )-C(=NR 19 )R 17 , -C 0-8 alkyl-C(O)NR 18 R 19 and -C 0-8 alkyl-N(R 18 )-C(O)R 17 .

[0409] "Cycloalkyl" or "carbocyclic" refers to saturated or partially unsaturated monocyclic or polycyclic cyclic aliphatic substituents, which means that the cyclic hydrocarbon can contain one or more (preferably 1, 2, or 3) double bonds, but no ring has a completely conjugated pi-electron system. Cycloalkyl groups are classified as monocyclic cycloalkyl groups, polycyclic cycloalkyl groups, preferably including cycloalkyl groups of 3 to 12 or 3 to 8 or 3 to 6 carbon atoms, for example, "C 3-12 "Cycloalkyl" refers to cycloalkyl groups including 3 to 12 carbon atoms, "C 3-10 "Cycloalkyl" refers to cycloalkyl groups including 3 to 10 carbon atoms, "C 3- "Cycloalkyl" refers to cycloalkyl groups including 3 to 8 carbon atoms, "C 3-6 "Cycloalkyl" refers to cycloalkyl groups including 3 to 6 carbon atoms, wherein:

[0410] Monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, and the like.

[0411] Polycyclic cycloalkyl groups include spirocyclic, fused, and bridged cycloalkyl groups. "Spirocycloalkyl" refers to polycyclic groups in which single rings share one carbon atom (referred to as a spiro atom) between rings, which can contain one or more (preferably 1, 2, or 3) double bonds, but no ring has a completely conjugated pi-electron system. Spirocycloalkyl groups are classified as mono-, bi-, or polycyclic spirocycloalkyl groups, including but not limited to:

[0412] "Fused cycloalkyl" refers to all-carbon polycyclic groups in which each ring in the system shares an adjacent pair of carbon atoms with other rings in the system, in which one or more rings can contain one or more (preferably 1, 2, or 3) double bonds, but no ring has a completely conjugated pi-electron system. Fused cycloalkyl groups can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic fused cycloalkyl groups, including but not limited to:

[0413] "Bridged cycloalkyl" refers to all-carbon polycyclic groups in which any two rings share two non-adjacent carbon atoms, which can contain one or more (preferably 1, 2, or 3) double bonds, but no ring has a completely conjugated pi-electron system. Bridged cycloalkyl groups can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic bridged cycloalkyl groups, including but not limited to:

[0414] The cycloalkyl rings can be fused to aryl, heteroaryl, or heterocycloalkyl rings, in which the ring that is attached to the parent structure is a cycloalkyl group, including but not limited to indanyl, tetrahydronaphthyl, benzocycloheptyl, and the like.

[0415] Cycloalkyl may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1- 10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 12 )R 13 、-C 0-8 Alkyl-N=S(O)R 13 R 14 、-C 0-8 Alkyl-N=SR 13 R 14 、-C 0-8 Alkyl-OS(O)2R 15 、-C 0-8 Alkyl-S(O) r R 15 、-C 0-8 Alkyl-OR 16 、-C 0-8 Alkyl-C(O)OR 16 、-C 0-8 Alkyl-C(O)SR 16 、-C 0-8 Alkyl-SC(O)R 17 、-C 0-8 Alkyl-C(O)R 17 、-C 0-8 Alkyl-OC(O)R 17 、-C 0- 8-alkyl-P(O)(R 17 )2. -C 0-8 Alkyl-NR 18 R 19 、-C 0-8 Alkyl-C(=NR 18 )R 17 、-C 0-8 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-8 Alkyl-C(O)NR 18 R 19 and -C0-8 Alkyl-N(R 18 )-C(O)R 17 substituted by a substituent.

[0416] "Cycloalkylene" refers to a group of the formula "=R a " group, wherein "R a " is a group after removing two hydrogen atoms from a "cycloalkyl" as defined above. Preferably, it includes a group after removing two hydrogen atoms from a cycloalkyl of 3 to 12, 3 to 8, or 3 to 6 carbon atoms, including but not limited to cyclopropylene Cyclobutylene Cyclopentylene etc. For example, in the following compound: The arrow indicates the cyclopropylene group.

[0417] Cycloalkylene may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0- 8-alkyl-S(O)(=NR 12 )R 13 、-C 0-8 Alkyl-N=S(O)R 13 R 14 、-C 0-8 Alkyl-N=SR 13 R 14 、-C 0-8 Alkyl-OS(O)2R 15 、-C 0-8 Alkyl-S(O) r R 15 、-C 0-8 Alkyl-OR 16 、-C 0-8 Alkyl-C(O)OR 16 、-C 0-8 Alkyl-C(O)SR 16 、-C 0-8 Alkyl-SC(O)R 17 、-C 0-8 Alkyl-C(O)R17 -C(O)R 0-8 alkyl-O-C(O)R 17 -C(O)R 0- 8alkyl-P(O)(R 17 )2 0-8 alkyl-NR 18 R 19 -C(O)R 0-8 alkyl-C(=NR 18 )R 17 -C(O)R 0-8 alkyl-N(R 18 )-C(=NR 19 )R 17 -C(O)R 0-8 alkyl-C(O)NR 18 R 19 -C(O)R 0-8 alkyl-N(R 18 )-C(O)R 17 .

[0418] "Heterocyclyl" or "heterocycle" means a saturated or partially unsaturated monocyclic or polycyclic ring cyclic aliphatic substituent, by which is meant that the cyclic aliphatic can contain one or more (preferably 1, 2, or 3) double bonds, but no ring has a completely conjugated pi-electron system, and one or more (preferably 1, 2, 3, or 4) ring atoms are selected from the group consisting of N, O, N+O- or S(O) r (wherein r is an integer of 0, 1, 2) heteroatoms, but excluding ring members of the type -O-O-, -O-S- or -S-S-, the remaining ring atoms being carbon. Preferred heterocyclyl groups include 3 to 12 or 3 to 8 or 3 to 6 ring atoms, for example, "3-6 membered heterocyclyl" means a heterocyclyl group containing 3 to 6 ring atoms, "3-8 membered heterocyclyl" means a heterocyclyl group containing 3 to 8 ring atoms, "4-8 membered heterocyclyl" means a heterocyclyl group containing 4 to 8 ring atoms, "4-10 membered heterocyclyl" means a heterocyclyl group containing 4 to 10 ring atoms, "5-8 membered heterocyclyl" means a heterocyclyl group containing 5 to 8 ring atoms, "3-12 membered heterocyclyl" means a heterocyclyl group containing 3 to 12 ring atoms.

[0419] Monocyclic heterocyclyl groups include, but are not limited to, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, oxetanyl, tetrahydrofuranyl and the like.

[0420] Polycyclic heterocyclyl groups include spiro, fused and bridged ring heterocyclyl groups. "Spiroheterocyclyl" means a polycyclic heterocyclyl group in which the single rings share a single atom (referred to as a spiro atom), wherein one or more (preferably 1, 2, 3, or 4) ring atoms are selected from the group consisting of N, O, N+O- or S(O) rheteroatoms, the remaining ring atoms being carbon. These can contain one or more double bonds (preferably 1, 2, or 3), but no ring has a completely conjugated pi-electron system. Spiroheterocyclyl groups are classified as mono-, bi-, or polycyclic depending on the number of rings that share a common spiro atom. Spiroheterocyclyl groups include, but are not limited to:

[0421] “Fused heterocyclyl” refers to a polycyclic heterocyclic radical wherein each ring in the system shares a pair of adjacent atoms with another ring in the system, one or more (preferably 1, 2, 3, or 4) rings can contain one or more (preferably 1, 2, or 3) double bonds, but no ring has a completely conjugated pi-electron system, wherein one or more (preferably 1, 2, 3, or 4) ring atoms are selected from N, O, N+O-, or S(O) r heteroatoms, the remaining ring atoms being carbon. Depending on the number of rings that make up the ring system, fused heterocycloalkyl groups can be bicyclic, tricyclic, tetracyclic, or polycyclic. Fused heterocyclyl groups include, but are not limited to:

[0422] “Bridged heterocyclyl” refers to a polycyclic heterocyclic radical wherein any two rings share two non-adjacent atoms, these can contain one or more (preferably 1, 2, or 3) double bonds, but no ring has a completely conjugated pi-electron system, wherein one or more (preferably 1, 2, 3, or 4) ring atoms are selected from N, O, N+O-, or S(O) r heteroatoms, the remaining ring atoms being carbon. Depending on the number of rings that make up the ring system, bridged heterocycloalkyl groups can be bicyclic, tricyclic, tetracyclic, or polycyclic. Bridged heterocyclyl groups include, but are not limited to:

[0423] The heterocyclyl ring can be fused to an aryl, heteroaryl, or cycloalkyl ring, wherein the ring that is attached to the parent structure is a heterocyclyl, including, but not limited to:

[0424] Heterocyclyl groups can be optionally substituted or unsubstituted, when substituted the substituent is preferably one or more (preferably 1, 2, 3, or 4) groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1- 10 alkyl, halosubstituted C 1-10 alkyl, deuterium-substituted C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-10 aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 alkyl-SF5, -C0-8 alkyl-S(O)(=N-R 12 )R 13 , -C 0-8 alkyl-N=S(O)R 13 R 14 , -C 0-8 alkyl-N=SR 13 R 14 , -C 0-8 alkyl-O-S(O)2R 15 , -C 0-8 alkyl-S(O) r R 15 , -C 0-8 alkyl-O-R 16 , -C 0-8 alkyl-C(O)OR 16 , -C 0-8 alkyl-C(O)SR 16 , -C 0-8 alkyl-S-C(O)R 17 , -C 0-8 alkyl-C(O)R 17 , -C 0-8 alkyl-O-C(O)R 17 , -C 0- 8alkyl-P(O)(R 17 )2, -C 0-8 alkyl-NR 18 R 19 , -C 0-8 alkyl-C(=NR 18 )R 17 , -C 0-8 alkyl-N(R 18 )-C(=NR 19 )R 17 , -C 0-8 alkyl-C(O)NR 18 R 19 , and -C 0-8 alkyl-N(R 18 )-C(O)R 17 .

[0425] "Heterocycloalkylene" refers to a group of the formula "=R b ", wherein "R b " is a "heterocycloalkyl" group as defined above less two hydrogen atoms. Preferred include groups of 3 to 12 or 3 to 8 carbon atoms or 3 to 6 carbon atoms less two hydrogen atoms, including but not limited to oxa aziridinylene yl, etc. For example, in the following compounds: The arrow-indicated box is an oxaspiro group.

[0426] Heterocycloalkyl groups can be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 alkyl, halosubstituted C 1-10 alkyl, deuterium-substituted C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-10 aryl, 5-10 membered heteroaryl, =0, =S, -C 0-8 alkyl-SF5, -C 0- 8alkyl-S(O)(=N-R 12 )R 13 , -C 0-8 alkyl-N=S(O)R 13 R 14 , -C 0-8 alkyl-N=SR 13 R 14 , -C 0-8 alkyl-O-S(O)2R 15 , -C 0-8 alkyl-S(O) r R 15 , -C 0-8 alkyl-O-R 16 , -C 0-8 alkyl-C(O)OR 16 , -C 0-8 alkyl-C(O)SR 16 , -C 0-8 alkyl-S-C(O)R 17 , -C 0-8 alkyl-C(O)R 17 , -C 0-8 alkyl-O-C(O)R 17 , -C 0- 8alkyl-P(O)(R 17 )2, -C 0-8 alkyl-NR 18 R 19 , -C 0-8 alkyl-C(=NR 18 )R 17 , -C 0-8 alkyl-N(R 18 )-C(=NR 19 )R 17 , -C 0-8alkyl-C(O)NR 18 R 19 and -C 0-8 alkyl-N(R 18 )-C(O)R 17 substituted by one or more (preferably 1, 2, 3, or 4) substituents independently selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C 6-10 alkyl, halo-substituted C 6-8 alkyl, deuterium-substituted C 1-10 alkyl, C 1-10 alkenyl, C 1-10 alkynyl, C 2-10 cycloalkyl, 3-12 membered heterocyclyl, C 2-10 aryl, 5-10 membered heteroaryl, -C 3-12 alkyl-SF5, -C 6-10 alkyl-S(O)(=N-R 0-8 )R 0-8 , -C 12 alkyl-N=S(O)R 13 R 0-8 , -C 13 alkyl-N=SR 14 R 0-8 , -C 13 alkyl-O-S(O)2R 14 , -C 0-8 alkyl-S(O) 15 R 0-8 , -C r alkyl-O-R 15 , -C 0-8 alkyl-C(O)OR 16 , -C 0-8 alkyl-C(O)SR 16 , -C 0-8 alkyl-C(O)NR 16 . 0-8

[0427] "Aryl" or "Aromatic ring" means a monocyclic or fused polycyclic (that is, sharing rings of adjacent pairs of carbon atoms) all-carbon ring having a conjugated pi-electron system (that is, it bears rings of adjacent pairs of carbon atoms), preferably a monocyclic all-carbon aryl group containing 6-10 or 6-8 carbons, for example, "C 6-10 "Aryl" means a monocyclic all-carbon aryl group containing 6-10 carbons, including but not limited to phenyl and naphthyl, "C 6-8 "Aryl" means a monocyclic all-carbon aryl group containing 6-8 carbons. The aryl ring can be fused to a heteroaryl, heterocyclyl, or cycloalkyl ring, where the ring that is attached to the parent structure is the aryl ring, including but not limited to:

[0428] "Aryl" can be substituted or unsubstituted, and when substituted, the substituents are preferably one or more (preferably 1, 2, 3, or 4) groups independently selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C 1-10 alkyl, halo-substituted C 1-10 alkyl, deuterium-substituted C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-10 aryl, 5-10 membered heteroaryl, -C 0-8 alkyl-SF5, -C 0-8 alkyl-S(O)(=N-R 12 )R 13 , -C 0-8 alkyl-N=S(O)R 13 R 14 , -C 0-8 alkyl-N=SR 13 R 14 , -C 0-8 alkyl-O-S(O)2R 15 , -C 0-8 alkyl-S(O) r R 15 , -C 0-8 alkyl-O-R 16 , -C 0-8 alkyl-C(O)OR 16 , -C 0-8 alkyl-C(O)SR 16 , -C 0-8alkyl-S-C(O)R 17 , -C 0-8 alkyl-C(O)R 17 , -C 0-8 alkyl-O-C(O)R 17 , -C 0-8 alkyl-P(O)(R 17 )2, -C 0-8 alkyl-NR 18 R 19 , -C 0-8 alkyl-C(=NR 18 )R 17 , -C 0-8 alkyl-N(R 18 )-C(=NR 19 )R 17 , -C 0-8 alkyl-C(O)NR 18 R 19 , and -C 0-8 alkyl-N(R 18 )-C(O)R 17 .

[0429] "Heteroaryl" refers to a heteroaromatic system comprising one or more (preferably 1, 2, 3, or 4) heteroatoms, including N, O, N, and S(O) r wherein r is an integer 0, 1, 2, preferably a heteroaromatic system containing 5-10 or 5-8 or 5-6 ring atoms, for example, "5-8 membered heteroaryl" refers to a heteroaromatic system containing 5-8 ring atoms, "5-10 membered heteroaryl" refers to a heteroaromatic system containing 5-10 ring atoms, including but not limited to furanyl, thienyl, pyridyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl, and the like. The heteroaryl ring can be fused to an aryl, heterocyclyl, or cycloalkyl ring, wherein the ring that is attached to the parent structure is a heteroaryl ring, including but not limited to:

[0430] "Heteroaryl" can be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more (preferably 1, 2, 3, or 4) groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 alkyl, halo-substituted C 1-10 alkyl, deuterium-substituted C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-10 aryl, 5-10 membered heteroaryl, -C 0-8 alkyl-SF5, -C0-8 alkyl-S(O)(=N-R 12 )R 13 , -C 0-8 alkyl-N=S(O)R 13 R 14 , -C 0-8 alkyl-N=SR 13 R 14 , -C 0-8 alkyl-O-S(O)2R 15 , -C 0-8 alkyl-S(O) r R 15 , -C 0-8 alkyl-O-R 16 , -C 0-8 alkyl-C(O)OR 16 , -C 0-8 alkyl-C(O)SR 16 , -C 0-8 alkyl-S-C(O)R 17 , -C 0-8 alkyl-C(O)R 17 , -C 0-8 alkyl-O-C(O)R 17 , -C 0-8 alkyl-P(O)(R 17 )2, -C 0-8 alkyl-NR 18 R 19 , -C 0-8 alkyl-C(=NR 18 )R 17 , -C 0-8 alkyl-N(R 18 )-C(=NR 19 )R 17 , -C 0-8 alkyl-C(O)NR 18 R 19 and -C 0-8 alkyl-N(R 18 )-C(O)R 17 .

[0431] "Alkenyl" refers to an alkyl group as defined above containing at least two carbon atoms and at least one carbon-carbon double bond, preferably a straight or branched chain alkenyl group containing from 2 to 10 or 2 to 4 carbons, for example, "C 2-10 "Alkenyl" refers to a straight or branched chain alkenyl group containing from 2 to 10 carbons, "C 2-4 "Alkenyl" refers to a straight or branched chain alkenyl group containing from 2 to 4 carbons. Included within this definition are ethenyl, 1-propenyl, 2-propenyl, 1-, 2-, or 3-butenyl, and the like.

[0432] "Alkenyl" may be substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 12 )R 13 、-C 0-8 Alkyl-N=S(O)R 13 R 14 、-C 0-8 Alkyl-N=SR 13 R 14 、-C 0-8 Alkyl-OS(O)2R 15 、-C 0-8 Alkyl-S(O) r R 15 、-C 0-8 Alkyl-OR 16 、-C 0-8 Alkyl-C(O)OR 16 、-C 0-8 Alkyl-C(O)SR 16 、-C 0-8 Alkyl-SC(O)R 17 、-C 0-8 Alkyl-C(O)R 17 、-C 0-8 Alkyl-OC(O)R 17 、-C 0-8 Alkyl-P(O)(R 17 )2. -C 0-8 Alkyl-NR 18 R 19 、-C 0-8 Alkyl-C(=NR 18 )R 17 、-C 0-8 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-8 Alkyl-C(O)NR 18 R19 and -C 0-8 Alkyl-N(R 18 )-C(O)R 17 substituted by a substituent.

[0433] "Alkynyl" refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon triple bond, preferably a straight or branched chain alkynyl group containing 2-10 or 2-4 carbon atoms, for example, "C 2-10 "Alkynyl" refers to a straight or branched chain alkynyl containing 2 to 10 carbon atoms. 2-4 "Alkynyl" refers to a straight or branched chain alkynyl containing 2-4 carbon atoms, including but not limited to ethynyl, 1-propynyl, 2-propynyl, 1-, 2- or 3-butynyl, etc.

[0434] "Alkynyl" may be substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 12 )R 13 、-C 0-8 Alkyl-N=S(O)R 13 R 14 、-C 0-8 Alkyl-N=SR 13 R 14 、-C 0-8 Alkyl-OS(O)2R 15 、-C 0-8 Alkyl-S(O) r R 15 、-C 0-8 Alkyl-OR 16 、-C 0-8 Alkyl-C(O)OR 16 、-C 0-8 Alkyl-C(O)SR 16 、-C 0-8 Alkyl-SC(O)R 17 、-C 0-8 Alkyl-C(O)R 17 、-C 0-8alkyl-O-C(O)R 17 , -C 0-8 alkyl-P(O)(R 17 )2, -C 0-8 alkyl-NR 18 R 19 , -C 0-8 alkyl-C(=NR 18 )R 17 , -C 0-8 alkyl-N(R 18 )-C(=NR 19 )R 17 , -C 0-8 alkyl-C(O)NR 18 R 19 , and -C 0-8 alkyl-N(R 18 )-C(O)R 17 .

[0435] "Alkoxy" means -O-alkyl, where alkyl is as defined above, for example, "C 1-10 "Alkoxy" means an alkyloxy radical containing 1 to 10 carbons, "C 1-4 "Alkoxy" means an alkyloxy radical containing 1 to 4 carbons, "C 1-2 "Alkoxy" means an alkyloxy radical containing 1 to 2 carbons, including but not limited to methoxy, ethoxy, propyloxy, butyloxy, and the like.

[0436] "Alkoxy" can be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more (preferably 1, 2, 3, or 4) groups independently selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C 1-10 alkyl, halosubstituted C 1-10 alkyl, deuterium- substituted C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-10 aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 alkyl-SF5-C 0-8 alkyl-S(O)(=N-R 12 )R 13 , -C 0-8 alkyl-N=S(O)R 13 R 14 , -C 0-8 alkyl-N=SR 13 R 14 , -C 0-8 alkyl-O-S(O)2R 15 , -C0-8 alkyl-S(O) r R 15 , -C 0-8 alkyl-O-R 16 , -C 0-8 alkyl-C(O)OR 16 , -C 0-8 alkyl-C(O)SR 16 , -C 0-8 alkyl-S-C(O)R 17 , -C 0-8 alkyl-C(O)R 17 , -C 0-8 alkyl-O-C(O)R 17 , -C 0- 8alkyl-P(O)(R 17 )2, -C 0-8 alkyl-NR 18 R 19 , -C 0-8 alkyl-C(=NR 18 )R 17 , -C 0-8 alkyl-N(R 18 )-C(=NR 19 )R 17 , -C 0-8 alkyl-C(O)NR 18 R 19 , and -C 0-8 alkyl-N(R 18 )-C(O)R 17 .

[0437] "Cycloalkoxy" or "cycloalkyloxy" refers to -O-cycloalkyl, wherein cycloalkyl is as defined above, for example, "C 3-12 cycloalkoxy" refers to cycloalkyloxy groups containing 3 to 12 carbons, "C 3-6 cycloalkoxy" refers to cycloalkyloxy groups containing 3 to 6 carbons, including, but not limited to, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.

[0438] "Cycloalkoxy" or "cycloalkyloxy" can be optionally substituted or unsubstituted, and when substituted, is preferably substituted with one or more (preferably 1, 2, 3, or 4) groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 alkyl, halosubstituted C 1-10 alkyl, deuterium- substituted C 1-10 alkyl, C 2-10 alkenyl, C 2- 10 alkynyl, C 3-12 cycloalkyl, 3- to 12-membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, =0, =S, -C 0- 8alkyl-SF5, -C 0-8 alkyl-S(O)(=N-R 12 )R 13 , -C 0-8 alkyl-N=S(O)R 13 R 14 , -C 0-8 alkyl-N=SR 13 R 14 , -C 0-8 alkyl-O-S(O)2R 15 , -C 0-8 alkyl-S(O) r R 15 , -C 0-8 alkyl-O-R 16 , -C 0-8 alkyl-C(O)OR 16 , -C 0-8 alkyl-C(O)SR 16 , -C 0-8 alkyl-S-C(O)R 17 , -C 0-8 alkyl-C(O)R 17 , -C 0- 8alkyl-O-C(O)R 17 , -C 0-8 alkyl-P(O)(R 17 )2, -C 0-8 alkyl-NR 18 R 19 , -C 0-8 alkyl-C(=NR 18 )R 17 , -C 0-8 alkyl-N(R 18 )-C(=NR 19 )R 17 , -C 0-8 alkyl-C(O)NR 18 R 19 and -C 0-8 alkyl-N(R 18 )-C(O)R 17 .

[0439] "Heterocyclyloxy" or "heterocyclyl-oxy" means -O-heterocyclyl, where heterocyclyl is as defined above, including, but not limited to, azetidinyloxy, oxetanyloxy, azetidinyl, oxetanyl, azetidinyl, oxetanyl, and the like.

[0440] "Heterocyclyloxy" or "heterocyclyloxy" may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2- 10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0- 8-alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 12 )R 13 、-C 0-8 Alkyl-N=S(O)R 13 R 14 、-C 0-8 Alkyl-N=SR 13 R 14 、-C 0-8 Alkyl-OS(O)2R 15 、-C 0-8 Alkyl-S(O) r R 15 、-C 0-8 Alkyl-OR 16 、-C 0-8 Alkyl-C(O)OR 16 、-C 0-8 Alkyl-C(O)SR 16 、-C 0-8 Alkyl-SC(O)R 17 、-C 0-8 Alkyl-C(O)R 17 、-C 0- 8-Alkyl-OC(O)R 17 、-C 0-8 Alkyl-P(O)(R 17 )2. -C 0-8 Alkyl-NR 18 R 19 、-C 0-8 Alkyl-C(=NR 18 )R 17 、-C 0-8 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-8 Alkyl-C(O)NR 18 R19 and -C 0-8 alkyl-N(R 18 )-C(O)R 17 substituted by the substituents defined in any of paragraphs 1 to 7.

[0441] "C 1-10 alkanoyl" refers to a carbonyl group, C(O), attached to an alkyi group, as in "C 1-10 alkanoyl" refers to a carbonyl group, C(O), attached to an alkyi group, as in "C 0- 9alkyl-C(O)-", for example, "C1alkyl-C(O)-" means acetyl; "C2alkyl-C(O)-" means propionyl; and "C3alkyl-C(O)-" means butyryl or isobutyryl.

[0442] "-C 0-8 alkyl-S(O)(=N-R 12 )R 13 " means the sulfur atom in -S(O)(=N-R 12 )R 13 is attached to a C 0-8 alkyl group, wherein C 0-8 alkyl is as previously described.

[0443] "-C 0-8 alkyl-N=S(O)R 13 R 14 " means the nitrogen atom in -N=S(O)R 13 R 14 is attached to a C 0-8 alkyl group, wherein C 0-8 alkyl is as previously described.

[0444] "-C 0-8 alkyl-N=SR 13 R 14 " means the nitrogen atom in -N=SR 13 R 14 is attached to a C 0-8 alkyl group, wherein C 0-8 alkyl is as previously described.

[0445] "-C 0-8 alkyl-O-S(O)2R 15 " means the oxygen atom in -O-S(O)2R 15 is attached to a C 0-8 alkyl group, wherein C 0- 8alkyl is as previously described.

[0446] "-C 0-8 alkyl-S(O) r R 15 " means the sulfur atom in -S(O) r R 15the sulfur atom in -S- is attached to the C 0-8 alkyl group, wherein the definition of C 0-8 alkyl is as indicated above.

[0447] "C(O)OR 0-8 alkyl-O-R 16 " means -O-R 16 the oxygen atom in -O- is attached to the C 0-8 alkyl group, wherein the definition of C 0-8 alkyl is as indicated above.

[0448] "C(O)OR 0-8 alkyl-C(O)OR 16 " means -C(O)OR 16 the carbonyl group in -C(O)- is attached to the C 0-8 alkyl group, wherein the definition of C 0-8 alkyl is as indicated above.

[0449] "C(O)OR 0-8 alkyl-C(O)SR 16 " means -C(O)SR 16 the carbonyl group in -C(O)- is attached to the C 0-8 alkyl group, wherein the definition of C 0-8 alkyl is as indicated above.

[0450] "C(O)OR 0-8 alkyl-S-C(O)R 17 " means -S-C(O)R 17 the sulfur atom in -S- is attached to the C 0-8 alkyl group, wherein the definition of C 0-8 alkyl is as indicated above.

[0451] "C(O)OR 0-8 alkyl-C(O)R 17 " means -C(O)R 17 the carbonyl group in -C(O)- is attached to the C 0-8 alkyl group, wherein the definition of C 0-8 alkyl is as indicated above.

[0452] "C(O)OR 0-8 alkyl-O-C(O)R 17 " means -O-C(O)R 17 the oxygen atom in -O- is attached to the C 0-8 alkyl group, wherein the definition of C 0-8 alkyl is as indicated above.

[0453] "C(O)OR 0-8 alkyl-P(O)(R 17 )2" means -P(O)(R 17 )2 wherein the phosphorus atom in -P(O)- is attached to the C 0-8 alkyl group, wherein the definition of C0-8 alkyl is as defined above.

[0454] "C(=NR 0-8 alkyl-NR 18 R 19 " means that the nitrogen atom in -NR 18 R 19 is attached to a C 0-8 alkyl group, wherein the C 0-8 alkyl is as defined above.

[0455] "C(=NR 0-8 alkyl-C(=NR 18 )R 17 " means that the carbon atom in -C(=NR 18 )R 17 is attached to a C 0-8 alkyl group, wherein the C 0-8 alkyl is as defined above.

[0456] "C(=NR 0-8 alkyl-N(R 18 )-C(=NR 19 )R 17 " means that the nitrogen atom in -N(R 18 )-C(=NR 19 )R 17 is attached to a C 0-8 alkyl group, wherein the C 0-8 alkyl is as defined above.

[0457] "C(=NR 0-8 alkyl-C(O)NR 18 R 19 " means that the carbonyl group in -C(O)NR 18 R 19 is attached to a C 0-8 alkyl group, wherein the C 0- 8alkyl is as defined above.

[0458] "C(=NR 0-8 alkyl-N(R 18 )-C(O)R 17 " means that the nitrogen atom in -N(R 18 )-C(O)R 17 is attached to a C 0-8 alkyl group, wherein the C 0-8 alkyl is as defined above.

[0459] "halo-substituted C 1-10 alkyl" means an alkyl group of 1-10 carbons in which the hydrogens are optionally replaced with fluorine, chlorine, bromine, iodine atoms, including but not limited to difluoromethyl, dichloromethyl, dibromomethyl, trifluoromethyl, trichloromethyl, tribromomethyl, and the like.

[0460] "halo-substituted C 1-10 "alkoxy" means an alkoxy group of 1 to 10 carbons in which the alkyl group is optionally substituted with fluorine, chlorine, bromine, iodine atoms. Included, but not limited to, difluoromethoxy, dichloromethoxy, dibromomethoxy, trifluoromethoxy, trichloromethoxy, tribromomethoxy, and the like.

[0461] "deuterium-substituted C 1-10 "alkyl" means an alkyl group of 1 to 10 carbons in which the hydrogen atoms are optionally substituted with deuterium atoms. Included, but not limited to, monodeuteromethyl, diduteromethyl, trideuteromethyl, and the like.

[0462] "halogen" means fluorine, chlorine, bromine, or iodine.

[0463] "optionally" or "optionally" means that the subsequently described event or circumstance can or can not occur, and thus the description includes instances where the event or circumstance occurs and instances where it does not, i.e., both substituted and non-substituted instances. For example, "heterocyclyl optionally substituted with alkyl" means that alkyl can or can not be present, and the description includes instances where the heterocyclyl group is substituted with alkyl and instances where the heterocyclyl group is not substituted with alkyl.

[0464] "substituted" means that one or more "hydrogen atoms" in a group are independently of one another replaced by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, in accordance with the valency theory of chemistry, and that the person skilled in the art is able to determine (experimentally or theoretically) possible or impossible substitutions without excessive effort. For example, an amino or hydroxyl group with a free hydrogen can be unstable when bound to a carbon atom with an unsaturated bond (such as an alkene).

[0465] "Stereoisomers," whose English name is stereoisomer, refer to isomers resulting from the different spatial arrangements of atoms in a molecule. They can be divided into two types: cis-trans isomers and enantiomers, or into two major categories: enantiomers and diastereomers. Stereoisomers caused by rotation about single bonds are called conformational stereoisomers, sometimes also called rotamers. Stereoisomers caused by bond length, bond angle, the presence of double bonds or rings in the molecule are called configuration stereoisomers, which are further divided into two categories. Among them, isomers caused by the inability to rotate freely around double bonds or single bonds of ring carbon atoms are called geometric isomers, also called cis-trans isomers, and are divided into two configurations: Z and E. For example, cis-2-butene and trans-2-butene are a pair of geometric isomers. Stereoisomers with different optical rotation properties due to the lack of anti-axial symmetry in the molecule are called optical isomers and are divided into R and S configurations. In this invention, "stereoisomers," unless otherwise specified, are understood to include one or more of the aforementioned enantiomers, configurational isomers, and conformational isomers.

[0466] "Pharmaceutically acceptable salt" in the present invention refers to pharmaceutically acceptable acid addition salts, including inorganic acid salts and organic acid salts, which can be prepared by methods known in the art.

[0467] A "pharmaceutical composition" refers to a mixture containing one or more compounds described herein, or their physiologically / pharmaceutically acceptable salts or prodrugs, together with other chemical components, as well as other components such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitating absorption of the active ingredient and thereby exerting its biological activity.

[0468] The present invention will be further described in detail and completely below with reference to the embodiments, but the present invention is by no means limited thereto, and the present invention is not limited to the contents of the embodiments.

[0469] The structures of the compounds of the present invention are determined by nuclear magnetic resonance (NMR) and / or liquid chromatography-mass spectrometry (LC-MS). NMR chemical shifts (δ) are given in parts per million (ppm). NMR measurements were performed using a Bruker AVANCE-400 / 500 NMR spectrometer, using deuterated dimethyl sulfoxide (DMSO-d6), deuterated methanol (CD3OD), and deuterated chloroform (CDCl3) as the solvents, with tetramethylsilane (TMS) as the internal standard.

[0470] LC-MS determination was performed using Agilent 6120 mass spectrometer. HPLC determination was performed using Agilent 1200 DAD high pressure liquid chromatograph (Sunfire C18 150x4.6mm column) and Waters 2695-2996 high pressure liquid chromatograph (Gimini C18 150x4.6mm column).

[0471] Thin layer chromatography silica gel plate was used Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate, TLC used specification was 0.15mm-0.20mm, thin layer chromatography separation and purification product used specification was 0.4mm-0.5mm. Column chromatography generally used Yantai Huanghai silica gel 200-300 mesh silica gel as carrier.

[0472] The starting materials in the embodiments of the present application are known and commercially available, or can be synthesized using or according to methods known in the art. The reagent "Pd-118" in the embodiments of the present application refers to "[1,1'-bis(di-tert-butylphosphino)ferrocene]palladium dichloride", and "XPhos Pd G4" refers to "(SP-4-3)-[dicyclohexyl[2,4,6-tris(isopropyl)[1,1-biphenyl]-2-yl]phosphine](methanesulfonic acid)[2-(methylamino)[1,1-biphenyl]-2-yl]palladium".

[0473] Unless otherwise specified, all reactions of the present application were carried out under continuous magnetic stirring under dry nitrogen or argon atmosphere, the solvent was dry solvent, and the reaction temperature unit was degree Celsius (℃).

[0474] I. Preparation of intermediates

[0475] Preparation of intermediate A1: (2-methylene-5-(3,4,5-trifluorophenyl)tetrahydro-1H-pyrrozine-7a(5H)-yl)methanol

[0476] First step: synthesis of (3,4,5-trifluorophenyl)magnesium bromide

[0477] 5-bromo-1,2,3-trifluorobenzene (25 g, 118.5 mmol) was dissolved in tetrahydrofuran (100 mL), and then magnesium (3 g, 123.4 mmol) and iodine (2.8 g, 11.0 mmol) were added. The reaction solution was reacted at 70℃ for 2 hours. (3,4,5-trifluorophenyl)magnesium bromide (100 g, crude) was obtained after the reaction was completed.

[0478] Second step: synthesis of methyl 2-((tert-butoxycarbonyl)amino)-5-oxo-5-(2,3,4-trifluorophenyl)pentanoate

[0479] (3,4,5-trifluorophenyl)magnesium bromide (100 g, crude) was added and the reaction was stirred at 20 °C for 10 h. After the reaction was completed by LCMS, the reaction was concentrated and the residue was separated by flash silica gel column [0-30%: ethyl acetate: petroleum ether] to give 2-((tert-butoxycarbonyl)amino)-5-oxo-5-(2,3,4- trifluorophenyl)pentanoic acid methyl ester (10 g, yield: 25.9%). MS m / z (ESI): 320.6 [M+1-56] + .

[0480] Step 3: Synthesis of 1-(tert-butyl) 2-methyl 5-(3,4,5-trifluorophenyl)pyrrolidine-1,2- dicarboxylate

[0481] Methyl 2-((tert-butoxycarbonyl)amino)-5-oxo-5-(2,3,4-trifluorophenyl)pentanoate (10 g, 26.6 mmol) was dissolved in dichloromethane (10 mL), and trifluoroacetic acid (5 mL) was added. The reaction was stirred at 20 °C for 10 h. Sodium borohydride (1 g, 26.4 mmol) was added to the reaction, and the reaction was stirred at 20 °C for 1 h. Sodium carbonate (6 g, 56.6 mmol) and di-tert-butyl dicarbonate (5.9 g, 27.0 mmol) were added to the reaction, and the reaction was stirred at 20 °C for 2 h. After the reaction was completed by LCMS, the reaction was concentrated and the residue was separated by flash silica gel column [0-30%: ethyl acetate: petroleum ether] to give 1-(tert-butyl) 2-methyl 5-(3,4,5-trifluorophenyl)pyrrolidine-1,2-dicarboxylate (5 g, yield: 52.2%). MS m / z (ESI): 304.6 [M+1-56] + .

[0482] Step 4: Synthesis of 1-(tert-butyl) 2-methyl 2-(2-(chloromethyl)allyl)-5-(3,4,5- trifluorophenyl)pyrrolidine-1,2-dicarboxylate

[0483] Dissolve 5-(3,4,5-trifluorophenyl)pyrrolidine-1,2-dicarboxylic acid 1-(tert-butyl) 2-methyl ester (5 g, 13.9 mmol) in tetrahydrofuran (20 mL) and condense at -78 °C, then add lithium bis(trimethylsilyl)amide (14 mL, 14.0 mmol) at -78 °C. After 1 hour of reaction at -78 °C, add 3-chloro-2-chloromethylpropene (1.8 g, 14.4 mmol), and stir at 25 °C for 18 hours. Concentrate the reaction solution under reduced pressure to remove the solvent, and separate the residue by flash silica gel column [0-15%: ethyl acetate: petroleum ether] to obtain 1-(tert-butyl) 2-methyl 2-(2-(chloromethyl)allyl)-5-(3,4,5-trifluorophenyl)pyrrolidine-1,2-dicarboxylate (3 g, yield: 48.1%). MS m / z (ESI): 392.6 [M+1-56] + .

[0484] Fifth step: Synthesis of methyl 2-methylene-5-(3,4,5-trifluorophenyl)tetrahydro-1H-pyrrozine-7a(5H)-carboxylate

[0485] Dissolve 1-(tert-butyl) 2-methyl 2-(2-(chloromethyl)allyl)-5-(3,4,5-trifluorophenyl)pyrrolidine-1,2-dicarboxylate (3 g, 6.70 mmol) in dichloromethane (5 mL) and trifluoroacetic acid (5 mL), and stir at 25 °C for 18 hours. Concentrate the reaction solution under reduced pressure to remove the solvent, and separate the residue by flash silica gel column [0-15%: ethyl acetate: petroleum ether] to obtain methyl 2-methylene-5-(3,4,5-trifluorophenyl)tetrahydro-1H-pyrrozine-7a(5H)-carboxylate (1.5 g, yield: 71.9%). MS m / z (ESI): 312.6 [M+1] + .

[0486] Sixth step: Synthesis of (2-methylene-5-(3,4,5-trifluorophenyl)tetrahydro-1H-pyrrozine-7a(5H)-yl)methanol

[0487] Dissolve methyl 2-methylene-5-(3,4,5-trifluorophenyl)tetrahydro-1H-pyrrozine-7a(5H)-carboxylate (0.5 g, 1.5 mmol) in tetrahydrofuran (5 mL), and add lithium aluminum hydride (1.5 mL 1.5 mmol) at 25 °C. Stir for 18 hours, and concentrate the reaction solution under reduced pressure to remove the solvent. Separate the residue by flash silica gel column [0-15%: dichloromethane: methanol] to obtain (2-methylene-5-(3,4,5-trifluorophenyl)tetrahydro-1H-pyrrozine-7a(5H)-yl)methanol (0.2 g, yield: 44.0%). MS m / z (ESI): 284.3 [M+1] +.

[0488] Preparation of Intermediate A2 Isomer 1 and Isomer 2: 3-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)tetrahydro-1H-pyrrolizin-7a(5H)-yl)methanol (Isomer 1 and Isomer 2)

[0489] (1) Synthesis of Intermediate A2 Isomer 1: 3-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)tetrahydro-1H-pyrrolizin-7a(5H)-yl)methanol (Isomer 1)

[0490] Ethyl 3-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)tetrahydro-1H-pyrrolizin-7a(5H)- carboxylate (Isomer 1) (2.80 g, 8.25 mmol, prepared by the method disclosed in patent document WO2023197984, page 78, example 140, first to fourth steps) was dissolved in tetrahydrofuran (50 mL), then lithium aluminum hydride tetrahydrofuran solution (6.60 mL, 16.50 mmol) was added dropwise at 0°C, and the reaction solution was reacted at 0°C for 1 hour. The reaction mixture was quenched with saturated aqueous ammonium chloride solution (200 mL) and extracted with ethyl acetate (200 mL), washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, and the solvent was removed by concentration under reduced pressure, and the residue was separated by flash silica gel column [0-30% EA in PE] to obtain 3-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)tetrahydro-1H-pyrrolizin-7a(5H)-yl)methanol (Isomer 1) (2 g, yield: 81.53%). ESI-MS: 298.4 [M+1] + .

[0491] (2) Synthesis of Intermediate A2 Isomer 2: 3-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)tetrahydro-1H-pyrrolizin-7a(5H)-yl)methanol (Isomer 2)

[0492] Prepared by the method of synthesis of Intermediate A2 Isomer 1.

[0493] Preparation of Intermediate A3: (2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'- pyrrolizin-7a'(5'H)-yl)methanol (Isomer 1, Isomer 2, Isomer 3 and Isomer 4)

[0494] First step: Synthesis of ethyl 2,2-difluoro-5'-oxodihydro-1'H,3'H-spiro(cyclopropane-1,2'- pyrrolizin-7a'(5'H)-carboxylate (Isomer B1 and Isomer B2)

[0495] Ethyl 2-methylene-5-oxotetrahydro-lH-pyrrolizine-7a(5H)-carboxylate (9.5 g, 45.4 mmol) and (bromodifluoromethyl)trimethylsilane (17.6 mL, 113 mmol) were dissolved in toluene (100 mL). Tetrabutylammonium bromide (0.704 g, 2.27 mmol) was added under nitrogen protection, and the reaction was carried out at 110 °C for 16 hours. The reaction solution was directly concentrated under reduced pressure to remove the solvent, and the residue was separated by flash silica gel column [0-30% EA in PE] to obtain ethyl 2,2-difluoro-5'-oxodihydro-l'H,3'H-spiro(cyclopropane-l,2'-pyrrolizine)-7a'(5'H)-carboxylate (isomer Bl) (5.3 g, yield: 45.0%) and ethyl 2,2-difluoro-5'-oxodihydro-l'H,3'H-spiro(cyclopropane-l,2'-pyrrolizine)-7a'(5'H)-carboxylate (isomer B2) (4.5 g, yield: 38.23%).

[0496] Isomer Bl:

[0497] 1 H NMR (400 MHz, CDCl3) δ 4.28 (q, J = 7.1 Hz, 2H), 4.06 (d, J = 12.0 Hz, 1H), 3.09 (br d, J = 12.0 Hz, 1H), 2.87-2.76 (m, 1H), 2.62 (ddd, J = 1.9, 9.1, 13.2 Hz, 1H), 2.49 (ddd, J = 2.0, 9.5, 16.7 Hz, 1H), 2.37-2.29 (m, 1H), 2.23-2.10 (m, 2H), 1.48-1.36 (m, 2H), 1.33 (t, J = 7.1 Hz, 3H).

[0498] Isomer B2:

[0499] 1 H NMR (400 MHz, CDCl3) δ 4.27 (q, J = 7.2 Hz, 2H), 3.70 (br d, J = 11.7 Hz, 1H), 3.43 (d, J = 11.7 Hz, 1H), 2.88-2.69 (m, 2H), 2.55-2.43 (m, 2H), 2.15 (td, J = 9.9, 12.4 Hz, 1H), 2.00 (td, J = 3.3, 13.0 Hz, 1H), 1.49-1.39 (m, 2H), 1.33 (t, J = 7.2 Hz, 3H).

[0500] Step 2: Synthesis of (2,2-difluorodihydro-l'H,3'H-spiro(cyclopropane-l,2'- pyrrolizine)-7a'(5'H)-yl)methanol (Isomer 1 and Isomer 2)

[0501] (1) Synthesis of Intermediate A3 Isomer 1: (2,2-difluorodihydro-l'H,3'H- spiro(cyclopropane-l,2'-pyrrolizine)-7a'(5'H)-yl)methanol (Isomer 1)

[0502] Ethyl 2,2-difluoro-5'-oxodihydro-l'H,3'H-spiro(cyclopropane-l,2'-pyrrolizine)-7a'(5'H)- carboxylate (Isomer 1) (5.1 g, 19.672 mmol) was dissolved in tetrahydrofuran (50 mL) and lithium aluminum hydride (1.49 g, 39.3 mmol) was added under nitrogen protection at 0 °C. The reaction was stirred at 60 °C for 2 hours. LC-MS showed the reaction was completed. The reaction was quenched by dropwise addition of water (1 mL), 15% sodium hydroxide solution (2 mL), water (1 mL) at 0 °C. The solid undissolved was removed by filtration and the solvent was removed by concentration under reduced pressure to give (2,2-difluorodihydro-l'H,3'H-spiro(cyclopropane-l,2'-pyrrolizine)-7a'(5'H)-yl)methanol (Intermediate A3 Isomer 1) (3.6 g, yield: 90.0%). ESI-MS: 204.1 [M+1] + .

[0503] 1 H NMR (400 MHz, CDCl3) δ 3.47-3.30 (m, 2H), 3.20-3.07 (m, 2H), 2.83 (d, J = 12.1 Hz, 1H), 2.73-2.61 (m, 1H), 2.08-1.96 (m, 1H), 1.95-1.84 (m, 3H), 1.82-1.60 (m, 2H), 1.41-1.32 (m, 1H), 1.31-1.18 (m, 1H).

[0504] (2) Synthesis of Intermediate A3 Isomer 2: (2,2-difluorodihydro-l'H,3'H- spiro(cyclopropane-l,2'-pyrrolizine)-7a'(5'H)-yl)methanol (Isomer 2)

[0505] Ethyl 2,2-difluoro-5'-oxodihydro-l'H,3'H-spiro(cyclopropane-l,2'-pyrrolizine)-7a'(5'H)- carboxylate (isomer 2) (4.3 g, 16.6 mmol) was dissolved in tetrahydrofuran (50 mL), and lithium aluminum hydride (1.57 g, 41.4 mmol) was added under nitrogen protection at 0 °C. The reaction was carried out at 60 °C for 2 h. LC-MS showed that the reaction was completed. The reaction was quenched by dropwise addition of water (1 mL), 15% sodium hydroxide solution (2 mL), and water (1 mL) at 0 °C. The solid undissolved matter was removed by filtration, and the solvent was removed by concentration under reduced pressure to obtain (2,2-difluorodihydro-l'H,3'H-spiro(cyclopropane-l,2'-pyrrolizine)-7a'(5'H)-yl)methanol (intermediate A3 isomer 2) (2.8 g, yield: 83.1%). ESI-MS: 204.1 [M+1] + .

[0506] 1 H NMR (400 MHz, CDC13) δ 3.42-3.30 (m, 2H), 3.26 (d, J = 11.0 Hz, 1H), 3.15-3.03 (m, 1H), 2.83-2.75 (m, 2H), 2.05 (d, J = 13.2 Hz, 1H), 2.00-1.90 (m, 2H), 1.89-1.68 (m, 3H), 1.38-1.29 (m, 2H).

[0507] Third Step: Synthesis of 7a'-(((tert-butyldiphenylsilyl)oxy)methyl)-2,2-difluorotetrahydro- l'H,3'H-spiro(cyclopropane-l,2'-pyrrolizine)

[0508] Intermediate A3 isomer 1 (8.8 g, 43.301 mmol) and tert-butyldiphenylsilyl chloride (16.8 mL, 64.9 mmol) were dissolved in dichloromethane (200 mL), and imidazole (5.9 g 86.6 mmol) was added under nitrogen protection at 0 °C. The reaction was carried out at 25 °C for 18 h. The reaction liquid was separated by extraction with water (100 mL) and dichloromethane (100 mL*3), and the organic phase was washed with saturated brine (100 mL). After drying over anhydrous sodium sulfate, the solvent was removed by concentration under reduced pressure. The residue was separated by flash silica gel column [0-30% EA in PE] to obtain 7a'-(((tert-butyldiphenylsilyl)oxy)methyl)-2,2-difluorotetrahydro-l'H,3'H-spiro(cyclopropane-l,2'-pyrrolizine) (14.2 g, yield: 74.3%). ESI-MS: 442.0 [M+1] + .

[0509] 1H NMR (400 MHz, CDC13) δ 7.69 (ddd, J = 1.5, 4.7, 7.8 Hz, 4H), 7.47 - 7.37 (m, 6H), 3.51 (s, 2H), 3.11 - 3.03 (m, 2H), 2.79 (d, J = 11.9 Hz, 1H), 2.64 - 2.55 (m, 1H), 2.11 - 2.01 (m, 2H), 1.90 (d, J = 13.4 Hz, 1H), 1.85 - 1.77 (m, 1H), 1.72 - 1.55 (m, 4H), 1.10 (s, 9H).

[0510] Fourth Step: Synthesis of Isomer CI and Isomer C2 of 7a'-(((tert-Butyldiphenylsilyl)oxy)methyl)-2,2-difluorotetrahydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolizine)

[0511] Isomer CI (6.2 g, purity: 99.770%, ee value: 99.98%) and Isomer C2 (5.8 g, purity: 99.687%, ee value: 99.76%) were obtained respectively by chiral resolution of 7a'-(((tert-butyldiphenylsilyl)oxy)methyl)-2,2-difluorotetrahydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolizine) (14.2 g) (Column: DAICEL CHIRALPAK IC (250 mm*50 mm, 10 um), Condition: CO2-EtOH (0.1% NH3H2O) Begin B: 20%, End B: 20% Flow Rate 200 mL / min)). ESI-MS: 442.0 [M+1] + .

[0512] Isomer CI:

[0513] 1 H NMR (400 MHz, CDC13) δ 7.72 - 7.66 (m, 4H), 7.47 - 7.37 (m, 6H), 3.51 (br s, 2H), 3.13 - 3.02 (m, 2H), 2.79 (br d, J = 12.1 Hz, 1H), 2.65 - 2.54 (m, 1H), 2.06 (dt, J = 6.1, 12.7 Hz, 2H), 1.90 (d, J = 13.2 Hz, 1H), 1.86 - 1.77 (m, 1H), 1.72 - 1.64 (m, 1H), 1.29 - 1.24 (m, 1H), 1.24 - 1.16 (m, 2H), 1.10 (s, 9H).

[0514] Isomer C2:

[0515] 1 H NMR(400MHz, CDCl3)δ7.69(ddd,J=1.4,5.5,7.0Hz,4H),7.47-7.36(m,6H),3.50(s,2H),3.11-3.01(m,2H),2.79(d,J=11.9Hz,1H), 2.63-2.55(m,1H),2.11-2.01(m,2H),1.90(d,J=13.2Hz,1H),1.85-1.76(m,1H),1.65-1.55(m,2H),1.23-1.15(m,2H),1.10(s,9H).

[0516] Step 5: Synthesis of (2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methanol Intermediate A3 Isomer 3 and Intermediate A Isomer 4

[0517] Isomer C1 (3 g, 6.79 mmol) was dissolved in methanol (30 mL) and potassium bifluoride (2.65 g, 33.9 mmol) was added. The reaction was allowed to react at 25°C for 5 hours. After completion of the reaction, the mixture was filtered and the filtrate was concentrated under reduced pressure to remove the solvent. The residue was separated using a flash silica gel column (0-30% EA in PE) to obtain Intermediate A3 Isomer 3 (1.1 g, 79.7% yield). ESI-MS: 204.1 [M+1] + .

[0518] 1 H NMR (400MHz, CDCl3) δ3.49-3.33(m,2H),3.24-3.10(m,2H),2.85(d,J=12.1Hz,1H),2.74-2.63(m,1H),2.06(br dd,J=6.3,13.3Hz,1H),1.97-1.85(m,3H),1.85-1.65(m,2H),1.42-1.25(m,2H).

[0519] Dissolve isomer C2 (0.9 g, 2.04 mmol) in methanol (15 mL) and add potassium bifluoride (3.18 g, 40.7 mmol) to react at 25°C for 5 hours. After the reaction is complete, filter and concentrate the filtrate under reduced pressure to remove the solvent. The residue is separated by a rapid silica gel column ( 20g 0-50% tetrahydrofuran-petroleum ether, 80mL / min) to give A3 isomer 4 (350mg, yield 78.1%). ESI-MS: 204.1[M+1] + .

[0520] 1 H NMR (400 MHz, CDC13) δ 3.43-3.31 (m, 2H), 3.18-3.06 (m, 2H), 2.83 (d, J = 12.3 Hz, 1H), 2.72-2.62 (m, 1H), 2.05-1.97 (m, 1H), 1.93-1.84 (m, 3H), 1.81-1.63 (m, 2H), 1.39-1.23 (m, 2H).

[0521] Preparation of Intermediate A4 Isomer 1 and Isomer 2: ((2S)-2-(methylthio)tetrahydro-1H-pyrrolizin-7a(5H)-yl)methanol (Isomer 1 and Isomer 2)

[0522] First Step: Synthesis of 1-(tert-butyl) 2-methyl (2R,4R)-4-((methylsulfonyl)oxy)pyrrolidine-1,2-dicarboxylate

[0523] Dissolve 1-(tert-butyl) 2-methyl (2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxylate (25 g, 101.92 mmol) in dichloromethane (200 mL), add methylsulfonic anhydride (14.36 mL, 112.12 mmol) and triethylamine (28.33 mL, 203.85 mmol) at 0 °C, and stir the reaction solution at room temperature for 2 hours. Extract the reaction mixture with water (300 mL) and ethyl acetate (300 mL), wash the organic phase with saturated brine (100 mL), dry over anhydrous sodium sulfate, and concentrate under reduced pressure to remove the solvent to obtain 1-(tert-butyl) 2-methyl (2R,4R)-4-((methylsulfonyl)oxy)pyrrolidine-1,2-dicarboxylate (20 g, yield: 60.7%). ESI-MS: 346.4 [M+Na] + .

[0524] Second Step: Synthesis of 1-(tert-butyl) 2-methyl (2R,4S)-4-(methylthio)pyrrolidine-1,2-dicarboxylate

[0525] To a solution of 1-(tert-butyl) 2-methyl (2R,4R)-4-hydroxypyrrolidine-1,2- dicarboxylate (20 g, 61.85 mmol) in tetrahydrofuran (200 mL) was added sodium methanethiolate (8.67 g, 123.70 mmol) and 15-crown-5 (12.39 mL, 61.85 mmol) and the reaction was stirred at 70 °C for 16 h. The reaction mixture was extracted with saturated brine (300 mL) and ethyl acetate (300 mL), the organic phase was washed with saturated brine (100 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to remove the solvent. The residue was separated by flash silica gel column [0-30% EA in PE] to give 1-(tert-butyl) 2-methyl (2R,4S)-4-(methylthio)pyrrolidine-1,2-dicarboxylate (5 g, yield: 29.4%). ESI-MS: 276.4 [M+1] + .

[0526] Third Step: Synthesis of 1-(tert-butyl) 2-methyl (4S)-2-(3-chloropropyl)-4- (methylthio)pyrrolidine-1,2-dicarboxylate

[0527] To a solution of 1-(tert-butyl) 2-methyl (2R,4S)-4-(methylthio)pyrrolidine-1,2- dicarboxylate (5 g, 18.16 mmol) in tetrahydrofuran (30 mL) was added lithium bis(trimethylsilyl)amide (27.24 mL, 27.24 mmol) dropwise at -78 °C under nitrogen atmosphere and the reaction was stirred at -78 °C for 0.5 h. To the reaction was then added a solution of 1-bromo-3-chloropropane (3.60 mL, 36.32 mmol) in tetrahydrofuran (10 mL) dropwise, the reaction was allowed to warm to room temperature and stirred at room temperature for 2 h. The reaction mixture was extracted with saturated ammonium chloride solution (100 mL) and ethyl acetate (100 mL), the aqueous phase was washed with ethyl acetate (20 mL), the combined organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to remove the solvent to give 1-(tert-butyl) 2-methyl (4S)-2-(3-chloropropyl)-4-(methylthio)pyrrolidine-1,2-dicarboxylate (4 g, yield: 62.6%). ESI-MS: 252.4 [M-99] + .

[0528] Fourth Step: Synthesis of methyl 2-(methylthio)tetrahydro-1H-pyrrolizine-7a(5H)- carboxylate (Isomer 1 and Isomer 2)

[0529] (4S)-2-(3-chloropropyl)-4-(methylthio)pyrrolidine-1,2-dicarboxylate (4 g, 11.37 mmol) was dissolved in dichloromethane (20 mL), followed by the addition of trifluoroacetic acid (10 mL, 134.63 mmol), and the reaction solution was stirred at room temperature for 0.5 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent, and then separated by a normal phase chromatographic column [0-30% EA in PE] to obtain methyl 2-(methylthio)tetrahydro-1H-pyrrolizine-7a(5H)-carboxylate (isomer 1) (250 mg, yield: 10.2%) and methyl 2-(methylthio)tetrahydro-1H-pyrrolizine-7a(5H)-carboxylate (isomer 1) (240 mg, yield: 9.8%). ESI-MS: 216.4 [M+1] + .

[0530] Fifth step: Synthesis of ((2S)-2-(methylthio)tetrahydro-1H-pyrrolizine-7a(5H)-yl)methanol (isomer 1 and isomer 2)

[0531] (1) Synthesis of ((2S)-2-(methylthio)tetrahydro-1H-pyrrolizine-7a(5H)-yl)methanol (isomer 1)

[0532] Methyl 2-(methylthio)tetrahydro-1H-pyrrolizine-7a(5H)-carboxylate (isomer 1) (240 mg, 1.12 mmol) was dissolved in tetrahydrofuran (10 mL), and lithium aluminum hydride (85 mg, 2.23 mmol) was added at 0°C, and the reaction solution was stirred at 0°C for 1 hour. The reaction mixture was extracted with saturated aqueous ammonium chloride solution (40 mL) and ethyl acetate (40 mL), and the organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent, and the residue was separated by a flash silica gel column [0-30% EA in PE] to obtain ((2S)-2-(methylthio)tetrahydro-1H-pyrrolizine-7a(5H)-yl)methanol (isomer 1) (140 mg, yield: 67.1%). ESI-MS: 188.4 [M+1] + .

[0533] (2) Synthesis of ((2S)-2-(methylthio)tetrahydro-1H-pyrrolizine-7a(5H)-yl)methanol (isomer 2)

[0534] The synthesis of ((2S)-2-(methylthio)tetrahydro-lH-pyrrolizine-7a(5H)-yl)methanol (Isomer 2) was carried out according to the synthesis of Intermediate A3 Isomer 1, replacing methyl 2-(methylthio)tetrahydro-lH-pyrrolizine-7a(5H)-carboxylate (Isomer 1) with methyl 2-(methylthio)tetrahydro-lH-pyrrolizine-7a(5H)-carboxylate (Isomer 2).

[0535] Preparation of Intermediate Bl: (9H-fluoren-9-yl)methyl (lR,5S)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate- 1,5-d2

[0536] First Step: Synthesis of tert-butyl (lR,5S)-3-trityl-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0537] Tert-butyl (lR,5S)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (3 g, 14.1 mmol) and Trityl-Cl (4.33 g, 15.5 mmol) were dissolved in dichloromethane (20 mL), triethylamine (2.35 mL, 16.9 mmol) was added, and the reaction solution was stirred at 25 °C for 18 hours. The reaction solution was poured into 100 mL of water, extracted with dichloromethane (200 mL), and the organic phase was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to remove the solvent. The residue was separated by flash silica gel column [0-30% EA in PE] to obtain tert-butyl (lR,5S)-3-trityl-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (6 g, yield: 93.4%).

[0538] 1 H NMR (400 MHz, CDC13) δ 7.37 - 7.24 (m, 12H), 7.20 - 7.14 (m, 3H), 4.24 - 4.12 (m, 1H), 4.05 (br s, 1H), 2.99 (br d, J = 10.9 Hz, 2H), 2.46 - 2.32 (m, 2H), 2.04 - 1.95 (m, 2H), 1.89 - 1.69 (m, 2H), 1.27 (s, 9H).

[0539] Second Step: Synthesis of tert-butyl (lR,5S)-3-trityl-3,8-diazabicyclo[3.2.1]octane-8-carboxylate- 1,5-d2

[0540] To a solution of tert-butyl (1R,5S)-3-trityl-3,8-diazabicyclo[3.2.1]octane-8- carboxylate (1 g, 2.20 mmol) and TMEDA (1.66 mL, 10.9 mmol) in tetrahydrofuran (20 mL) was added tert-butyllithium (8.46 mL, 10.9 mmol) dropwise under nitrogen. After the addition was complete, the mixture was stirred at 0 °C for 0.5 h. Then deuterium water (0.8 mL, 44.0 mmol) was added dropwise, and the mixture was stirred at 0 °C for 0.5 h. The reaction was quenched with saturated aqueous ammonium chloride solution (20 mL) and extracted with ethyl acetate (60 mL). The organic phase was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to remove the solvent to give tert-butyl (1R,5S)-3-trityl-3,8-diazabicyclo[3.2.1]octane-8-carboxylate-1,5-d2 (650 mg, yield: 65.0%).

[0541] 1 H NMR (400 MHz, CDC13) δ ppm 7.35 - 7.24 (m, 12H), 7.20 - 7.12 (m, 3H), 2.99 (br d, J = 11.1 Hz, 2H), 2.37 (br d, J = 6.8 Hz, 2H), 2.00 (br d, J = 7.5 Hz, 2H), 1.87 - 1.72 (m, 2H), 1.30 - 1.25 (m, 9H).

[0542] ESI-MS: 215 [M+1] + .

[0543] Third Step: Synthesis of tert-butyl (1R,5S)-3,8-diazabicyclo[3.2.1]octane-8- carboxylate-1,5-d2

[0544] To a solution of tert-butyl (1R,5S)-3-trityl-3,8-diazabicyclo[3.2.1]octane-8- carboxylate-1,5-d2 (4 g, 8.760 mmol) in anhydrous acetic acid (40 mL) was stirred at 25 °C for 18 h. LC-MS showed that the reaction was completed. The reaction was directly concentrated under reduced pressure to remove the solvent to give tert-butyl (1R,5S)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate-1,5-d2 (1.88 g of crude product). ESI-MS: 159.1 [M-55] + .

[0545] Fourth Step: Synthesis of 3-((9H-fluoren-9-yl)methyl) 8-(tert-butyl) (1R,5S)- 3,8-diazabicyclo[3.2.1]octane-3,8-dicarboxylate-1,5-d2

[0546] tert-Butyl (1R,5S)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate-1,5-d2 (1.88 g, 8.772 mmol) was dissolved in anhydrous dichloromethane (40 mL), Fmoc-Cl (2.72 g, 10.5 mmol) and triethylamine (7.32 mL, 52.6 mmol) were added at 0 °C, and the mixture was stirred at 25 °C for 2 h. LC-MS showed that the reaction was complete. Saturated aqueous ammonium chloride solution (45 mL) was added to the reaction solution, extracted with dichloromethane (3*40 mL), and the organic phases were combined and washed with saturated brine (25 mL*2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was separated by flash silica gel column [0-30% EA in PE] to give 3-((9H-fluoren-9-yl)methyl) 8-(tert-butyl) (1R,5S)-3,8-diazabicyclo[3.2.1]octane-3,8-dicarboxylate-1,5-d2 (2 g, yield: 26.1%). ESI-MS: 459.3 [M+23] + .

[0547] Fifth step: synthesis of (9H-fluoren-9-yl)methyl (1R,5S)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate-1,5-d2

[0548] 3-((9H-fluoren-9-yl)methyl) 8-(tert-butyl) (1R,5S)-3,8-diazabicyclo[3.2.1]octane-3,8-dicarboxylate-1,5-d2 (1 g, 1.14 mmol) was dissolved in a hydrochloric acid / dioxane solution (30 mL, 2N), and the reaction was carried out at 25 °C for 16 h. LC-MS showed that the reaction was complete. The reaction solution was directly concentrated under reduced pressure to remove the solvent to give (9H-fluoren-9-yl)methyl (1R,5S)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate-1,5-d2 (0.8 g, yield: 92.3%).

[0549] Preparation of intermediate B2: 2-oxa-6-azabicyclo[5.1.0]octane

[0550] First step: synthesis of benzyl 1,4-oxazepane-4-carboxylate

[0551] Hydrochloric acid 1,4-oxazepane (12.7 g, 92.3 mmol) was dissolved in dichloromethane (130 mL), and triethylamine (38.5 mL, 277 mmol) and benzyl chloroformate (13.4 mL, 94.1 mmol) were added dropwise at 0 °C under nitrogen atmosphere. The reaction solution was stirred at 25 °C for 2 hours. After completion of the reaction, the reaction solution was concentrated under reduced pressure, and the residue was separated with a flash silica gel column [0-30% EA in PE] to obtain benzyl 1,4-oxazepane-4-carboxylate (19.0 g, yield: 83.1%).

[0552] 1 H NMR (400 MHz, DMSO-d6) δ 7.13-7.51 (m, 5H), 5.09 (d, J = 1.54 Hz, 2H), 3.59-3.66 (m, 4H), 3.46-3.54 (m, 4H), 1.77 (quin, J = 5.61 Hz, 2H).

[0553] Second step: Synthesis of benzyl 3-methoxy-1,4-oxazepane-4-carboxylate

[0554] Benzyl 1,4-oxazepane-4-carboxylate (14.0 g, 59.5 mmol) was dissolved in anhydrous methanol (150 mL), and p-toluenesulfonic acid tetraethylamine ester (0.900 g, 2.98 mmol) was added at 25 °C. Constant current electrolysis (graphite electrode) was performed at 100 mA (terminal voltage 20-30 V). After 2.5 F mol-1of current was passed, it was stirred at 25 °C for 18 hours. After completion of the reaction, the reaction solution was concentrated under reduced pressure, and the residue was separated with a flash silica gel column [0-30% EA in PE] to obtain benzyl 3-methoxy-1,4-oxazepane-4-carboxylate (13.0 g, yield: 74.1%).

[0555] 1 H NMR (400 MHz, DMSO-d6) δ 7.18-7.51 (m, 5H), 5.29-5.44 (m, 1H), 5.07-5.23 (m, 2H), 3.88-4.11 (m, 1H), 3.64-3.77 (m, 2H), 3.37 (br s, 1H), 3.07-3.25 (m, 5H), 2.16-2.38 (m, 1H), 1.69-1.85 (m, 1H).

[0556] Third step: Synthesis of benzyl 6,7-dihydro-1,4-oxazepine-4(5H)-carboxylate

[0557] Benzyl 3-methoxy-l,4-oxazepane-4-carboxylate (16.0 g, 60.3 mmol) and N,N- diisopropylethylamine (26.3 mL, 159 mmol) were dissolved in dichloromethane (300 mL), and trimethylsilyl trifluoromethanesulfonate (28.9 mL, 159 mmol) was added dropwise at 0 °C. The mixture was stirred at 0 °C for 3 hours under a nitrogen atmosphere. After completion of the reaction, the reaction solution was quenched and diluted with water, extracted with dichloromethane (400 mL), and the organic phase was washed with saturated aqueous sodium chloride solution (200 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was separated by flash silica gel column [0-30% EA in PE] to obtain benzyl 6,7-dihydro-l,4-oxazepine-4(5H)-carboxylate (2.50 g, yield: 17.8%).

[0558] 1 H NMR (400 MHz, CDC13) δ 7.17-7.48 (m, 5H), 5.60-5.88 (m, 2H), 5.08 (s, 2H), 4.00 (br d, J = 4.63 Hz, 2H), 3.76 (br t, J = 5.19 Hz, 2H), 1.78-2.00 (m, 2H).

[0559] Fourth Step: Synthesis of Benzyl 2-Oxa-6-azabicyclo[5.1.0]octane-6-carboxylate

[0560] Benzyl 6,7-dihydro-l,4-oxazepine-4(5H)-carboxylate (2.50 g, 10.7 mmol) and diiodomethane (7.78 mL, 96.5 mmol) were dissolved in toluene (25 mL), and the mixture was stirred at 0 °C for 30 minutes under a nitrogen atmosphere. Then diethyl zinc (107 mL, 107 mmol) was added dropwise to the solution. The reaction solution was stirred at 25 °C for 17.5 hours under a nitrogen atmosphere. After completion of the reaction, the reaction solution was quenched and diluted with water, extracted with ethyl acetate (300 mL), and the organic phase was washed with saturated aqueous sodium chloride solution (200 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was separated by flash silica gel column [0-30% EA in PE] to obtain benzyl 2-oxa-6-azabicyclo[5.1.0]octane-6-carboxylate (2.43 g, yield: 87.1%).

[0561] 1H NMR (400 MHz, CDC13) δ 7.18 - 7.48 (m, 5H), 4.94 - 5.23 (m, 2H), 3.80 - 4.18 (m, 2H), 3.50 - 3.66 (m, 1H), 3.25 - 3.41 (m, 1H), 2.95 - 3.16 (m, 1H), 2.37 (br s, 1H), 1.61 - 1.94 (m, 2H), 0.98 - 1.23 (m, 2H).

[0562] Fifth step: Synthesis of 2-oxa-6-azabicyclo[5.1.0]octane

[0563] Benzyl 2-oxa-6-azabicyclo[5.1.0]octane-6-carboxylate (500 mg, 2.02 mmol) was dissolved in hydrobromic acid in acetic acid (10 mL) and the reaction was stirred at 25 °C under nitrogen atmosphere for 18 hours. After completion of the reaction, the reaction was concentrated under reduced pressure to obtain 2-oxa-6-azabicyclo[5.1.0]octane (500 mg, yield: 95.6%).

[0564] 1 H NMR (400 MHz, CDC13) δ 10.04 - 10.54 (m, 1H), 8.56 - 9.11 (m, 1H), 4.14 (br d, J=12.10 Hz, 1H), 3.52 - 3.86 (m, 3H), 3.05 - 3.24 (m, 1H), 2.73 - 2.89 (m, 1H), 2.46 - 2.65 (m, 1H), 1.99 (br d, J=9.24 Hz, 2H), 1.15 - 1.30 (m, 1H).

[0565] Preparation of Intermediate B3: N,N-di(4-methoxybenzyl)-3-(1-(methylamino)ethyl)pyridin-2-amine

[0566] First step: Synthesis of 1-(2-(di(4-methoxybenzyl)amino)pyridin-3-yl)ethan-1-one

[0567] To a solution of 3-acetyl-2-chloropyridine (10 g, 64.3 mmol) in dry N,N-dimethylformamide (100 mL) was added triethylamine (13 g, 128 mmol) and bis(4-methoxybenzyl)amine (32.9 g, 128 mmol). The mixture was then stirred at 110 °C for 18 h. LCMS showed the reaction was completed. The reaction mixture was poured into water (300 mL) and extracted with ethyl acetate (100 mL*2). The combined organic phase was washed with saturated brine (200 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was separated by flash silica gel column [0-30% EA in PE] to give 1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethan-1-one (14 g, yield: 57.9%). ESI-MS: 362.9 [M+1] + .

[0568] 1 H NMR (400 MHz, DMSO-d6) d 8.27 (dd, J = 4.57, 1.56 Hz, 1H) 7.84 (dd, J = 7.50, 1.63 Hz, 1H) 7.26 (s, 1H) 7.04 (d, J = 8.50 Hz, 4H) 6.84 (br d, J = 8.63 Hz, 4H) 4.42 (s, 4H) 3.71 (s, 6H) 2.42 (s, 3H).

[0569] Second Step: Synthesis of (Z)-N,N-bis(4-methoxybenzyl)-3-(1-(methylimino)ethyl)pyridin-2-amine

[0570] To a solution of 1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethan-1-one (14 g, 37.2 mmol) in dry ethanol (150 mL) was added tetraethyl titanate (17 g, 74.4 mmol) and methylamine tetrahydrofuran solution (37.2 mL, 3N, 112 mmol). The mixture was then stirred at 80 °C for 18 h. TLC showed the starting material was consumed. The reaction mixture was used directly for the next step.

[0571] Third Step: Synthesis of N,N-bis(4-methoxybenzyl)-3-(1-(methylamino)ethyl)pyridin-2-amine

[0572] (Z)-N,N-di(4-methoxybenzyl)-3-(1-(methylimino)ethyl)pyridin-2-amine (reaction solution of previous step, 37.2 mmol) was cooled to 0 °C under nitrogen protection. Sodium borohydride (5.6 g, 149 mmol) was added slowly in batches, and then stirred at 0 °C for 2 hours. The LCMS detection result showed that the reaction was completed. Water (30 mL) was added dropwise to the reaction solution, filtered through diatomite, the filtrate was concentrated, and the residue was separated by flash silica gel column [0-30% EA in PE] to obtain N,N-di(4-methoxybenzyl)-3-(1-(methylamino)ethyl)pyridin-2-amine (6 g, yield: 41.2%). ESI-MS: 392.0 [M+1] + .

[0573] 1 H NMR (400 MHz, DMSO-d6) δ ppm 8.17 (dd, J=4.63, 1.88 Hz, 1 H) 7.79 (dd, J=7.63, 1.75 Hz, 1 H) 7.17 (d, J=8.63 Hz, 4 H) 7.05 (dd, J=7.57, 4.69 Hz, 1 H) 6.84 (d, J=8.50 Hz, 4 H) 4.12 (m, 5 H) 3.70 (s, 6 H) 1.97 (s, 3 H) 1.14 (d, J=6.38 Hz, 3 H).

[0574] Preparation of intermediate B4: 3-chloro-N,N-dimethyl-5,6,7,8-tetrahydro-4H-pyrazolo[l,5- a] [l,4]diazepine-2-carboxamide

[0575] First step: synthesis of 5-(tert-butyl) 2-methyl 7,8-dihydro-4H-pyrazolo[l,5-a] [l,4]diazepine- 2,5(6H)-dicarboxylate

[0576] To a solution of 5-(tert-butoxycarbonyl)-5,6,7,8-tetrahydro-4H-pyrazolo[l,5- a][l,4]diazepine-2-carboxylic acid (500 mg, 1.77 mmol) in N,N-dimethylformamide (10 mL) was added cesium carbonate (1737 mg, 5.33 mmol) and iodomethane (0.166 mL, 2.66 mmol). The reaction mixture was stirred at 25 °C for 2 h. LCMS showed the reaction was completed. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (2*30 mL). The combined organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 5-(tert-butyl) 2-methyl 7,8-dihydro-4H-pyrazolo[l,5-a][l,4]diazepine-2,5(6H)- dicarboxylate (400 mg, yield: 76.2%). ESI-MS: 296.1 [M+1] + .

[0577] 1 H NMR (400 MHz, DMSO-d6) δ 6.71 - 6.55 (m, 1H), 4.57 - 4.36 (m, 4H), 3.78 (s, 3H), 3.65 (br s, 2H), 1.87 - 1.69 (m, 2H), 1.33 (br s, 9H).

[0578] Second Step: Synthesis of 5-(tert-butyl)-2-methyl 3-chloro-7,8-dihydro-4H- pyrazolo[l,5-a][l,4]diazepine-2,5(6H)-dicarboxylate

[0579] To a solution of 5-(tert-butyl) 2-methyl 7,8-dihydro-4H-pyrazolo[l,5-a][l,4]diazepine- 2,5(6H)-dicarboxylate (400 mg, 1.35 mmol) in N,N-dimethylformamide (5 mL) was added N-chlorosuccinimide (180 mg, 1.35 mmol). The reaction mixture was stirred at 80 °C for 2 h. LCMS showed the reaction was completed. The reaction mixture was diluted with water (30 mL) and extracted with ethyl acetate (2*20 mL). The combined organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 5-(tert-butyl)-2-methyl 3-chloro-7,8-dihydro-4H-pyrazolo[l,5-a][l,4]diazepine- 2,5(6H)-dicarboxylate (350 mg, yield: 78.3%). ESI-MS: 330.0 [M+1] + .

[0580] 1H NMR (400 MHz, DMSO-d6) δ 4.63 - 4.43 (m, 4H), 3.85 - 3.76 (m, 3H), 3.67 (br s, 2H), 1.82 (br s, 2H), 1.36 (s, 9H).

[0581] Step 3: Synthesis of 5-(tert-butoxycarbonyl)-3-chloro-5,6,7,8-tetrahydro-4H- pyrazolo[l,5-a][l,4]diazepine-2-carboxylic acid

[0582] Diazepine-2,5(6H)-dicarboxylate (300 mg, 0.91 mmol) was dissolved in anhydrous methanol (5 mL) and water (2 mL), then potassium hydroxide (255. mg, 4.54 mmol) was added, stirred at 25 °C for 1 hour. LCMS detected that the reaction was completed. The methanol was removed by reduced pressure concentration, to the residue was added dilute hydrochloric acid (1 M), adjusted pH = ~ 6-7, extracted with ethyl acetate (2*20 mL), combined organic phase, washed with saturated brine (20 mL), concentrated under reduced pressure to give 5-(tert- butoxycarbonyl)-3-chloro-5,6,7,8-tetrahydro-4H-pyrazolo[l,5-a][l,4]diazepine-2- carboxylic acid (250 mg, yield: 87%). ESI-MS: 319.5 [M+1] + .

[0583] Step 4: Synthesis of tert-butyl 3-chloro-2-(dimethylcarbamoyl)-7,8-dihydro-4H- pyrazolo[l,5-a][l,4]diazepine-5(6H)-carboxylate

[0584] To a solution of 5-(tert-butoxycarbonyl)-3-chloro-5,6,7,8-tetrahydro-4H- pyrazolo[l,5-a][l,4]diazepine-2-carboxylic acid (200 mg, 0.633 mmol) in N,N- dimethylformamide (5 mL) was added N,N-diisopropyl ethylamine (0.314 mL, 1.9 mmol) and HATU (240 mg, 0.633 mmol) and stirred at 25 °C for 0.5 h. Then dimethylamine hydrochloride (57.1 mg, 1.26 mmol) was added to the solution and stirred for 2 h. LCMS showed the reaction was completed. Water (30 mL) was added to the reaction and extracted with ethyl acetate (2*20 mL), the organic phase was combined and washed with saturated brine (20 mL), the solvent was removed under reduced pressure, the residue was separated by flash silica gel column [0-30% EA in PE] to give tert-butyl 3-chloro-2-(dimethylcarbamoyl)-7,8-dihydro-4H-pyrazolo[l,5- a][l,4]diazepine-5(6H)-carboxylate (200 mg, yield: 92.1%). ESI-MS: 343.1 [M+1] + .

[0585] 1 H NMR (400 MHz, DMSO-d6) δ 4.59 - 4.33 (m, 4H), 3.67 (br s, 2H), 2.97 (s, 6H), 1.82 (br d, J = 2.6 Hz, 2H), 1.37 (s, 9H).

[0586] Fifth Step: Synthesis of 3-chloro-N,N-dimethyl-5,6,7,8-tetrahydro-4H-pyrazolo[l,5- a][l,4]diazepine-2-carboxamide

[0587] Tert-butyl 3-chloro-2-(dimethylcarbamoyl)-7,8-dihydro-4H-pyrazolo[l,5-a][l,4]diazepine- 5(6H)-carboxylate (200 mg, 0.583 mmol) was dissolved in acetonitrile (5 mL) and then added to hydrochloric acid dioxane (10 mL, 2M) and stirred at 25 °C for 1 h. LCMS showed the reaction was completed. The reaction was directly concentrated under reduced pressure to give 3-chloro-N,N-dimethyl-5,6,7,8-tetrahydro-4H-pyrazolo[l,5- a][l,4]diazepine-2-carboxamide (140 mg, yield: 98.8%). ESI-MS: 243.1 [M+1] + .

[0588] Intermediate C1 : Preparation of 6-bromo-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4- f]quinazolin-1 -ol

[0589] Step 1: Synthesis of 4-bromo-5-fluoro-6-nitroisobenzofuran-1 (3H)-one

[0590] Dissolve 5-fluoroisobenzofuran-1 (3H)-one (20 g, 131 mmol) in concentrated sulfuric acid (200 mL), then heat to 65 °C, slowly drop concentrated HNO3 (26.80 g, 289 mmol), the mixture is stirred at 65 °C for 1 hour, TLC detection of raw ...

Claims

1. A compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof: in, is a double bond or a single bond; Y1 is O, S, N, N(R 9a ), CH2, CH, CH2CH2 or CH=CH; Y2 is O, S, N, N(R 9b ), CH2, CH, CH2CH2 or CH=CH; Y3 is O, S, N, N(R 9c ), CH2, CH, CH2CH2 or CH=CH; Z1 is N or C(R 10a ); Z2 is N or C(R 10b ); Ring A is selected from the following structures: R1 is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic and 5-10 membered heteroaryl substituted C 1-10 Alkyl, R2 is selected from hydrogen, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic group, or, R1 and R2 together with the nitrogen atom to which they are directly connected form a 4-12 membered heterocyclic group, said 4-12 membered heterocyclic group is optionally fused to a 5-10 membered heteroaryl group, said group is optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 12 )R 13 、-C 0-8 Alkyl-N=S(O)R 13 R 14 、-C 0-8 Alkyl-N=SR 13 R 14 、-C 0-8 Alkyl-OS(O)2R 15 、-C 0-8 Alkyl-S(O) r R 15 、-C 0-8 Alkyl-OR 16 、-C 0-8 Alkyl-C(O)OR 16 、-C 0-8 Alkyl-C(O)SR 16 、-C 0-8 Alkyl-SC(O)R 17 、-C 0-8 Alkyl-C(O)R 17 、-C 0-8 Alkyl-OC(O)R 17 、-C 0-8 Alkyl-P(O)(R 17 )2. -C 0-8 Alkyl-NR 18 R 19 、-C 0-8 Alkyl-C(=NR 18 )R 17 、-C 0-8 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-8 Alkyl-C(O)NR 18 R 19 and -C 0-8 Alkyl-N(R 18 )-C(O)R 17 The above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 12 )R 13 、-C 0-8 Alkyl-N=S(O)R 13 R 14 、-C 0-8 Alkyl-N=SR 13 R 14 、-C 0-8 Alkyl-OS(O)2R 15 、-C 0-8 Alkyl-S(O) r R 15 、-C 0-8 Alkyl-OR 16 、-C 0-8 Alkyl-C(O)OR 16 、-C 0-8 Alkyl-C(O)SR 16 、-C 0-8 Alkyl-SC(O)R 17 、-C 0-8 Alkyl-C(O)R 17 、-C 0-8 Alkyl-OC(O)R 17 、-C 0-8 Alkyl-P(O)(R 17 )2. -C 0-8 Alkyl-NR 18 R 19 、-C 0-8 Alkyl-C(=NR 18 )R 17 、-C 0-8 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-8 Alkyl-C(O)NR 18 R 19 and -C 0-8 Alkyl-N(R 18 )-C(O)R 17 substituted by a substituent; Each R3 and each R4 are independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 12 )R 13 、-C 0-8 Alkyl-N=S(O)R 13 R 14 、-C 0-8 Alkyl-N=SR 13 R 14 、-C 0-8 Alkyl-OS(O)2R 15 、-C 0-8 Alkyl-S(O) r R 15 、-C 0-8 Alkyl-OR 16 、-C 0-8 Alkyl-C(O)OR 16 、-C 0-8 Alkyl-C(O)SR 16 、-C 0-8 Alkyl-SC(O)R 17 、-C 0-8 Alkyl-C(O)R 17 、-C 0-8 Alkyl-OC(O)R 17 、-C 0-8 Alkyl-P(O)(R 17 )2. -C 0-8 Alkyl-NR 18 R 19 、-C 0-8 Alkyl-C(=NR 18 )R 17 、-C 0-8 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-8 Alkyl-C(O)NR 18 R 19 and -C 0-8 Alkyl-N(R 18 )-C(O)R 17 Alternatively, R3 and R4 together with the carbon atom to which they are directly attached form a C(=CH2), C(O), C 3-6 Cycloalkyl or 4-6 membered heterocyclic group, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 12 )R 13 、-C 0-8 Alkyl-N=S(O)R 13 R 14 、-C 0-8 Alkyl-N=SR 13 R 14 、-C 0-8 Alkyl-OS(O)2R 15 、-C 0-8 Alkyl-S(O) r R 15 、-C 0-8 Alkyl-OR 16 、-C 0-8 Alkyl-C(O)OR 16 、-C 0-8 Alkyl-C(O)SR 16 、-C 0-8 Alkyl-SC(O)R 17 、-C 0-8 Alkyl-C(O)R 17 、-C 0-8 Alkyl-OC(O)R 17 、-C 0-8 Alkyl-P(O)(R 17 )2. -C 0-8 Alkyl-NR 18 R 19 、-C 0-8 Alkyl-C(=NR 18 )R 17 、-C 0-8 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-8 Alkyl-C(O)NR 18 R 19 and -C 0-8 Alkyl-N(R 18 )-C(O)R 17 substituted by a substituent; R5 is selected from -NR 11a R 11b 、C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1- 10 Alkyl, C 2-10 Alkenyl, C 1-10 Alkylene, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 aryl, 3-12 membered heterocyclic group, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 12 )R 13 、-C 0-8 Alkyl-N=S(O)R 13 R 14 、-C 0-8 Alkyl-N=SR 13 R 14 、-C 0-8 Alkyl-OS(O)2R 15 、-C 0-8 Alkyl-S(O) r R 15 、-C 0-8 Alkyl-OR 16 、-C 0-8 Alkyl-C(O)OR 16 、-C 0- 8-Alkyl-C(O)SR 16 、-C 0-8 Alkyl-SC(O)R 17 、-C 0-8 Alkyl-C(O)R 17 、-C 0-8 Alkyl-OC(O)R 17 、-C 0-8 Alkyl-P(O)(R 17 )2. -C 0-8 Alkyl-NR 18 R 19 、-C 0-8 Alkyl-C(=NR 18 )R 17 、-C 0-8 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-8 Alkyl-C(O)NR 18 R 19 and -C 0-8 Alkyl-N(R 18 )-C(O)R 17 The above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0- 8-alkyl-S(O)(=NR 12 )R 13 、-C 0-8 Alkyl-N=S(O)R 13 R 14 、-C 0-8 Alkyl-N=SR 13 R 14 、-C 0-8 Alkyl-OS(O)2R 15 、-C 0-8 Alkyl-S(O) r R 15 、-C 0-8 Alkyl-OR 16 、-C 0-8 Alkyl-C(O)OR 16 、-C 0-8 Alkyl-C(O)SR 16 、-C 0-8 Alkyl-SC(O)R 17 、-C 0-8 Alkyl-C(O)R 17 、-C 0-8 Alkyl-OC(O)R 17 、-C 0- 8-alkyl-P(O)(R 17 )2. -C 0-8 Alkyl-NR 18 R 19 、-C 0-8 Alkyl-C(=NR 18 )R 17 、-C 0-8 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-8 Alkyl-C(O)NR 18 R 19 and -C 0-8 Alkyl-N(R 18 )-C(O)R 17 substituted by a substituent; Each R6 is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 12 )R 13 、-C 0-8 Alkyl-N=S(O)R 13 R 14 、-C 0-8 Alkyl-N=SR 13 R 14 、-C 0-8 Alkyl-OS(O)2R 15 、-C 0-8 Alkyl-S(O) r R 15 、-C 0-8 Alkyl-OR 16 、-C 0-8 Alkyl-C(O)OR 16 、-C 0-8 Alkyl-C(O)SR 16 、-C 0-8 Alkyl-SC(O)R 17 、-C 0-8 Alkyl-C(O)R 17 、-C 0-8 Alkyl-OC(O)R 17 、-C 0-8 Alkyl-P(O)(R 17 )2. -C 0-8 Alkyl-NR 18 R 19 、-C 0-8 Alkyl-C(=NR 18 )R 17 、-C 0-8 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-8 Alkyl-C(O)NR 18 R 19 and -C 0-8 Alkyl-N(R 18 )-C(O)R 17 ; R7 is selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 12 )R 13 、-C 0-8 Alkyl-N=S(O)R 13 R 14 、-C 0-8 Alkyl-N=SR 13 R 14 、-C 0-8 Alkyl-OS(O)2R 15 、-C 0-8 Alkyl-S(O) r R 15 、-C 0-8 Alkyl-OR 16 、-C 0-8 Alkyl-C(O)OR 16 、-C 0-8 Alkyl-C(O)SR 16 、-C 0-8 Alkyl-SC(O)R 17 、-C 0-8 Alkyl-C(O)R 17 、-C 0-8 Alkyl-OC(O)R 17 、-C 0-8 Alkyl-P(O)(R 17 )2. -C 0-8 Alkyl-NR 18 R 19 、-C 0-8 Alkyl-C(=NR 18 )R 17 、-C 0-8 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-8 Alkyl-C(O)NR 18 R 19 and -C 0-8 Alkyl-N(R 18 )-C(O)R 17 ; Each R8 is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, cyano substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0- 8-alkyl-S(O)(=NR 12 )R 13 、-C 0-8 Alkyl-N=S(O)R 13 R 14 、-C 0-8 Alkyl-N=SR 13 R 14 、-C 0-8 Alkyl-OS(O)2R 15 、-C 0-8 Alkyl-S(O) r R 15 、-C 0-8 Alkyl-OR 16 、-C 0-8 Alkyl-C(O)OR 16 、-C 0-8 Alkyl-C(O)SR 16 、-C 0-8 Alkyl-SC(O)R 17 、-C 0-8 Alkyl-C(O)R 17 、-C 0-8 Alkyl-OC(O)R 17 、-C 0- 8-alkyl-P(O)(R 17 )2. -C 0-8 Alkyl-NR 18 R 19 、-C 0-8 Alkyl-C(=NR 18 )R 17 、-C 0-8 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-8 Alkyl-C(O)NR 18 R 19 and -C 0-8 Alkyl-N(R 18 )-C(O)R 17 ； R 9a 、R 9b and R 9c Each independently selected from hydrogen, cyano, C 1-10 Alkyl, C 2-10 Alkenyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-S(O) r R 15 、-C 0-8 Alkyl-OR 16 、-C 0-8 Alkyl-C(O)OR 16 、-C 0-8 Alkyl-C(O)SR 16 、-C 0-8 Alkyl-C(O)R 17 、-C 0-8 Alkyl-OC(O)R 17 、-C 0-8 Alkyl-NR 18 R 19 、-C 0-8 Alkyl-C(O)NR 18 R 19 and -C 0-8 Alkyl-N(R 18 )-C(O)R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1- 10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 12 )R 13 、-C 0-8 Alkyl-N=S(O)R 13 R 14 、-C 0-8 Alkyl-N=SR 13 R 14 、-C 0-8 Alkyl-OS(O)2R 15 、-C 0-8 Alkyl-S(O) r R 15 、-C 0-8 Alkyl-OR 16 、-C 0-8 Alkyl-C(O)OR 16 、-C 0-8 Alkyl-C(O)SR 16 、-C 0-8 Alkyl-SC(O)R 17 、-C 0-8 Alkyl-C(O)R 17 、-C 0-8 Alkyl-OC(O)R 17 、-C 0- 8-alkyl-P(O)(R 17 )2. -C 0-8 Alkyl-NR 18 R 19 、-C 0-8 Alkyl-C(=NR 18 )R 17 、-C 0-8 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-8 Alkyl-C(O)NR 18 R 19 and -C 0-8 Alkyl-N(R 18 )-C(O)R 17 substituted by a substituent; R 10a and R 10b are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 12 )R 13 、-C 0-8 Alkyl-N=S(O)R 13 R 14 、-C 0-8 Alkyl-N=SR 13 R 14 、-C 0-8 Alkyl-OS(O)2R 15 、-C 0-8 Alkyl-S(O) r R 15 、-C 0-8 Alkyl-OR 16 、-C 0-8 Alkyl-C(O)OR 16 、-C 0-8 Alkyl-C(O)SR 16 、-C 0-8 Alkyl-SC(O)R 17 、-C 0-8 Alkyl-C(O)R 17 、-C 0-8 Alkyl-OC(O)R 17 、-C 0-8 Alkyl-P(O)(R 17 )2. -C 0-8 Alkyl-NR 18 R 19 、-C 0-8 Alkyl-C(=NR 18 )R 17 、-C 0-8 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-8 Alkyl-C(O)NR 18 R 19 and -C 0-8 Alkyl-N(R 18 )-C(O)R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2- 10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0- 8-alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 12 )R 13 、-C 0-8 Alkyl-N=S(O)R 13 R 14 、-C 0-8 Alkyl-N=SR 13 R 14 、-C 0-8 Alkyl-OS(O)2R 15 、-C 0-8 Alkyl-S(O) r R 15 、-C 0-8 Alkyl-OR 16 、-C 0-8 Alkyl-C(O)OR 16 、-C 0-8 Alkyl-C(O)SR 16 、-C 0-8 Alkyl-SC(O)R 17 、-C 0-8 Alkyl-C(O)R 17 、-C 0- 8-Alkyl-OC(O)R 17 、-C 0-8 Alkyl-P(O)(R 17 )2. -C 0-8 Alkyl-NR 18 R 19 、-C 0-8 Alkyl-C(=NR 18 )R 17 、-C 0-8 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-8 Alkyl-C(O)NR 18 R 19 and -C 0-8 Alkyl-N(R 18 )-C(O)R 17 substituted by a substituent; R 11a and R 11b are independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-10 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylene, halogen substituted C 1-10 Alkylene, deuterium substituted C 1-10 Alkylene, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, mono C 1-10 Alkylamino, di-C 1-10 Alkylamino and C 1- 10 substituted with an alkanoyl substituent; Or, R 11a and R 11b Together with the nitrogen atom directly connected thereto, a 4-10 membered heterocyclic group or a 5-10 membered heteroaryl group is formed, wherein the 4-10 membered heterocyclic group or the 5-10 membered heteroaryl group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, ═O, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylene, halogen substituted C 1- 10 Alkylene, deuterium substituted C 1-10 Alkylene, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, mono C 1-10 Alkylamino, di-C 1-10 Alkylamino and C 1-10 substituted with an alkanoyl substituent; Each R 12 are each independently selected from hydrogen, deuterium, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-S(O) r R 15 、-C 0-8 Alkyl-C(O)OR 16 、-C 0-8 Alkyl-C(O)R 17 and -C 0-8 Alkyl-C(O)NR 18 R 19 The above groups are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2- 10 Alkynyl, halogen-substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6- 10 Aryl, 5-10 membered heteroaryl, =O, -C 0-8 Alkyl-S(O) r R 15 、-C 0-8 Alkyl-OR 16 、-C 0-8 Alkyl-C(O)OR 16 、-C 0-8 Alkyl-C(O)R 17 、-C 0-8 Alkyl-OC(O)R 17 、-C 0-8 Alkyl-NR 18 R 19 、-C 0-8 Alkyl-C(=NR 18 )R 17 、-C 0-8 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-8 Alkyl-C(O)NR 18 R 19 and -C 0-8 Alkyl-N(R 18 )-C(O)R 17 substituted by a substituent; Each R 13 and each R 14 are independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, or R 13 and R 14 Together with the sulfur atom directly connected thereto, a 3-10 membered heterocyclic group is formed, wherein the above group is optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen-substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-S(O) r R 15 、-C 0-8 Alkyl-OR 16 、-C 0-8 Alkyl-C(O)OR 16 、-C 0-8 Alkyl-C(O)R 17 、-C 0-8 Alkyl-OC(O)R 17 、-C 0-8 Alkyl-NR 18 R 19 、-C 0-8 Alkyl-C(=NR 18 )R 17 、-C 0-8 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-8 Alkyl-C(O)NR 18 R 19 and -C 0-8 Alkyl-N(R 18 )-C(O)R 17 substituted by a substituent; Each R 15 independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl and -NR 18 R 19 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 18 R 19 substituted by a substituent; Each R 16 independently selected from hydrogen, deuterium, C 1-10 Alkyl, C 2-10 Alkenyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6- 10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 18 R 19 substituted by a substituent; Each R 17 independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 1-10 Alkoxy, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 18 R 19 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 18 R 19 substituted by a substituent; Each R 18 and each R 19 are independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-10 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen-substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, mono C 1-10 Alkylamino, di-C 1-10 Alkylamino and C 1-10 substituted with an alkanoyl substituent; Or, R 18 and R 19 Together with the nitrogen atom directly connected thereto, a 4-10 membered heterocyclic group or a 5-10 membered heteroaryl group is formed, wherein the 4-10 membered heterocyclic group or the 5-10 membered heteroaryl group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, ═O, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen-substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, mono C 1- 10 Alkylamino, di-C 1-10 Alkylamino and C 1-10 substituted with an alkanoyl substituent; m is 0, 1, 2, 3 or 4; n is 0, 1, 2, 3, 4, 5 or 6; o is 0, 1 or 2; and each r is independently 0, 1 or 2.

2. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R1 is selected from C 3-6 Cycloalkyl, 3-6 membered heterocyclic and 5-8 membered heteroaryl substituted C 1-4 Alkyl, R2 is selected from hydrogen, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic group, or, R1 and R2 together with the nitrogen atom to which they are directly connected form a 4-12 membered heterocyclic group, said 4-12 membered heterocyclic group is optionally fused to a 5-10 membered heteroaryl group, said group is optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 12 )R 13 、-C 0-4 Alkyl-N=S(O)R 13 R 14 、-C 0-4 Alkyl-N=SR 13 R 14 、-C 0-4 Alkyl-OS(O)2R 15 、-C 0-4 Alkyl-S(O) r R 15 、-C 0-4 Alkyl-OR 16 、-C 0-4 Alkyl-C(O)OR 16 、-C 0-4 Alkyl-C(O)SR 16 、-C 0-4 Alkyl-SC(O)R 17 、-C 0-4 Alkyl-C(O)R 17 、-C 0-4 Alkyl-OC(O)R 17 、-C 0-4 Alkyl-P(O)(R 17 )2. -C 0-4 Alkyl-NR 18 R 19 、-C 0-4 Alkyl-C(=NR 18 )R 17 、-C 0-4 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-4 Alkyl-C(O)NR 18 R 19 and -C 0-4 Alkyl-N(R 18 )-C(O)R 17 The above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 12 )R 13 、-C 0-4 Alkyl-N=S(O)R 13 R 14 、-C 0-4 Alkyl-N=SR 13 R 14 、-C 0-4 Alkyl-OS(O)2R 15 、-C 0-4 Alkyl-S(O) r R 15 、-C 0-4 Alkyl-OR 16 、-C 0-4 Alkyl-C(O)OR 16 、-C 0-4 Alkyl-C(O)SR 16 、-C 0-4 Alkyl-SC(O)R 17 、-C 0-4 Alkyl-C(O)R 17 、-C 0- 4-Alkyl-OC(O)R 17 、-C 0-4 Alkyl-P(O)(R 17 )2. -C 0-4 Alkyl-NR 18 R 19 、-C 0-4 Alkyl-C(=NR 18 )R 17 、-C 0-4 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-4 Alkyl-C(O)NR 18 R 19 and -C 0-4 Alkyl-N(R 18 )-C(O)R 17 substituted by a substituent; Each R3 and each R4 are independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 12 )R 13 、-C 0-4 Alkyl-N=S(O)R 13 R 14 、-C 0-4 Alkyl-N=SR 13 R 14 、-C 0-4 Alkyl-OS(O)2R 15 、-C 0-4 Alkyl-S(O) r R 15 、-C 0-4 Alkyl-OR 16 、-C 0-4 Alkyl-C(O)OR 16 、-C 0-4 Alkyl-C(O)SR 16 、-C 0-4 Alkyl-SC(O)R 17 、-C 0-4 Alkyl-C(O)R 17 、-C 0-4 Alkyl-OC(O)R 17 、-C 0-4 Alkyl-P(O)(R 17 )2. -C 0-4 Alkyl-NR 18 R 19 、-C 0-4 Alkyl-C(=NR 18 )R 17 、-C 0-4 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-4 Alkyl-C(O)NR 18 R 19 and -C 0-4 Alkyl-N(R 18 )-C(O)R 17 Alternatively, R3 and R4 together with the carbon atom to which they are directly attached form a C(=CH2), C(O), C 3-6 Cycloalkyl or 4-6 membered heterocyclic group, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 12 )R 13 、-C 0-4 Alkyl-N=S(O)R 13 R 14 、-C 0- 4-alkyl-N=SR 13 R 14 、-C 0-4 Alkyl-OS(O)2R 15 、-C 0-4 Alkyl-S(O) r R 15 、-C 0-4 Alkyl-OR 16 、-C 0-4 Alkyl-C(O)OR 16 、-C 0-4 Alkyl-C(O)SR 16 、-C 0-4 Alkyl-SC(O)R 17 、-C 0-4 Alkyl-C(O)R 17 、-C 0-4 Alkyl-OC(O)R 17 、-C 0-4 Alkyl-P(O)(R 17 )2. -C 0-4 Alkyl-NR 18 R 19 、-C 0-4 Alkyl-C(=NR 18 )R 17 、-C 0-4 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-4 Alkyl-C(O)NR 18 R 19 and -C 0-4 Alkyl-N(R 18 )-C(O)R 17 substituted by a substituent; R5 is selected from -NR 11a R 11b 、C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-8 Aryl and 5-8 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1- 4 alkyl, C 2-4 Alkenyl, C 1-4 Alkylene, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 aryl, 3-6 membered heterocyclic group, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 12 )R 13 、-C 0-4 Alkyl-N=S(O)R 13 R 14 、-C 0-4 Alkyl-N=SR 13 R 14 、-C 0-4 Alkyl-OS(O)2R 15 、-C 0-4 Alkyl-S(O) r R 15 、-C 0-4 Alkyl-OR 16 、-C 0-4 Alkyl-C(O)OR 16 、-C 0-4 Alkyl-C(O)SR 16 、-C 0-4 Alkyl-SC(O)R 17 、-C 0-4 Alkyl-C(O)R 17 、-C 0-4 Alkyl-OC(O)R 17 、-C 0-4 Alkyl-P(O)(R 17 )2. -C 0-4 Alkyl-NR 18 R 19 、-C 0-4 Alkyl-C(=NR 18 )R 17 、-C 0-4 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-4 Alkyl-C(O)NR 18 R 19 and -C 0-4 Alkyl-N(R 18 )-C(O)R 17 The above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, nitro, azido, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 12 )R 13 、-C 0-4 Alkyl-N=S(O)R 13 R 14 、-C 0-4 Alkyl-N=SR 13 R 14 、-C 0-4 Alkyl-OS(O)2R 15 、-C 0-4 Alkyl-S(O) r R 15 、-C 0-4 Alkyl-OR 16 、-C 0-4 Alkyl-C(O)OR 16 、-C 0-4 Alkyl-C(O)SR 16 、-C 0-4 Alkyl-SC(O)R 17 、-C 0-4 Alkyl-C(O)R 17 、-C 0-4 Alkyl-OC(O)R 17 、-C 0-4 Alkyl-P(O)(R 17 )2. -C 0-4 Alkyl-NR 18 R 19 、-C 0-4 Alkyl-C(=NR 18 )R 17 、-C 0-4 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-4 Alkyl-C(O)NR 18 R 19 and -C 0-4 Alkyl-N(R 18 )-C(O)R 17 substituted by a substituent; Each R6 is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 12 )R 13 、-C 0-4 Alkyl-N=S(O)R 13 R 14 、-C 0-4 Alkyl-N=SR 13 R 14 、-C 0-4 Alkyl-OS(O)2R 15 、-C 0-4 Alkyl-S(O) r R 15 、-C 0-4 Alkyl-OR 16 、-C 0-4 Alkyl-C(O)OR 16 、-C 0-4 Alkyl-C(O)SR 16 、-C 0-4 Alkyl-SC(O)R 17 、-C 0-4 Alkyl-C(O)R 17 、-C 0-4 Alkyl-OC(O)R 17 、-C 0-4 Alkyl-P(O)(R 17 )2. -C 0-4 Alkyl-NR 18 R 19 、-C 0-4 Alkyl-C(=NR 18 )R 17 、-C 0-4 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-4 Alkyl-C(O)NR 18 R 19 and -C 0-4 Alkyl-N(R 18 )-C(O)R 17 ; R7 is selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 12 )R 13 、-C 0-4 Alkyl-N=S(O)R 13 R 14 、-C 0-4 Alkyl-N=SR 13 R 14 、-C 0-4 Alkyl-OS(O)2R 15 、-C 0-4 Alkyl-S(O) r R 15 、-C 0-4 Alkyl-OR 16 、-C 0-4 Alkyl-C(O)OR 16 、-C 0-4 Alkyl-C(O)SR 16 、-C 0-4 Alkyl-SC(O)R 17 、-C 0-4 Alkyl-C(O)R 17 、-C 0-4 Alkyl-OC(O)R 17 、-C 0-4 Alkyl-P(O)(R 17 )2. -C 0-4 Alkyl-NR 18 R 19 、-C 0-4 Alkyl-C(=NR 18 )R 17 、-C 0-4 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-4 Alkyl-C(O)NR 18 R 19 and -C 0-4 Alkyl-N(R 18 )-C(O)R 17 ; Each R8 is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, cyano substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3- 6-membered cycloalkyl, 3-6-membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 12 )R 13 、-C 0-4 Alkyl-N=S(O)R 13 R 14 、-C 0-4 Alkyl-N=SR 13 R 14 、-C 0-4 Alkyl-OS(O)2R 15 、-C 0-4 Alkyl-S(O) r R 15 、-C 0-4 Alkyl-OR 16 、-C 0-4 Alkyl-C(O)OR 16 、-C 0-4 Alkyl-C(O)SR 16 、-C 0-4 Alkyl-SC(O)R 17 、-C 0-4 Alkyl-C(O)R 17 、-C 0-4 Alkyl-OC(O)R 17 、-C 0-4 Alkyl-P(O)(R 17 )2. -C 0-4 Alkyl-NR 18 R 19 、-C 0-4 Alkyl-C(=NR 18 )R 17 、-C 0-4 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-4 Alkyl-C(O)NR 18 R 19 and -C 0-4 Alkyl-N(R 18 )-C(O)R 17 ； R 11a and R 11b are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-10 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkylene, halogen substituted C 1-4 Alkylene, deuterium substituted C 1-4 Alkylene, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3- 6-membered cycloalkoxy, 3-6-membered heterocyclic group, 3-6-membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono C 1-4 Alkylamino, di-C 1-4 Alkylamino and C 1-4 substituted with an alkanoyl substituent; Or, R 11a and R 11b Together with the nitrogen atom directly connected thereto, a 4-6 membered heterocyclic group or a 5-8 membered heteroaryl group is formed, wherein the 4-6 membered heterocyclic group or the 5-8 membered heteroaryl group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, ═O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkylene, halogen substituted C 1-4 Alkylene, deuterium substituted C 1-4 Alkylene, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono C 1-4 Alkylamino, di-C 1-4 Alkylamino and C 1-4 substituted with an alkanoyl substituent; Among them, R 12 、R 13 、R 14 、R 15 、R 16 、R 17 、R 18 、R 19 and r as claimed in claim 1.

3. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R 9a 、R 9b and R 9c Each independently selected from hydrogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 3- 6-membered cycloalkyl, 3-6-membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-S(O) r R 15 、-C 0-4 Alkyl-OR 16 、-C 0-4 Alkyl-C(O)OR 16 、-C 0-4 Alkyl-C(O)SR 16 、-C 0-4 Alkyl-C(O)R 17 、-C 0-4 Alkyl-OC(O)R 17 、-C 0-4 Alkyl-NR 18 R 19 、-C 0-4 Alkyl-C(O)NR 18 R 19 and -C 0-4 Alkyl-N(R 18 )-C(O)R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1- 4 alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 12 )R 13 、-C 0-4 Alkyl-N=S(O)R 13 R 14 、-C 0-4 Alkyl-N=SR 13 R 14 、-C 0-4 Alkyl-OS(O)2R 15 、-C 0-4 Alkyl-S(O) r R 15 、-C 0-4 Alkyl-OR 16 、-C 0-4 Alkyl-C(O)OR 16 、-C 0-4 Alkyl-C(O)SR 16 、-C 0-4 Alkyl-SC(O)R 17 、-C 0-4 Alkyl-C(O)R 17 、-C 0-4 Alkyl-OC(O)R 17 、-C 0-4 Alkyl-P(O)(R 17 )2. -C 0-4 Alkyl-NR 18 R 19 、-C 0-4 Alkyl-C(=NR 18 )R 17 、-C 0-4 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-4 Alkyl-C(O)NR 18 R 19 and -C 0-4 Alkyl-N(R 18 )-C(O)R 17 substituted by a substituent; R 10a and R 10b are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 12 )R 13 、-C 0-4 Alkyl-N=S(O)R 13 R 14 、-C 0-4 Alkyl-N=SR 13 R 14 、-C 0-4 Alkyl-OS(O)2R 15 、-C 0-4 Alkyl-S(O) r R 15 、-C 0-4 Alkyl-OR 16 、-C 0-4 Alkyl-C(O)OR 16 、-C 0-4 Alkyl-C(O)SR 16 、-C 0-4 Alkyl-SC(O)R 17 、-C 0-4 Alkyl-C(O)R 17 、-C 0- 4-Alkyl-OC(O)R 17 、-C 0-4 Alkyl-P(O)(R 17 )2. -C 0-4 Alkyl-NR 18 R 19 、-C 0-4 Alkyl-C(=NR 18 )R 17 、-C 0-4 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-4 Alkyl-C(O)NR 18 R 19 and -C 0-4 Alkyl-N(R 18 )-C(O)R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1- 4 alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 12 )R 13 、-C 0-4 Alkyl-N=S(O)R 13 R 14 、-C 0-4 Alkyl-N=SR 13 R 14 、-C 0-4 Alkyl-OS(O)2R 15 、-C 0-4 Alkyl-S(O) r R 15 、-C 0-4 Alkyl-OR 16 、-C 0-4 Alkyl-C(O)OR 16 、-C 0-4 Alkyl-C(O)SR 16 、-C 0-4 Alkyl-SC(O)R 17 、-C 0-4 Alkyl-C(O)R 17 、-C 0-4 Alkyl-OC(O)R 17 、-C 0-4 Alkyl-P(O)(R 17 )2. -C 0-4 Alkyl-NR 18 R 19 、-C 0-4 Alkyl-C(=NR 18 )R 17 、-C 0-4 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-4 Alkyl-C(O)NR 18 R 19 and -C 0-4 Alkyl-N(R 18 )-C(O)R 17 substituted by a substituent; Among them, R 12 、R 13 、R 14 、R 15 、R 16 、R 17 、R 18 、R 19 and r as claimed in claim 1; Preferably, R 9a 、R 9b and R 9c Each independently selected from hydrogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 3- 6-membered cycloalkyl, 3-6-membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-C(O)R 17 、-OC(O)R 17 、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1- 4-alkyl, deuterium-substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=NR 12 )R 13 、-N=S(O)R 13 R 14 、-N=SR 13 R 14 、-OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(=NR 18 )R 17 、-N(R 18 )-C(=NR 19 )R 17 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; R 10a and R 10b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2- 4-chain alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=NR 12 )R 13 、-N=S(O)R 13 R 14 、-N=SR 13 R 14 、-OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(=NR 18 )R 17 、-N(R 18 )-C(=NR 19 )R 17 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=NR 12 )R 13 、-N=S(O)R 13 R 14 、-N=SR 13 R 14 、-OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(=NR 18 )R 17 、-N(R 18 )-C(=NR 19 )R 17 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Among them, R 12 、R 13 、R 14 、R 15 、R 16 、R 17 、R 18 、R 19 and r as claimed in claim 1; More preferably, R 9a 、R 9b and R 9c are each independently selected from hydrogen and C 1-4 Alkyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 substituted by a cycloalkyl group or a 3-6 membered heterocyclic group; R 10a and R 10b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl and C 3-6 Cycloalkyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1- 4-alkyl, deuterium-substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 The alkyl group may be substituted by a cycloalkyl group, a 3-6 membered heterocyclyl group, =O, =S and -SF5 substituents.

4. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R 12 are each independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-S(O) r R 15 、-C 0-4 Alkyl-C(O)OR 16 、-C 0-4 Alkyl-C(O)R 17 and -C 0-4 Alkyl-C(O)NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen-substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-S(O) r R 15 、-C 0-4 Alkyl-OR 16 、-C 0-4 Alkyl-C(O)OR 16 、-C 0-4 Alkyl-C(O)R 17 、-C 0-4 Alkyl-OC(O)R 17 、-C 0-4 Alkyl-NR 18 R 19 、-C 0-4 Alkyl-C(=NR 18 )R 17 、-C 0-4 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-4 Alkyl-C(O)NR 18 R 19 and -C 0-4 Alkyl-N(R 18 )-C(O)R 17 substituted by a substituent; Each R 13 and each R 14 are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2- 4-chain alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl and 5-8 membered heteroaryl, or R 13 and R 14 Together with the sulfur atom directly connected thereto, a 3-6 membered heterocyclic group is formed, wherein the above group is optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen-substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-S(O) r R 15 、-C 0-4 Alkyl-OR 16 、-C 0-4 Alkyl-C(O)OR 16 、-C 0-4 Alkyl-C(O)R 17 、-C 0-4 Alkyl-OC(O)R 17 、-C 0-4 Alkyl-NR 18 R 19 、-C 0-4 Alkyl-C(=NR 18 )R 17 、-C 0-4 Alkyl-N(R 18 )-C(=NR 19 )R 17 、-C 0-4 Alkyl-C(O)NR 18 R 19 and -C 0-4 Alkyl-N(R 18 )-C(O)R 17 substituted by a substituent; Each R 15 independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl and -NR 18 R 19 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6- 8-membered aryloxy, 5-8-membered heteroaryl, 5-8-membered heteroaryloxy and -NR 18 R 19 substituted by a substituent; Each R 16 independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl and 5-8 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 18 R 19 substituted by a substituent; Each R 17 independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 18 R 19 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1- 4 alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6- 8 aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 18 R 19 substituted by a substituent; Each R 18 and each R 19 are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2- 4-chain alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-10 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen-substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6- 8 aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono C 1-4 Alkylamino, di-C 1-4 Alkylamino and C 1-4 substituted with an alkanoyl substituent; Or, R 18 and R 19 Together with the nitrogen atom directly connected thereto, a 4-6 membered heterocyclic group or a 5-8 membered heteroaryl group is formed, wherein the 4-6 membered heterocyclic group or the 5-8 membered heteroaryl group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, ═O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen-substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6- 8 aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono C 1-4 Alkylamino, di-C 1-4 Alkylamino and C 1-4 substituted with an alkanoyl substituent; and each r is independently 0, 1 or 2.

5. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) is a compound of formula (IIa), formula (IIb), formula (IIc), formula (IId), formula (IIe) or formula (IIf): Wherein, each ring A is independently selected from the following structures: Each R1 is independently selected from C 3-6 Cycloalkyl, 3-6 membered heterocyclic and 5-8 membered heteroaryl substituted C 1- 4 alkyl, each R2 is independently selected from hydrogen, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic group, or, R1 and R2 together with the nitrogen atom to which they are directly connected form a 4-12 membered heterocyclic group, said 4-12 membered heterocyclic group is optionally fused to a 5-10 membered heteroaryl group, said group is optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=NR 12 )R 13 、-N=S(O)R 13 R 14 、-N=SR 13 R 14 、-OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(=NR 18 )R 17 、-N(R 18 )-C(=NR 19 )R 17 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 The above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=NR 12 )R 13 、-N=S(O)R 13 R 14 、-N=SR 13 R 14 、-OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(=NR 18 )R 17 、-N(R 18 )-C(=NR 19 )R 17 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R3 and each R4 are independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=NR 12 )R 13 、-N=S(O)R 13 R 14 、-N=SR 13 R 14 、-OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(=NR 18 )R 17 、-N(R 18 )-C(=NR 19 )R 17 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 Alternatively, R3 and R4 together with the carbon atom to which they are directly attached form a C(=CH2), C(O), C 3-6 Cycloalkyl or 4-6 membered heterocyclic group, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=NR 12 )R 13 、-N=S(O)R 13 R 14 、-N=SR 13 R 14 、-OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(=NR 18 )R 17 、-N(R 18 )-C(=NR 19 )R 17 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R5 is independently selected from -NR 11a R 11b 、C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1- 4 alkyl, C 2-4 Alkenyl, C 1-4 Alkylene, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 aryl, 3-6 membered heterocyclic group, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=NR 12 )R 13 、-N=S(O)R 13 R 14 、-N=SR 13 R 14 、-OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(=NR 18 )R 17 、-N(R 18 )-C(=NR 19 )R 17 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 The above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkylene, halogen substituted C 1-4 Alkylene, deuterium substituted C 1-4 Alkylene, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=NR 12 )R 13 、-N=S(O)R 13 R 14 、-N=SR 13 R 14 、-OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(=NR 18 )R 17 、-N(R 18 )-C(=NR 19 )R 17 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R6 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=NR 12 )R 13 、-N=S(O)R 13 R 14 、-N=SR 13 R 14 、-OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(=NR 18 )R 17 、-N(R 18 )-C(=NR 19 )R 17 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ; Each R7 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=NR 12 )R 13 、-N=S(O)R 13 R 14 、-N=SR 13 R 14 、-OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(=NR 18 )R 17 、-N(R 18 )-C(=NR 19 )R 17 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ; Each R8 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, cyano substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=NR 12 )R 13 、-N=S(O)R 13 R 14 、-N=SR 13 R 14 、-OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(=NR 18 )R 17 、-N(R 18 )-C(=NR 19 )R 17 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ; Each R 11a and each R 11b are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-10 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkylene, halogen substituted C 1-4 Alkylene, deuterium substituted C 1-4 Alkylene, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono C 1-4 Alkylamino, di-C 1-4 Alkylamino and C 1-4 substituted with an alkanoyl substituent; Or, R 11a and R 11b Together with the nitrogen atom directly connected thereto, a 4-6 membered heterocyclic group is formed, wherein the 4-6 membered heterocyclic group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkylene, halogen substituted C 1-4 Alkylene, deuterium substituted C 1-4 Alkylene, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono C 1-4 Alkylamino, di-C 1-4 Alkylamino and C 1-4 substituted with an alkanoyl substituent; Among them, R 12 、R 13 、R 14 、R 15 、R 16 、R 17 、R 18 、R 19 , r, m, n and o as described in claim 1.

6. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) is a compound of formula (IIIa), formula (IIIb), formula (IIIc), formula (IIId), formula (IIIe) or formula (IIIf): Wherein, each ring A is independently selected from the following structures: Each R1 is independently selected from C 3-6 Cycloalkyl, 3-6 membered heterocyclic and 5-8 membered heteroaryl substituted C 1- 4 alkyl, each R2 is independently selected from hydrogen, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic group, or, R1 and R2 together with the nitrogen atom to which they are directly connected form a 4-12 membered heterocyclic group, said 4-12 membered heterocyclic group is optionally fused to a 5-10 membered heteroaryl group, said group is optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -OR 16 、-C(O)R 17 and -NR 18 R 19 The above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=NR 12 )R 13 、-N=S(O)R 13 R 14 、-N=SR 13 R 14 、-OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(=NR 18 )R 17 、-N(R 18 )-C(=NR 19 )R 17 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R3 and each R4 are independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -OR 16 and -NR 18 R 19 Alternatively, R3 and R4 together with the carbon atom to which they are directly attached form a C(=CH2), C(O), C 3-6 Cycloalkyl or 4-6 membered heterocyclic group, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=NR 12 )R 13 、-N=S(O)R 13 R 14 、-N=SR 13 R 14 、-OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(=NR 18 )R 17 、-N(R 18 )-C(=NR 19 )R 17 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R5 is independently selected from -NR 11a R 11b 、C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1- 4 alkyl, C 2-4 Alkenyl, C 1-4 Alkylene, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O) r R 15 、-OR 16 and -NR 18 R 19 The above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkylene, halogen substituted C 1-4 Alkylene, deuterium substituted C 1-4 Alkylene, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=NR 12 )R 13 、-N=S(O)R 13 R 14 、-N=SR 13 R 14 、-OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(=NR 18 )R 17 、-N(R 18 )-C(=NR 19 )R 17 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R6 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ; Each R7 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ; Each R 8a and each R 8b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, cyano substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ; Each R 11a and each R 11b are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-10 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkylene, halogen substituted C 1-4 Alkylene, deuterium substituted C 1-4 Alkylene, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono C 1-4 Alkylamino, di-C 1-4 Alkylamino and C 1-4 substituted with an alkanoyl substituent; Or, R 11a and R 11b Together with the nitrogen atom directly connected thereto, a 4-6 membered heterocyclic group is formed, wherein the 4-6 membered heterocyclic group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkylene, halogen substituted C 1-4 Alkylene, deuterium substituted C 1-4 Alkylene, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono C 1-4 Alkylamino, di-C 1-4 Alkylamino and C 1-4 substituted with an alkanoyl substituent; Among them, R 12 、R 13 、R 14 、R 15 、R 16 、R 17 、R 18 、R 19 , r, m and n as described in claim 1.

7. The compound of formula (I) according to claim 6, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) is a compound of formula (IVa1), formula (IVb1), formula (IVc1), formula (IVd1), formula (IVe1) or formula (IVf1): Wherein, each ring A is independently selected from the following structures: Each R 1a and each R 1b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)R 17 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R 1c are each independently selected from hydrogen, deuterium, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)R 17 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R3 and each R4 are independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -OR 16 and -NR 18 R 19 Alternatively, R3 and R4 together with the carbon atom to which they are directly attached form a C(=CH2), C(O), C 3-6 Cycloalkyl or 4-6 membered heterocyclic group, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R 5a , each R 5b and each R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 、-OR 16 and -NR 18 R 19 , or, R 5a With R 5b or R 5c One of them together with its directly connected part forms a C 3-4 Cycloalkyl or 3-4 membered heterocyclic group, R 5b or R 5c Another definition is as above, or, R 5a With R 5b Together with the carbon atom to which it is directly attached, it forms C(=CH2), R 5c As defined above, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 、-OR 16 and -NR 18 R 19 , or, R 5d and R 5e Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R 5f and each R 5g are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 、-OR 16 and -NR 18 R 19 , or, R 5f and R 5g Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R6 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ; Each R7 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ; Each R 8a and each R 8b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, cyano substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ; Each s is independently 0 or 1; Among them, R 12 、R 13 、R 14 、R 15 、R 16 、R 17 、R 18 、R 19 , r and n as described in claim 6.

8. The compound of formula (I) according to claim 7, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R 1a and each R 1b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)R 17 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -OR 16 and -NR 18 R 19 substituted by a substituent; Each R 1c are each independently selected from hydrogen, deuterium, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)R 17 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -OR 16 and -NR 18 R 19 substituted by a substituent; Each R 5a and R 5b Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -OR 16 、-C(O)OR 16 , and -NR 18 R 19 substituted by a substituent; Each R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 ; Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, -S(O) r R 15 、-OR 16 and -NR 18 R 19 , or, R 5d and R 5e Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 substituted by a substituent; Each R 5f and each R 5g are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, -S(O) r R 15 、-OR 16 and -NR 18 R 19 , or, R 5f and R 5g Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)OR 16 、-OC(O)R 17 and -NR 18 R 19 substituted by a substituent; Among them, R 15 、R 16 、R 17 、R 18 、R 19 and r as claimed in claim 7; Preferably, each R 1a and each R 1b are each independently selected from hydrogen, deuterium, halogen, cyano and C 1-4 Alkyl, the above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl and deuterium substituted C 1-4 substituted by an alkyl substituent; Each R 1c are each independently selected from hydrogen, deuterium, cyano, C 1-4 Alkyl and -C(O)R 17 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1- 4 alkyl, =O, =S and -OR 16 substituted by a substituent; Each R 5a and R 5b Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl and deuterium substituted C 1-4 substituted by an alkyl substituent; Each R 5c are each independently selected from hydrogen, deuterium, halogen, cyano and C 1-4 alkyl; Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl and -SR 15 , or, R 5d and R 5e Together with the carbon atom to which it is directly attached, it forms C(=CH2), and the above groups are independently optionally further substituted with one or more radicals selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl and deuterium substituted C 1- 4 alkyl substituents; Each R 5f and each R 5g are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 6-8 Aryl and C 6-8 Aryl and 3-6 membered heterocyclic group, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, -OR 16 、-C(O)OR 16 、-OC(O)R 17 and -OC(O)R 17 substituted by a substituent; Among them, R 15 、R 16 and R 17 As claimed in claim 7; More preferably, each R 1a and each R 1b are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano and methyl, the above groups being optionally further substituted by one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl; Each R 1c are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl and -C(O)R 17a , the above groups are optionally further substituted by one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, =O, =S and hydroxy; Each R 5a and R 5b Together with the carbon atom to which it is directly attached, it forms a cyclopropyl or cyclobutyl group, which groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl; Each R 5c are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl and isopropyl; Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl and -S-CH3, or, R 5d and R 5e Together with the carbon atom to which it is directly attached, they form C(=CH2), the above groups being independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl; Each R 5f and each R 5g are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, phenyl and The above groups are independently optionally further substituted with one or more selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl, trideuterium methyl, -OR 16a 、-C(O)OR 16a and -OC(O)R 17a substituted by a substituent; R 16a is selected from the group consisting of pyrimidinyl, pyridinyl, phenyl, amino and dimethylamino; R 17a Selected from cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, amino, dimethylamino, 9. The compound of formula (I) according to claim 7, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R 1a and each R 1b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)R 17 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -OR 16 and -NR 18 R 19 substituted by a substituent; Each R 1c are each independently selected from hydrogen, deuterium, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)R 17 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -OR 16 and -NR 18 R 19 substituted by a substituent; Each R 5a and R 5b Together with the carbon atom to which it is directly attached, it forms C(=CH2), and the above groups are independently optionally further substituted with one or more radicals selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -OR 16 、-C(O)OR 16 and -NR 18 R 19 substituted by a substituent; Each R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 ; Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, -S(O) r R 15 、-OR 16 and -NR 18 R 19 , or, R 5d and R 5e Together with the carbon atom to which it is directly attached, it forms a 3-4 membered heterocyclic group or C(=CH2), wherein the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 substituted by a substituent; Each R 5f and each R 5g are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, -S(O) r R 15 、-OR 16 and -NR 18 R 19 , or, R 5f and R 5g Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)OR 16 、-OC(O)R 17 and -NR 18 R 19 substituted by a substituent; Among them, R 15 、R 16 、R 17 、R 18 、R 19 and r as claimed in claim 7; Preferably, each R 1a and each R 1b are each independently selected from hydrogen, deuterium, halogen, cyano and C 1-4 Alkyl, the above groups are optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl and deuterium substituted C 1-4 substituted by an alkyl substituent; Each R 1c are each independently selected from hydrogen, deuterium, cyano, C 1-4 Alkyl and -C(O)R 17 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1- 4 alkyl, =O, =S and -OR 16 substituted by a substituent; Each R 5a and R 5b Together with the carbon atom to which it is directly attached, it forms C(=CH2), and the above groups are independently optionally further substituted with one or more radicals selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl and deuterium substituted C 1-4 substituted by an alkyl substituent; Each R 5c are each independently selected from hydrogen, deuterium, halogen, cyano and C 1-4 alkyl; Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl and -SR 15 , or, R 5d and R 5e Together with the carbon atom to which it is directly attached, it forms C(=CH2), and the above groups are independently optionally further substituted with one or more radicals selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl and deuterium substituted C 1- 4 alkyl substituents; Each R 5f and each R 5g are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 6-8 Aryl and C 6-8 Aryl and 3-6 membered heterocyclic group, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, -OR 16 、-C(O)OR 16 、-OC(O)R 17 and -OC(O)R 17 substituted by a substituent; Among them, R 15 、R 16 and R 17 As claimed in claim 7; More preferably, each R 1a and each R 1b are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano and methyl, the above groups being optionally further substituted by one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl; Each R 1c are each independently selected from hydrogen, deuterium, cyano, methyl, ethyl, n-propyl, isopropyl and -C(O)R 17a , the above groups are optionally further substituted by one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, =O, =S and hydroxy; Each R 5a and R 5b Together with the carbon atom to which it is directly attached, they form C(=CH2), the above groups being independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl; Each R 5c are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl and isopropyl; Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl and -S-CH3, or, R 5d and R 5e Together with the carbon atom to which it is directly attached, they form C(=CH2), the above groups being independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl; Each R 5f and each R 5g are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, phenyl and The above groups are independently optionally further substituted with one or more selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl, trideuterium methyl, -OR 16a 、-C(O)OR 16a and -OC(O)R 17a substituted by a substituent; R 16a is selected from the group consisting of pyrimidinyl, pyridinyl, phenyl, amino and dimethylamino; R 17a Selected from cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, amino, dimethylamino, 10. The compound of formula (I) according to claim 7, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R 1a and each R 1b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)R 17 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -OR 16 and -NR 18 R 19 substituted by a substituent; Each R 1c are each independently selected from hydrogen, deuterium, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)R 17 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -OR 16 and -NR 18 R 19 substituted by a substituent; Each R 5a and R 5c Together with its directly connected parts, it forms a C 3-4 Cycloalkyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -OR 16 、-C(O)OR 16 , and -NR 18 R 19 substituted by a substituent; Each R 5b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 ; Each R 5d and R 5e are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, -S(O) r R 15 、-OR 16 and -NR 18 R 19 , or, R 5d and R 5e Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 substituted by a substituent; Each R 5f and R 5g are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, -S(O) r R 15 、-OR 16 and -NR 18 R 19 , or, R 5f and R 5g Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)OR 16 、-OC(O)R 17 and -NR 18 R 19 substituted by a substituent; Among them, R 15 、R 16 、R 17 、R 18 、R 19 and r as claimed in claim 7; Preferably, each R 1a and each R 1b are each independently selected from hydrogen, deuterium, halogen, cyano and C 1-4 Alkyl, the above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl and deuterium substituted C 1-4 substituted by an alkyl substituent; Each R 1c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl and -C(O)R 17 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, =O, =S and -OR 16 substituted by a substituent; Each R 5a and R 5c Together with its directly connected parts, it forms a C 3-4 Cycloalkyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl and deuterium substituted C 1-4 substituted by an alkyl substituent; Each R 5b are each independently selected from hydrogen, deuterium, halogen, cyano and C 1-4 alkyl; Each R 5d and R 5e are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl and -SR 15 , or, R 5d and R 5e Together with the carbon atom to which it is directly attached, it forms C(=CH2), and the above groups are independently optionally further substituted with one or more radicals selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl and deuterium substituted C 1-4 substituted by an alkyl substituent; Each R 5f and R 5g are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 6-8 Aryl and C 6- 8 aryl and 3-6 membered heterocyclic group, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, -OR 16 、-C(O)OR 16 、-OC(O)R 17 and -OC(O)R 17 substituted by a substituent; Among them, R 15 、R 16 and R 17 As claimed in claim 7; More preferably, each R 1a and each R 1b are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano and methyl, the above groups being optionally further substituted by one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl; Each R 1c are each independently selected from hydrogen, deuterium, cyano, methyl, ethyl, n-propyl, isopropyl and -C(O)R 17a , the above groups are optionally further substituted by one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, =O, =S and hydroxy; Each R 5a and R 5c Together with the moiety to which it is directly attached, it forms a cyclopropyl or cyclobutyl group, which groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl; Each R 5b are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl and isopropyl; Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl and -S-CH3, or, R 5d and R 5e Together with the carbon atom to which it is directly attached, they form C(=CH2), the above groups being independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl; Each R 5f and each R 5g are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, phenyl and The above groups are independently optionally further substituted with one or more selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl, trideuterium methyl, -OR 16a 、-C(O)OR 16a and -OC(O)R 17a substituted by a substituent; R 16a is selected from the group consisting of pyrimidinyl, pyridinyl, phenyl, amino and dimethylamino; R 17a Selected from cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, amino, dimethylamino, 11. The compound of formula (I) according to claim 7, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: In the compound of formula (IVa1), R 1a and R 1b are each independently selected from deuterium, halogen, cyano, C 1- 4 alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)R 17 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 substituted by a substituent; R 1c Selected from hydrogen, deuterium, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-NR 18 R 19 and -C(O)R 17 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2- 4-chain alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -OR 16 and -NR 18 R 19 substituted by a substituent; R 5a 、R 5b and R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl and 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -SF5, -OR 16 and -NR 18 R 19 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 substituted by a substituent; R 5d and R 5e are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl and 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -SF5, -OR 16 and -NR 18 R 19 , or, R 5d and R 5e Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-NR 18 R 19 and -C(O)OR 16 substituted by a substituent; R 5f and R 5g are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl and 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -SF5, -OR 16 and -NR 18 R 19 , or, R 5f and R 5g Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)OR 16 、-OC(O)R 17 and -NR 18 R 19 substituted by a substituent; Among them, R 16 、R 17 、R 18 and R 19 As claimed in claim 7; Preferably, R 1a and R 1b are each independently selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic groups, the above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 substituted by a substituent; R 1c Selected from hydrogen, deuterium, cyano, C 1-4 Alkyl and -C(O)R 17 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, =O, =S and -OR 16 substituted by a substituent; R 5a 、R 5b and R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl and C 3-6 Cycloalkyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 substituted by a substituent; R 5d and R 5e are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl and 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -OR 16 and -NR 18 R 19 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -C(O)OR 16 substituted by a substituent; R 5f and R 5g are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl and 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 , or, R 5f and R 5g Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)OR 16 、-OC(O)R 17 and -NR 18 R 19 substituted by a substituent; Among them, R 16 、R 17 、R 18 and R 19 As claimed in claim 7; More preferably, R 1a and R 1b are each independently selected from deuterium, fluorine and chlorine; R 1c Selected from hydrogen, deuterium, cyano, methyl, ethyl, n-propyl, isopropyl and -C(O)R 17a , the above groups are optionally further substituted by one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, =O, =S and hydroxy; R 5a 、R 5b and R 5c are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, C 1-4 Alkyl and C 3-6 Cycloalkyl, the aforementioned groups independently being optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, hydroxyl and amino; R 5d and R 5e are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, -S-CH3, phenyl and The above groups are independently optionally further substituted with one or more selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuterium, -OR 16a and -C(O)OR 16a substituted by a substituent; R 5f and R 5g are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, -S-CH3, phenyl and Or, R 5f and R 5g The carbon atom to which it is directly attached forms a cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl or C(=CH2), which groups are independently optionally further substituted by one or more groups selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteromethyl, -OR 16a 、-C(O)OR 16a and -OC(O)R 17a substituted by a substituent; R 16a is selected from the group consisting of pyrimidinyl, pyridinyl, phenyl, amino and dimethylamino; R 17a Selected from cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, amino, dimethylamino, 12. The compound of formula (I) according to claim 7, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: In the compound of formula (IVa1), R 1a and R 1b are each independently hydrogen; R 1c -C(O)R 17 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1- 4 alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -OR 16 and -NR 18 R 19 substituted by a substituent; R 5a 、R 5b and R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl and 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -OR 16 and -NR 18 R 19 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 substituted by a substituent; R 5d and R 5e are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 、-OR 16 and -NR 18 R 19 , or, R 5d and R 5e Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; R 5f and R 5g are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 、-OR 16 and -NR 18 R 19 , or, R 5f and R 5g Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Among them, R 15 、R 16 、R 17 、R 18 、R 19 and r as claimed in claim 7; Preferably, R 1a and R 1b are each independently hydrogen; R 1c -C(O)R 17 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1- 4 alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, =O, =S and -OR 16 substituted by a substituent; R 5a 、R 5b and R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl and C 3-6 Cycloalkyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 substituted by a substituent; R 5d and R 5e are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl and 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -SF5, -OR 16 and -NR 18 R 19 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -C(O)OR 16 substituted by a substituent; R 5f and R 5g are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl and 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 , or, R 5f and R 5g Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)OR 16 、-OC(O)R 17 and -NR 18 R 19 substituted by a substituent; Among them, R 16 、R 17 、R 18 and R 19 As claimed in claim 7; More preferably, R 1a and R 1b are each independently hydrogen; R 1c -C(O)R 17a , the above groups are optionally further substituted by one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, =O, =S and hydroxy; R 5a 、R 5b and R 5c are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, C 1-4 Alkyl and C 3-6 Cycloalkyl, the aforementioned groups independently being optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, hydroxyl and amino; R 5d and R 5e are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, -S-CH3, phenyl and The above groups are independently optionally further substituted with one or more selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuterium, -OR 16a and -C(O)OR 16a substituted by a substituent; R 5f and R 5g are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, -S-CH3, phenyl and Or, R 5f and R 5g The carbon atom to which it is directly attached forms a cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl or C(=CH2), which groups are independently optionally further substituted by one or more groups selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteromethyl, -OR 16a 、-C(O)OR 16a and -OC(O)R 17a substituted by a substituent; R 16a is selected from the group consisting of pyrimidinyl, pyridinyl, phenyl, amino and dimethylamino; R 17a Selected from cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, amino, dimethylamino, 13. The compound of formula (I) according to claim 7, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: In the compound of formula (IVa1), R 1a and R 1b are each independently hydrogen; R 1c is hydrogen; R 5a 、R 5b and R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl and 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -OR 16 and -NR 18 R 19 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 substituted by a substituent; R 5d and R 5e are each independently selected from hydrogen, C 1-4 Alkyl, C 6-8 Aryl, C 6-8 aryl, 3-6 membered heterocyclic group, 5-8 membered heteroaryl and -S(O) r R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; R 5f and R 5g are each independently selected from hydrogen, C 1-4 Alkyl, C 6-8 Aryl, C 6-8 aryl, 3-6 membered heterocyclic group, 5-8 membered heteroaryl and -S(O) r R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; provided that, R 5d and R 5f Not at the same time H; Among them, R 15 、R 16 、R 17 、R 18 、R 19 and r as claimed in claim 7; Preferably, R 1a and R 1b are each independently hydrogen; R 1c is hydrogen; R 5a 、R 5b and R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl and C 3-6 Cycloalkyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 substituted by a substituent; R 5d and R 5e are each independently selected from hydrogen, C 6-8 Aryl and 3-6 membered heterocyclic group and -S-CH3, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -C(O)OR 16 substituted by a substituent; R 5f and R 5g are each independently selected from hydrogen, C 1-4 Alkyl, C 6-8 Aryl, C 6-8 Aryl and 3-6 membered heterocyclic group and -S-CH3, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)OR 16 、-OC(O)R 17 and -NR 18 R 19 substituted by a substituent; provided that, R 5d and R 5f Not at the same time H; Among them, R 16 、R 17 、R 18 and R 19 As claimed in claim 7; More preferably, R 1a and R 1b are each independently hydrogen; R 1c is hydrogen; R 5a 、R 5b and R 5c are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl and cyclobutyl, each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, hydroxyl and amino; R 5d and R 5e are each independently selected from hydrogen or -S-CH3; R 5f and R 5g are each independently selected from hydrogen, -CH2-OC(O)R 17a and The above groups are independently optionally further substituted by one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl and trideuteriomethyl; provided that R 5d and R 5f Not at the same time H; R 17a Selected from cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, amino, dimethylamino, 14. The compound of formula (I) according to claim 7, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: In the compound of formula (IVb1), formula (IVc1), formula (IVd1), formula (IVe1) or formula (IVf1), each R 1a and each R 1b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2- 4-chain alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)R 17 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1- 4 alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R 1c are each independently selected from hydrogen, deuterium, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-NR 18 R 19 and -C(O)R 17 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R 5a , each R 5b and each R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 、-OR 16 and -NR 18 R 19 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1- 4 alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 、-OR 16 and -NR 18 R 19 , or, R 5d and R 5e Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R 5f and each R 5g are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 、-OR 16 and -NR 18 R 19 , or, R 5f and R 5g Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Among them, R 15 、R 16 、R 17 、R 18 、R 19 and r as claimed in claim 7; Preferably, each R 1a and each R 1b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic groups, the above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3- 6-membered cycloalkyl, 3-6-membered heterocyclic group, -OR 16 and -NR 18 R 19 substituted by a substituent; Each R 1c are each independently selected from hydrogen, deuterium, cyano, C 1-4 Alkyl and -C(O)R 17 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1- 4 alkyl, =O, =S and -OR 16 substituted by a substituent; Each R 5a , each R 5b and each R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl and C 3-6 Cycloalkyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1- 4 alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 substituted by a substituent; Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 、-OR 16 and -NR 18 R 19 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -C(O)OR 16 substituted by a substituent; Each R 5f and each R 5g are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, -S(O) r R 15 、-OR 16 and -NR 18 R 19 , or, R 5f and R 5g Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)OR 16 、-OC(O)R 17 and -NR 18 R 19 substituted by a substituent; Among them, R 15 、R 16 、R 17 、R 18 、R 19 and r as claimed in claim 7; More preferably, each R 1a and each R 1b are each independently selected from hydrogen, deuterium, fluorine and chlorine; Each R 1c are each independently selected from hydrogen, deuterium, cyano, methyl, ethyl, n-propyl, isopropyl and -C(O)R 17a , the above groups are optionally further substituted by one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, =O, =S and hydroxy; Each R 5a , each R 5b and each R 5c are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, C 1-4 Alkyl and C 3-6 Cycloalkyl, the aforementioned groups independently being optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, hydroxyl and amino; Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, -S-CH3, phenyl and The above groups are independently optionally further substituted with one or more selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuterium, -OR 16a and -C(O)OR 16a substituted by a substituent; Each R 5f and each R 5g are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, -S-CH3, phenyl and Or, R 5f and R 5g The carbon atom to which it is directly attached forms a cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl or C(=CH2), which groups are independently optionally further substituted by one or more groups selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteromethyl, -OR 16a 、-C(O)OR 16a and -OC(O)R 17a substituted by a substituent; R 16a is selected from the group consisting of pyrimidinyl, pyridinyl, phenyl, amino and dimethylamino; R 17a Selected from cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, amino, dimethylamino, 15. The compound of formula (I) according to claim 6, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) is a compound of formula (IVa2), formula (IVb2), formula (IVc2), formula (IVd2), formula (IVe2) or formula (IVf2): Wherein, each ring A is independently selected from the following structures: Each R 1a , each R 1b and each R 1c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)R 17 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R3 and each R4 are independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -OR 16 and -NR 18 R 19 Alternatively, R3 and R4 together with the carbon atom to which they are directly attached form a C(=CH2), C(O), C 3-6 Cycloalkyl or 4-6 membered heterocyclic group, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R 5a , each R 5b and each R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 、-OR 16 and -NR 18 R 19 , or, R 5a With R 5b or R 5c One of them together with its directly connected part forms a C 3-4 Cycloalkyl or 3-4 membered heterocyclic group, R 5b or R 5c Another definition is as above, or, R 5a With R 5b Together with the carbon atom to which it is directly attached, it forms C(=CH2), R 5c As defined above, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 、-OR 16 and -NR 18 R 19 , or, R 5d and R 5e Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R 5f and each R 5g are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 、-OR 16 and -NR 18 R 19 , or, R 5f and R 5g Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R6 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ; Each R7 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ; Each R 8a and each R 8b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, cyano substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ; Each s is independently 0 or 1; Among them, R 12 、R 13 、R 14 、R 15 、R 16 、R 17 、R 18 、R 19 , r and n as described in claim 6.

16. The compound of formula (I) according to claim 15, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R 1a , each R 1b and each R 1c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, -OR 16 and -NR 18 R 19 substituted by a substituent; Among them, R 16 、R 18 and R 19 As claimed in claim 15; Preferably, each R 1a , each R 1b and each R 1c each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino, and dimethylamino, optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino, and dimethylamino; More preferably, each R 1a , each R 1b and each R 1c are each independently hydrogen.

17. The compound of formula (I) according to claim 15, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R 5a , each R 5b and each R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl and 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 , or, R 5a With R 5b or R 5c One of them together with its directly connected part forms a C 3- 4-membered cycloalkyl or 3-4-membered heterocyclic group, R 5b or R 5c Another definition is as above, or, R 5a With R 5b Together with the carbon atom to which it is directly attached, it forms C(=CH2), R 5c As defined above, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 substituted by a substituent; Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl and 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 , or, R 5d and R 5e Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R 5f and each R 5g are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl and 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 , or, R 5f and R 5g Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Among them, R 16 、R 17 、R 18 and R 19 As claimed in claim 15; Preferably, each R 5a , each R 5b and each R 5c are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, phenyl, hydroxyl, amino and dimethylamino, or R 5a With R 5b or R 5c One of them together with the part to which it is directly attached forms a cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine or azetidinyl group, R 5b or R 5c Another definition is as above, or, R 5a With R 5b Together with the carbon atom to which it is directly attached, it forms C(=CH2), R 5c The definitions are as described above, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino; Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, phenyl, hydroxyl, amino and dimethylamino, or R 5d and R 5e together with the carbon atom to which it is directly attached, form a cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl or C(═CH 2 ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino; Each R 5f and each R 5g are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, phenyl, hydroxyl, amino and dimethylamino, or R 5f and R 5g together with the carbon atom to which it is directly attached, form a cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl or C(═CH 2 ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino; More preferably, each R 5a , each R 5b and each R 5c are each independently selected from hydrogen, deuterium and fluorine; Each R 5d and each R 5e are each independently hydrogen; Each R 5f and each R 5g are each independently hydrogen.

18. The compound of formula (I) according to claim 6, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) is a compound of formula (IVa3), formula (IVb3), formula (IVc3), formula (IVd3), formula (IVe3) or formula (IVf3): Wherein, each ring A is independently selected from the following structures: Each R 1a and each R 1b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)R 17 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R 1c are each independently selected from hydrogen, deuterium, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)R 17 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R3 and each R4 are independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -OR 16 and -NR 18 R 19 Alternatively, R3 and R4 together with the carbon atom to which they are directly attached form a C(=CH2), C(O), C 3-6 Cycloalkyl or 4-6 membered heterocyclic group, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R 5a , each R 5b and each R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 、-OR 16 and -NR 18 R 19 , or, R 5a With R 5b or R 5c One of them together with its directly connected part forms a C 3-4 Cycloalkyl or 3-4 membered heterocyclic group, R 5b or R 5c Another definition is as above, or, R 5a With R 5b Together with the carbon atom to which it is directly attached, it forms C(=CH2), R 5c As defined above, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 、-OR 16 and -NR 18 R 19 , or, R 5d and R 5e Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R 5f and each R 5g are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 、-OR 16 and -NR 18 R 19 , or, R 5f and R 5g Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R6 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ; Each R7 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ; Each R 8a and each R 8b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, cyano substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ; Each s is independently 0 or 1; each t is independently 0, 1 or 2; Among them, R 15 、R 16 、R 17 、R 18 、R 19 , r and n as described in claim 6.

19. The compound of formula (I) according to claim 18, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R 1a and each R 1b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, -OR 16 and -NR 18 R 19 substituted by a substituent; Each R 1c are each independently selected from hydrogen, deuterium, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, -OR 16 and -NR 18 R 19 substituted by a substituent; Among them, R 16 、R 18 and R 19 As claimed in claim 18; Preferably, each R 1a and each R 1b each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino, and dimethylamino, optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino, and dimethylamino; Each R 1c Each is independently selected from hydrogen, deuterium, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxyl, amino and dimethylamino, and the above groups are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxyl, amino and dimethylamino.

20. The compound of formula (I) according to claim 18, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R 5a , each R 5b and each R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl and 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 , or, R 5a With R 5b or R 5c One of them together with its directly connected part forms a C 3- 4-membered cycloalkyl or 3-4-membered heterocyclic group, R 5b or R 5c Another definition is as above, or, R 5a With R 5b Together with the carbon atom to which it is directly attached, it forms C(=CH2), R 5c As defined above, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 substituted by a substituent; Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl and 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 , or, R 5d and R 5e Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R 5f and each R 5g are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl and 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 , or, R 5f and R 5g Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Among them, R 16 、R 17 、R 18 and R 19 As claimed in claim 18; Preferably, each R 5a , each R 5b and each R 5c are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, phenyl, hydroxyl, amino and dimethylamino, or R 5a With R 5b or R 5c One of them together with the part to which it is directly attached forms a cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine or azetidinyl group, R 5b or R 5c Another definition is as above, or, R 5a With R 5b Together with the carbon atom to which it is directly attached, it forms C(=CH2), R 5c The definitions are as described above, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino; Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, phenyl, hydroxyl, amino and dimethylamino, or R 5d and R 5e together with the carbon atom to which it is directly attached, form a cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl or C(═CH 2 ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino; Each R 5f and each R 5g are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, phenyl, hydroxyl, amino and dimethylamino, or R 5f and R 5g Together with the carbon atom to which it is directly attached, it forms a cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl or C(=CH2), and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxy, amino and dimethylamino.

21. The compound of formula (I) according to claim 6, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) is a compound of formula (IVa4), formula (IVb4), formula (IVc4), formula (IVd4), formula (IVe4) or formula (IVf4): Wherein, each ring A is independently selected from the following structures: Each R 1a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)R 17 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R 1b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)R 17 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R 1c are each independently selected from hydrogen, deuterium, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)R 17 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R3 and each R4 are independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -OR 16 and -NR 18 R 19 Alternatively, R3 and R4 together with the carbon atom to which they are directly attached form a C(=CH2), C(O), C 3-6 Cycloalkyl or 4-6 membered heterocyclic group, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R 5a , each R 5b and each R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 、-OR 16 and -NR 18 R 19 , or, R 5a With R 5b or R 5c One of them together with its directly connected part forms a C 3-4 Cycloalkyl or 3-4 membered heterocyclic group, R 5b or R 5c Another definition is as above, or, R 5a With R 5b Together with the carbon atom to which it is directly attached, it forms C(=CH2), R 5c As defined above, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 、-OR 16 and -NR 18 R 19 , or, R 5d and R 5e Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R 5f and each R 5g are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 、-OR 16 and -NR 18 R 19 , or, R 5f and R 5g Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R6 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ; Each R7 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ; Each R 8a and each R 8b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, cyano substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ; Each s is independently 0 or 1; Among them, R 15 、R 16 、R 17 、R 18 、R 19 , r and n as described in claim 6.

22. The compound of formula (I) according to claim 21, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R 1a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, -OR 16 and -NR 18 R 19 substituted by a substituent; Each R 1b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, -OR 16 and -NR 18 R 19 substituted by a substituent; Each R 1c are each independently selected from hydrogen, deuterium, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, -OR 16 and -NR 18 R 19 substituted by a substituent; Among them, R 16 、R 18 and R 19 As claimed in claim 21; Preferably, each R 1a each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino, and dimethylamino, optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino, and dimethylamino; Each R 1b each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino, and dimethylamino, optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino, and dimethylamino; Each R 1c Each is independently selected from hydrogen, deuterium, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxyl, amino and dimethylamino, and the above groups are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxyl, amino and dimethylamino.

23. The compound of formula (I) according to claim 21, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R 5a , each R 5b and each R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl and 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 , or, R 5a With R 5b or R 5c One of them together with its directly connected part forms a C 3- 4-membered cycloalkyl or 3-4-membered heterocyclic group, R 5b or R 5c Another definition is as above, or, R 5a With R 5b Together with the carbon atom to which it is directly attached, it forms C(=CH2), R 5c As defined above, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 substituted by a substituent; Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl and 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 , or, R 5d and R 5e Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R 5f and each R 5g are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl and 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 , or, R 5f and R 5g Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Among them, R 16 、R 17 、R 18 and R 19 As claimed in claim 21; Preferably, each R 5a , each R 5b and each R 5c are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, phenyl, hydroxyl, amino and dimethylamino, or R 5a With R 5b or R 5c One of them together with the part to which it is directly attached forms a cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine or azetidinyl group, R 5b or R 5c Another definition is as above, or, R 5a With R 5b Together with the carbon atom to which it is directly attached, it forms C(=CH2), R 5c The definitions are as described above, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino; Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, phenyl, hydroxyl, amino and dimethylamino, or R 5d and R 5e together with the carbon atom to which it is directly attached, form a cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl or C(═CH 2 ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino; Each R 5f and each R 5g are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, phenyl, hydroxyl, amino and dimethylamino, or R 5f and R 5g together with the carbon atom to which it is directly attached, form a cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl or C(═CH 2 ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino; More preferably, each R 5a , each R 5b and each R 5c are each independently selected from hydrogen, deuterium and fluorine; Each R 5d and each R 5e are each independently hydrogen; Each R 5f and each R 5g are each independently hydrogen.

24. The compound of formula (I) according to claim 6, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) is a compound of formula (IVa5), formula (IVb5), formula (IVc5), formula (IVd5), formula (IVe5) or formula (IVf5): Wherein, each ring A is independently selected from the following structures: Each R 1a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)R 17 、-C(O)NR 18 R 19 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R 1b and each R 1c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)R 17 、-C(O)NR 18 R 19 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R3 and each R4 are independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -OR 16 and -NR 18 R 19 Alternatively, R3 and R4 together with the carbon atom to which they are directly attached form a C(=CH2), C(O), C 3-6 Cycloalkyl or 4-6 membered heterocyclic group, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R 5a , each R 5b and each R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 、-OR 16 and -NR 18 R 19 , or, R 5a With R 5b or R 5c One of them together with its directly connected part forms a C 3-4 Cycloalkyl or 3-4 membered heterocyclic group, R 5b or R 5c Another definition is as above, or, R 5a With R 5b Together with the carbon atom to which it is directly attached, it forms C(=CH2), R 5c As defined above, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 、-OR 16 and -NR 18 R 19 , or, R 5d and R 5e Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R 5f and each R 5g are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl 3-6 membered heterocyclic group, 5-8 membered heteroaryl, -SF5, -S(O) r R 15 、-OR 16 and -NR 18 R 19 , or, R 5f and R 5g Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R6 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ; Each R7 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ; Each R 8a and each R 8b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, cyano substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ; Each s is independently 0 or 1; Among them, R 15 、R 16 、R 17 、R 18 、R 19 , r and n as described in claim 6.

25. The compound of formula (I) according to claim 24, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R 1a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)NR 18 R 19 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, -OR 16 and -NR 18 R 19 substituted by a substituent; Each R 1b and each R 1c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)NR 18 R 19 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, -OR 16 and -NR 18 R 19 substituted by a substituent; Among them, R 16 、R 18 and R 19 As claimed in claim 24; Preferably, each R 1a are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxyl, -C(O)NR 18 R 19 and -NR 18 R 19 , the above groups are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino; Each R 1b and each R 1c are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxyl, -C(O)NR 18 R 19 and -NR 18 R 19 , the above groups are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino; R 18 and R 19 Each is independently selected from hydrogen, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine and azetidinyl.

26. The compound of formula (I) according to claim 24, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R 5a , each R 5b and each R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl and 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 , or, R 5a With R 5b or R 5c One of them together with its directly connected part forms a C 3- 4-membered cycloalkyl or 3-4-membered heterocyclic group, R 5b or R 5c Another definition is as above, or, R 5a With R 5b Together with the carbon atom to which it is directly attached, it forms C(=CH2), R 5c As defined above, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 substituted by a substituent; Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl and 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 , or, R 5d and R 5e Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R 5f and each R 5g are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryl and 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 , or, R 5f and R 5g Together with the carbon atom to which it is directly attached, it forms a C 3-4 Cycloalkyl, 3-4 membered heterocyclic group or C(=CH2), the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Among them, R 16 、R 17 、R 18 and R 19 As claimed in claim 24; Preferably, each R 5a , each R 5b and each R 5c are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, phenyl, hydroxyl, amino and dimethylamino, or R 5a With R 5b or R 5c One of them together with the part to which it is directly attached forms a cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine or azetidinyl group, R 5b or R 5c Another definition is as above, or, R 5a With R 5b Together with the carbon atom to which it is directly attached, it forms C(=CH2), R 5c The definitions are as described above, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino; Each R 5d and each R 5e are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, phenyl, hydroxyl, amino and dimethylamino, or R 5d and R 5e together with the carbon atom to which it is directly attached, form a cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl or C(═CH 2 ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino; Each R 5f and each R 5g are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, phenyl, hydroxyl, amino and dimethylamino, or R 5f and R 5g Together with the carbon atom to which it is directly attached, it forms a cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl or C(=CH2), and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxy, amino and dimethylamino.

27. The compound of formula (I) according to claim 6, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R3 and each R4 are independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 Alternatively, R3 and R4 together with the carbon atom to which they are directly attached form a C(=CH2), C(O), C 3-6 Cycloalkyl or 4-6 membered heterocyclic group, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 substituted by a cycloalkyl substituent; Among them, R 16 、R 18 and R 19 As claimed in claim 6; Preferably, each R3 and each R4 are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxy, amino and dimethylamino, or, R3 and R4 together with the carbon atom to which they are directly attached form a C(=CH2), C(O), cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine or azetidinyl, which groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl and cyclobutyl.

28. The compound of formula (I) according to claim 6, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) is a compound of formula (IVa6), formula (IVb6), formula (IVc6), formula (IVd6), formula (IVe6) or formula (IVf6): Wherein, each ring A is independently selected from the following structures: Each R 1a and each R 1b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)R 17 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R 1c are each independently selected from hydrogen, deuterium, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)R 17 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R3 and each R4 are independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -OR 16 and -NR 18 R 19 Alternatively, R3 and R4 together with the carbon atom to which they are directly attached form a C(=CH2), C(O), C 3-6 Cycloalkyl or 4-6 membered heterocyclic group, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R6 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ; Each R7 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ; Each R 8a and each R 8b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, cyano substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ; Each R 11a and each R 11b are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-10 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkylene, halogen substituted C 1-4 Alkylene, deuterium substituted C 1-4 Alkylene, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono C 1-4 Alkylamino, di-C 1-4 Alkylamino and C 1-4 substituted with an alkanoyl substituent; Or, R 11a and R 11b Together with the nitrogen atom directly connected thereto, a 4-6 membered heterocyclic group is formed, wherein the 4-6 membered heterocyclic group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkylene, halogen substituted C 1-4 Alkylene, deuterium substituted C 1-4 Alkylene, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono C 1-4 Alkylamino, di-C 1-4 Alkylamino and C 1-4 substituted with an alkanoyl substituent; Among them, R 15 、R 16 、R 17 、R 18 、R 19 , r and n as described in claim 6.

29. The compound of formula (I) according to claim 28, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R 1a and each R 1b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 substituted by a substituent; Each R 1c are each independently selected from hydrogen, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl and -C(O)R 17 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -OR 16 and -NR 18 R 19 substituted by a substituent; Among them, R 16 、R 17 、R 18 and R 19 As claimed in claim 28; Preferably, each R 1a and each R 1b each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino, and dimethylamino, optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino, and dimethylamino; Each R 1c are each independently selected from hydrogen, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl and -C(O)R 17a , the above groups are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino; R 17a Selected from cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, amino, dimethylamino, 30. The compound of formula (I) according to claim 28, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that Each R3 and each R4 together with the carbon atom to which they are directly attached form a C(=CH2), C(O), C 3-6 Cycloalkyl or 4-6 membered heterocyclic group, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2- 4-chain alkynyl, C 3-6 substituted by a cycloalkyl substituent; Preferably, each R3 and each R4 together with the carbon atom to which they are directly attached form a C(=CH2), C(O), cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine or azetidinyl, each of which is independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl and cyclobutyl.

31. The compound of formula (I) according to claim 28, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R 11a and each R 11b Each independently selected from hydrogen, hydroxyl, C 1-4 Alkyl, C 3-6 Cycloalkyl and -6-membered heterocyclic groups, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 1-4 Alkylene, halogen substituted C 1-4 Alkylene, deuterium substituted C 1-4 Alkylene, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, amino group, mono C 1-4 Alkylamino, di-C 1-4 Alkylamino and C 1-4 substituted with an alkanoyl substituent; Or, R 11a and R 11b Together with the nitrogen atom directly connected thereto, a 4-6 membered heterocyclic group is formed, wherein the 4-6 membered heterocyclic group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 1-4 Alkylene, halogen substituted C 1-4 Alkylene, deuterium substituted C 1-4 Alkylene, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, amino group, mono C 1-4 Alkylamino, di-C 1-4 Alkylamino and C 1-4 substituted with an alkanoyl substituent; Preferably, each R 11a and each R 11b each independently selected from hydrogen, hydroxy, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine and azetidinyl, each of which is optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, hydroxy, =0, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuterium, methylene, monofluoromethylene, difluoromethylene, methoxy, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, amino and dimethylamino; Or, R 11a and R 11b Together with the nitrogen atom to which it is directly attached, it forms an oxirane, oxetanyl, oxolanyl, oxhexyl, aziridine, azetidinyl, azetyl, azetyl, azetyl or The above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, hydroxyl, =0, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, methylene, monofluoromethylene, difluoromethylene, methoxy, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, amino and dimethylamino.

32. The compound of formula (I) according to claim 6, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) is a compound of formula (IVa7), formula (IVb7), formula (IVc7), formula (IVd7), formula (IVe7) or formula (IVf7): Wherein, each ring A is independently selected from the following structures: Each R 1a and each R 1b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)R 17 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R 1c are each independently selected from hydrogen, deuterium, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-C(O)R 17 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R3 and each R4 are independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -OR 16 and -NR 18 R 19 Alternatively, R3 and R4 together with the carbon atom to which they are directly attached form a C(=CH2), C(O), C 3-6 Cycloalkyl or 4-6 membered heterocyclic group, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 substituted by a substituent; Each R6 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ; Each R7 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ; Each R 8a and each R 8b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, cyano substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 15 、-S(O) r R 15 、-OR 16 、-C(O)OR 16 、-C(O)SR 16 、-SC(O)R 17 、-C(O)R 17 、-OC(O)R 17 、-P(O)(R 17 )2、-NR 18 R 19 、-C(O)NR 18 R 19 and -N(R 18 )-C(O)R 17 ; Each R 11a are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 1-4 Alkylene, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl and 5-8 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2- 4-chain alkynyl, C 1-4 Alkylene, halogen substituted C 1-4 Alkylene, deuterium substituted C 1-4 Alkylene, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono C 1-4 Alkylamino, di-C 1-4 Alkylamino and C 1-4 substituted with an alkanoyl substituent; Each R 11b are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl and 5-8 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1- 4 Alkylene, halogen substituted C 1-4 Alkylene, deuterium substituted C 1-4 Alkylene, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono C 1-4 Alkylamino, di-C 1-4 Alkylamino and C 1-4 substituted with an alkanoyl substituent; Each R 11c are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl and 5-8 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1- 4 Alkylene, halogen substituted C 1-4 Alkylene, deuterium substituted C 1-4 Alkylene, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono C 1-4 Alkylamino, di-C 1-4 Alkylamino and C 1-4 substituted with an alkanoyl substituent; Among them, R 15 、R 16 、R 17 、R 18 、R 19 , r and n as described in claim 6.

33. The compound of formula (I) according to claim 32, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R 1a and each R 1b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 and -NR 18 R 19 substituted by a substituent; Each R 1c are each independently selected from hydrogen, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl and -C(O)R 17 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -OR 16 and -NR 18 R 19 substituted by a substituent; Among them, R 16 、R 17 、R 18 and R 19 As claimed in claim 28; Preferably, each R 1a and each R 1b are each independently hydrogen; Each R 1c are each independently hydrogen.

34. The compound of formula (I) according to claim 32, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that Each R3 and each R4 are each independently hydrogen or deuterium.

35. The compound of formula (I) according to claim 32, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that Each R 11a are each independently selected from hydrogen, deuterium, hydroxy, methyl, ethyl and methylene, the above groups being independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine or hydroxy; Each R 11b are each independently selected from hydrogen, deuterium, hydroxy, methyl and ethyl, the above groups being independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine or hydroxy; Each R 11c Each is independently selected from hydrogen, deuterium, hydroxy, methyl, ethyl and methylene, and the above groups are independently optionally further substituted by one or more substituents selected from deuterium, fluorine, chlorine or hydroxy.

36. The compound of formula (I) according to claim 6, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that Each Each is independently selected from the following structures: Each R 6a , each R 6b , each R 6c and each R 6d are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -OR 16 and -NR 18 R 19 ; Among them, R 16 、R 18 and R 19 As claimed in claim 6; Preferably, each Each is independently selected from the following structures: Each R 6a , each R 6b , each R 6c and each R 6d Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, methoxy, ethoxy, n-propoxy, isopropoxy, cyclopropyloxy, amino, monomethylamino and dimethylamino.

37. The compound of formula (I) according to claim 6, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that Each R7 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1- 4-alkyl, deuterium-substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -OR 16 、-OC(O)R 17 、-NR 18 R 19 and -N(R 18 )-C(O)R 17 ; Among them, R 16 、R 17 、R 18 and R 19 As claimed in claim 6; Preferably, each R7 is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, methoxy, ethoxy, n-propoxy, isopropoxy, cyclopropyloxy, amino, monomethylamino and dimethylamino.

38. The compound of formula (I) according to claim 6, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that Each R 8a and each R 8b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, cyano substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -OR 16 、-NR 18 R 19 and -N(R 18 )-C(O)R 17 ; Among them, R 16 、R 17 、R 18 and R 19 As claimed in claim 6; Preferably, each R 8a and each R 8b Each is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyano-substituted methyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, -SF5, hydroxyl, methoxy, ethoxy, n-propoxy, isopropoxy, cyclopropyloxy, amino, monomethylamino and dimethylamino.

39. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Selected from the following compounds:

40. A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 39, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

41. Use of a compound of formula (I) according to any one of claims 1 to 39, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating KRAS-related tumors.

42. Use according to claim 41, characterized in that The KRAS-associated tumor is a tumor associated with wild-type KRAS, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D or KRAS Q61H; preferably, the tumor is cancer.

43. The method according to claim 41, wherein The tumor is adenoma, lymphoma, mesothelioma, lung cancer, esophageal cancer, gastric cancer, pancreatic cancer, liver cancer, bile duct cancer, gallbladder cancer, ampullary cancer, small intestine cancer, large intestine cancer, kidney cancer, testicular cancer, blood cancer, hemangioma, myeloma, chondroma, skull cancer, brain cancer, glioma, uterine cancer, vulvar cancer, vaginal cancer, fallopian tube cancer, bladder cancer, urethra cancer, prostate cancer, adrenal tumor, sarcoma, myxoma, rhabdomyomas, fibromas, lipomas, bronchogenic carcinoma, Hodgkin's disease, malignant melanoma, basal cell carcinoma, squamous cell carcinoma, chondrodysplasia, psoriasis or neuroblastoma.

44. A compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 39 for use in treating tumors associated with wild-type KRAS, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D, or KRAS Q61H.

Images